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SUMMARY 
In eukaryotes, DNA is packaged into a highly condensed structure, known as chromatin. 
Several complexes facilitate the remodelling of chromatin, for example, INO80, NURD 
and SWI/SNF, which attach to tightly bound chromatin, allowing its relaxation by 
nucleosome sliding, unwrapping, histone eviction and exchange of histone variants. The 
activities carried out by these chromatin remodelling complexes are thought to be 
integral in the prevention of cancer cell formation. Recently, whole exome sequencing 
has identified frequent mutations in subunits of the SWI/SNF chromatin remodelling 
complex, at a frequency that rivals p53. Strikingly, the BAF180 (PBRM1) subunit of the 
PBAF variant of SWI/SNF remodelers is mutated in over 40% of clear cell renal cell 
carcinoma (ccRCC), a cancer with typically poor prognosis and limited treatment options 
to date. 
This work embodies four main results chapters that aim to identify novel synthetic lethal 
gene candidates with BAF180, with a view to targeting these gene candidates with 
chemotherapeutic drugs. In the first chapter we work through a short list of hypothesis 
driven potential synthetic lethal candidates and identify the genes KAT2A, RNF4, EZH2 
and BAP1 as potential synthetic lethal partners for BAF180. Chapter two describes the 
development of both stable shRNA and CRISPR/Cas9-derived BAF180-deficient cell lines 
that were used both in this study as well as for other ongoing projects. The third chapter 
outlines the set-up of a high-throughput synthetic lethal siRNA (HTS) screen and 
determines potential synthetic lethal interactions identified here. The final chapter 
examines various PARP genes, identified as hits in HTS screening, to further explore the 
interaction between PARP and BAF180. We find that PARP1 and PARP3 are synthetic 
lethal with BAF180 and treatment with various siRNA’s and PARP inhibitors in BAF180 
deficient mammalian cells results in specific cell death. A phenotype that could be 
clinically exploited for treatment of ccRCC.  
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1.1. Genome Damage and Stability 
 
The maintenance of genome stability by the correct replication of DNA and repair 
of damage is vital for optimal fitness in all living organisms. Genomes hold all the 
biological information needed for life and are made of DNA (Deoxyribonucleic 
Acid). When unwanted alterations are made to the DNA sequence it is possible to 
develop cancer, broadly described as a group of diseases that are capable of 
abnormal cell growth. Hanahan and Weinberg described, in 2000 and again in 
2011, the hallmarks of cancer, encompassing the capabilities acquired by 
tumours for sustained growth (Hanahan and Weinberg 2000, Hanahan and 
Weinberg 2011). These included, but aren’t limited to evading growth 
suppressors, inducing angiogenesis, avoiding immune destruction and most 
importantly for the discussion in this thesis, genome instability and mutation 
(Hanahan and Weinberg 2011). Genome maintenance systems within cells have 
a vital role in resolving defects or damage acquired on DNA to ensure 
spontaneous rates of mutation are low during each cell generation (Hanahan and 
Weinberg 2011). This DNA-maintenance machinery is diverse and components 
of this machinery are often referred to as “caretakers” of the genome, which have 
tumour suppressing activity (Kinzler and Vogelstein 1997). The tumour 
suppressor TP53, has a key role in the surveillance of genetic integrity and is 
known as the “guardian of the genome” (Lane 1992). It is when genome 
maintenance by components of the machinery like this fail, for any number of 
reasons, that leads to the onset and progression of cancer. Currently the leading 
treatments for cancer include resection by surgery, which is an invasive process, 
as well as radiation and chemotherapy, which work by severely damaging DNA 
to trigger cancer cell death, none of which are entirely successful and can be 
damaging by themselves alone, thus leaving scope for development of new 
treatments. The research field of genome stability and DNA repair is important 
for the advancement of cancer treatment. Study in this field generates vital 
knowledge about the biology of cancer and how these diseases develop over time, 
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as well as studying how they respond to current treatments and ultimately aims 
to improve and identify new therapies for the treatment of cancer. This first 
section of this introduction chapter will aim to introduce DNA damage and the 
pathways that are involved in the repair of this damage.  
 
1.1.1. Deoxyribonucleic Acid 
 
DNA was first discovered in the late 1860’s by a Swiss biochemist, Johann 
Friedrich Miescher, defining what he found as being acidic, rich in phosphorous 
and having the potential to have large individual molecules. It wasn’t until much 
later, in 1953 when James Watson and Francis Crick as well as other research 
teams headed by Maurice Wilkins and Rosalind Franklin, made their seminal 
discovery about the structure of DNA (Franklin and Gosling 1953, Watson and 
Crick 1953, Wilkins, Stokes et al. 1953). Rosalind Franklin’s data, based on X-ray 
diffraction studies, supported the theory of a DNA double helix, but it was in fact 
Watson and Crick who first solved the double helix structure of DNA, a discovery 
which has come to be known as the single most important biological 
breakthrough of the twentieth century.  
The DNA double helix exists as two hydrogen-bonded DNA polymers that run 
alongside each other in opposite directions, therefore making anti-parallel 
strands (Watson and Crick 1953). A pentose sugar-phosphate backbone is the 
supporting scaffolding of these polymers, joining together four chemically 
distinct nitrogenous bases cytosine (2’-deoxycytidine 5’-triphosphate, dCTP), 
thymine (2’-deoxythymidine 5’-triphosphate, dTTP), which are single ring 
pyrimidines and adenine (2’-deoxyadenosine 5’-triphosphate, dATP) or guanine 
(2’-deoxyguanosine 5’-triphosphate, dGTP), which are double-ring purines 
(Figure 1.1a). 2’-Deoxyribose is a pentose sugar that consists of five carbons 
named 1’,2’ (one prime, two prime) etc. Phosphate groups are composed of one, 
two or three linked phosphate units, designated α, β and γ. Nucleotides, the single 
unit of the DNA polymer, are formed when a nitrogenous base is attached to the 
first carbon of the 2’-deoxyribose pentose sugar and when the α-phosphate unit 
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joins to the 5’-carbon of the sugar (Figure 1.1b). Polynucleotides are formed when 
individual nucleotides are joined by phosphodiester bonds (Figure 1.2) between 
their 5’ and 3’ carbons. This type of bonding gives the polymer a chemical 
direction, denoted as 5’→3’, in which all natural DNA polymerase enzymes follow 
during DNA replication. In eukaryotic cells, DNA is tightly packaged with proteins 








































Figure 1.1. Nucleotide Structure (A) The four nitrogenous bases, the 
pyrimidines cytosine and thymine and the purines guanine and adenine. (B) 




























































































































































































































































1.1.2. DNA Damage and Repair Pathways 
 
Damaging agents that lead to the generation of cytotoxic or mutagenic DNA 
adducts via both endogenous and exogenous sources threaten the genomic 
integrity of all living organisms. If DNA is damaged in this way, it is imperative 
that it be effectively and swiftly repaired for proper DNA replication and proper 
chromosome segregation to preserve chromosomal integrity. Replication of 
damaged DNA can lead to mutations that could become tumorigenic or cause 
lesions that result in cellular senescence or cell death via the block of replication 
or transcription. Per cell cycle it has been estimated that a eukaryotic cell can 
come under assault from up to 10,000 single-stranded DNA lesions caused by 
endogenous sources of damage that they are forced to repair, a number that is 
increased by lesions caused by exposure to environmental toxins, ultraviolet (UV) 
damage and other radiations.  
To add to the complication of trying to overcome thousands of DNA lesions at any 
one time, these lesions occur within and must be detected and repaired in the 
context of chromatin, which is a dynamic and highly complex structure. To deal 
with the day to day onslaught of DNA lesions a complex DNA damage response 
has evolved within cells that encompasses several different DNA repair pathways, 
which include nucleotide excision repair (NER), base excision repair (BER), 
mismatch repair (MMR), non-homologous end-joining (NHEJ) and homologous 
recombination (HR), which will be further described in the text below. 
 
1.1.2.1. Reversal Repair 
 
In addition to the repair pathways named above, there are also mechanisms that 
have evolved to initiate repair by directly reversing the damage through direct 
removal, usually carried out by a single repair protein without needing to alter 
the physical structure of DNA. Only a small set of DNA lesions benefit from this 
direct DNA repair, including some UV induced damage and some forms of 
alkylated bases. The process is thought to be quite simple and essentially error-
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free and can be divided in to three major mechanisms. The first mechanism by 
which UV light-induced photolesions are reversed by photolyases, the second 
where O-alkylated DNA damage is reversed by O6-alkylguanine-DNA 
alkyltransferases (AGTs) and the third where the AlkB family dioxygenases 
reverse N-alkylated base adducts (Yi and He 2013). These mechanisms all work 
to catalyse the reversal of damage done to the DNA with a view to restoring the 
DNA to its original state.  
 
1.1.2.2. Nucleotide Excision Repair 
 
Bulky DNA lesions in mammalian cells, for example, those that are caused by UV 
induced cyclobutane pyrimidine dimers (CPDs) and 6-4 photoproducts, 
environmental mutagens and some cancer chemotherapeutic agents such as 
cisplatin, are mainly subjected to repair by the nucleotide excision repair (NER) 
pathway (Scharer 2013). NER can be divided in to two sub-pathways; global 
genome NER (GG-NER) or transcription-coupled NER (TC-NER) (Gillet and 
Scharer 2006, Hanawalt and Spivak 2008). GG-NER can occur at both 
transcriptionally active and inactive regions of DNA, opposed to TC-NER, which 
is responsible for repair at transcriptionally active regions of DNA only. The study 
of rare autosomal recessive disorders, such as Xeroderma pigmentosa (XP), 
which is associated with patients being extremely prone to developing skin-
cancer, and Cockayne syndrome (CS), which is associated with microcephaly, 
helped to identify and characterise the GG-NER and TC-NER pathways (Diderich, 
Alanazi et al. 2011). Both pathways require the core NER factors (Figure 1.3) for 
the process of excision and thus repair. Specifically, GG-NER is initiated by XPC-
RAD23B, whereas TC-NER is initiated by RNA polymerase stalled at a lesion, 
which uses the TC-NER specific factors CSA, CSB and XAB2 (Scharer 2013). A 





























Figure 1.3. Model for the core NER reaction, taken from (Scharer 2013). 
(A) Bulky DNA lesions are introduced into DNA by a damaging agent. (B) In 
GG-NER lesions are detected by XPC-RAD23B and binds the undamaged 
strand of DNA opposite the lesion. (C) TFIIH interacts with XPC-RAD23B. The 
XPB subunit of TFIIH opens DNA allowing XPD to move along DNA until it 
identifies/verifies the lesion. (D) XPA, RPA and XPG are recruited to the 
complex when XPD has stopped at the specific lesion. (E) ERCC1-XPF is 
recruited by XPA and initiates an incision 5’ to the lesion. (F) Pol δ, Pol κ, Pol ε 
and their associated factors initiate repair, subsequently allowing the 3’ 
incision by XPG. (G) DNAligaseIIIα/XRCC1 or DNA ligase I then complete the 
repair process and seals the nicked DNA. 
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As with all DNA repair mechanisms, NER is carried out in the context of chromatin, 
which requires the coordination between NER factors and chromatin modifying 
enzymes to allow the chromatin to be accessible for repair. Multiple chromatin 
remodelers have been implicated with NER, with varied roles and level of 
contribution. The complex UV-DDB, which is composed of a damage binding 
protein DDB2 and an adaptor protein DDB1, and also forms a ubiquitin ligase 
complex with CUL4A and ROC1 (Groisman, Polanowska et al. 2003), is thought to 
have an influential role in NER. At the sites of UV induced lesions, DDB2 targets 
the XPC-RAD23 complex to facilitate early NER steps (Wakasugi, Kawashima et 
al. 2002, Fitch, Nakajima et al. 2003). After UV damage the UV-DDB/CUL4A/ROC1 
complex localises at chromatin and destabilises the nucleosome structure 
through the ubiquitination of histones H2A, H3 and H4 (Bergink, Salomons et al. 
2006, Kapetanaki, Guerrero-Santoro et al. 2006). XPC and DDB2 are also 
ubiquitinated by this complex, resulting in the degradation of DDB2 and the 
stabilisation of XPC to DNA (Sugasawa, Okuda et al. 2005, Nishi, Alekseev et al. 
2009). The localisation of XPC to damaged sites in chromatin where NER takes 
place is thought to be facilitated by this ubiquitination (Fei, Kaczmarek et al. 
2011).  
DDB2 can also mediate chromatin modification by aiding PARP-mediated 
polyribosylation and recruitment of ALC1, an enzyme part of the SNF2/SWI2 
family of chromatin remodelers (Pines, Vrouwe et al. 2012). 
Poly(ADP)ribosylation (which will be introduced fully in section 1.7) of DDB2 
prevents it from exposure to ubiquitination and degradation and this is thought 
to provide enough time to aid chromatin decondensation (Pines, Vrouwe et al. 
2012). Post-translational modifications, such as this, stabilise DDB2 and 
therefore control its activity as well as the time spent on chromatin damaged by 
UV irradiation. 
Other chromatin remodelers have been implicated in NER, for example the 
SWI/SNF subunits BRG1 and SNF5 (which will be introduced in section 1.4), 
which are recruited to NER complexes in an XPC-dependent manner (Ray, Mir et 
al. 2009, Zhao, Wang et al. 2009). These subunits are presumed to work 
downstream of the initial recognition of DNA damage and are thought to 
complete the NER process by aiding the decompaction of chromatin (Scharer 
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2013). Following NER, the repaired DNA must be reassembled in to chromatin. 
The histone chaperone CAF-1 (chromatin assembly factor) allows this chromatin 
























1.1.2.3. Base Excision Repair 
 
The base excision repair (BER) pathway repairs spontaneous DNA damage 
caused by oxidation, deamination and alkylation that must be repaired, but is not 
significant enough to impede the helical structure of DNA (Krokan and Bjoras 
2013). A choice of several mammalian DNA glycosylases initiates BER, which then 
allows for the removal and replacement of a damaged base. Once removed an 
abasic site is processed by short-patch repair, which is the main type of BER, or 
by long-patch repair (Figure 1.4). Both of which use multiple different proteins 
to facilitate the resultant repair. The process of these types of repair and the 
choice between them have been extensively reviewed by Kim and Wilson, Krokan 
and Bjoras and others (Kim and Wilson 2012, Krokan and Bjoras 2013).  
An understanding of the involvement of chromatin remodelling complexes in 
different DNA repair pathways is emerging. It has been suggested that chromatin 
remodelling is important for several DNA repair mechanisms, including BER. The 
SWI/SNF remodelling complex was found to facilitate the processing of induced 
8-oxoG lesions by OGG1 and APE1 (Menoni, Gasparutto et al. 2007). 
BER can occur in the nuclei as well as the mitochondria of a cell and is known to 
protect against cancer, aging and neurodegeneration (Krokan and Bjoras 2013). 
BER has been linked to the cellular response to chemotherapeutic agents and 
radiotherapy and it is thought that activation of BER enzymes can lead to 
resistance to DNA-damaging agents (Kim and Wilson 2012). Introduction of BER 
inhibitors to the clinic could work to overcome resistance to chemotherapeutic 
































Figure 1.4. The base excision repair pathway. BER can occur via Short-
Patch BER or Long-Patch BER. 
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1.1.2.4. Mismatch Repair 
 
During DNA replication, errors can occur that lead to incorrectly incorporated 
bases, strand misalignments and small loops of extrahelical nucleotides that form 
as a result of slippage. These errors are dealt with by the mismatch repair (MMR) 
system, which removes them by excising the piece of nascent DNA with the mis-
pair and facilitating its error-free re-synthesis (Jiricny 2013). Mismatches can 
only be recognised while two strands of DNA are annealed together, so repair 
must happen quickly. If two strands of DNA with a mismatch separate, the 
‘damaged’ DNA will no longer be recognisable by MMR and the strands will 
continue through to replication, resulting in 50% of the progeny DNA containing 
a mutation (Jiricny 2013). The MMR system is thought to be integral for genomic 
integrity, errors here can lead to genomic instability and the development of 
cancer. Cancers that arise because of a malfunction in MMR include hereditary 
nonpolyposis colon cancer (HNPCC), also known as Lynch syndrome (reviewed 
in (Lynch, Lynch et al. 2009)). The defect in MMR is characterised by 
microsatellite instability (MSI), brought about by unrepaired insertion/deletion 
loops (IDL’s) within repeated sequences of DNA (microsatellites) (Jiricny 2013). 
This phenotype of microsatellite instability has been useful as a diagnostic tool 
for characterising the status of MMR tumours (Hampel, Frankel et al. 2005).  
In mammals, MMR is regulated by the MutS heterodimers, MutSα and MutSβ, as 
well as the MutL heterodimers, MutLα, MutLβ and MutLγ. Distortions or 
mismatches that occur during replication are recognised and bound to by the 
MutS heterodimer, subsequently initiating the recruitment of MutL heterodimers 
to the site of the mismatch (Drotschmann, Yang et al. 2001). MutL has intrinsic 
endonuclease activity, which is activated when bound to replication factors such 
as proliferating cell nuclear antigen (PCNA) and replication factor C (RFC) 
(Kadyrov, Dzantiev et al. 2006). This activation facilitates MutL to generate a nick 
in the DNA backbone, which is used by the exonuclease Exo1 to remove the 
damaged base. Repair is completed by the replicative polymerase, DNA polδ and 
the ligase, DNA ligase I (Iyama and Wilson 2013). 
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1.1.3. Double Strand Break Repair  
 
DNA double-strand breaks (DSBs) can occur after exposure to multiple 
endogenous and exogenous agents. In eukaryotes the repair of these breaks is 
either undertaken by the homologous recombination (HR) or non-homologous 
end-joining (NHEJ) pathways (Liu and Huang 2016). It is important to repair 
DSBs as they are the most dangerous example of DNA damage. Cells that are 
unable to repair DNA DSBs can undergo apoptosis or fall in to senescence, 
alternatively, if a DSB is mis-repaired it can result in genomic instability, for 
example in the form of chromosome translocations and can ultimately lead to 
carcinogenesis (Davis and Chen 2013). Choosing between the HR and NHEJ 
pathways in response to DNA DSBs is well studied, but still not fully understood, 
here I will give a brief overview of these two complex and vital pathways. 
 
1.1.3.1. Non-Homologous End Joining 
 
Non-homologous end-joining (NHEJ) is a major DNA DSB repair pathway and is 
known to function in all cell cycle phases (Jeggo and Downs 2014). The term NHEJ 
can refer to canonical NHEJ (c-NHEJ), which is well studied and has clear roles in 
the response to DNA DSBs, or to alternative NHEJ (alt-NHEJ), which is thought to 
be a less efficient mechanism of repair. Regardless, both pathways work to re-join 
two DNA DSB ends without using extended homology as a guide, by detection, 
processing and ligation (Chiruvella, Liang et al. 2013). As well as repairing DNA 
DSBs, NHEJ is also essential for V(D)J (V (variable) D (diversity) J (joining)) 
recombination, a site specific recombination process that occurs during T- and B-
cell lymphocyte development (Malu, Malshetty et al. 2012, Davis and Chen 2013). 
On recognition of a DNA DSB, the abundant Ku heterodimer initiates NHEJ by 
binding at the break site (Cary, Peterson et al. 1997, Walker, Corpina et al. 2001). 
DNA-PKcs, the catalytic subunit of the DNA-dependent protein kinase complex, is 
recruited to the break by Ku and facilitates end-processing steps as well as 
allowing for a complex cellular response, for example cell cycle checkpoint 
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activation that helps to prevent replication errors (Gottlieb and Jackson 1993, 
Yaneva, Kowalewski et al. 1997). The Mre11-Rad50-Nbs1 (MRN) complex, which 
is known for its role in HR-mediated DSB repair and damage signalling (Tauchi, 
Kobayashi et al. 2002) is additionally recruited to work with Ku and DNA-PKcs to 
stimulate end resection and enhances DNA-PKcs autophosphorylation (Zhou and 
Paull 2013). When ends require processing (~10-15% of DSBs in G2), the end 
processing factor Artemis is bound to DNA-PKcs and generates reconcilable DNA 
ends, via its exonuclease and endonuclease activity, that can be ligated by the 
XRCC4-DNALigaseIV-XLF ligation complex (Figure 1.5) (Grawunder, Wilm et al. 
1997, Ma, Pannicke et al. 2002, Goodarzi, Yu et al. 2006). Although there are three 
components to the ligation complex, only XRCC4 directly interacts with DNA 
ligase IV (Critchlow, Bowater et al. 1997). DNA ligase IV is the enzyme required 
for ligation of the repaired ends and its activity is dependent on XRCC4 for 
stabilisation (Jeggo and Downs 2014). XRCC4 interacts with XLF for the 
alignment of DNA ends (Ahnesorg, Smith et al. 2006, Tsai, Kim et al. 2007, Andres, 
Vergnes et al. 2012) and more recently it has been suggested that the two could 
form heterofilament bundles that surround DNA in a sheath (Ropars, Drevet et al. 
2011, Wu, Ochi et al. 2011, Andres, Vergnes et al. 2012, Mahaney, Hammel et al. 
2013, Brouwer, Sitters et al. 2016). It has been postulated that the potential 
flexibility of these XRCC4/XLF heterofilaments could either wrap around 
chromatin-bound DNA or that it provides stabilisation to the DNA strands after 
nucleosome disassembly (Jeggo and Downs 2014). Cells deficient in NHEJ 
proteins, such as those described above, are found to present with various 
phenotypes, including radio-sensitivity (Goodarzi and Jeggo 2013). 
If a DNA DSB is not repaired by NHEJ in G2, then DNA resection promotes repair 



























Figure 1.5. The non-homologous end-joining pathway. The Ku70/Ku80 
heterodimer binds DNA double strand breaks. DNA-PKcs initiate the 
recruitment of end processing factors, such as Artemis that allow the XRCC4-
LigaseIV-XLF ligation complex to complete the DNA repair Adapted from 
(Davis and Chen 2013). 
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1.1.3.2. Homologous Recombination 
 
The repair of DNA double strand breaks can also be carried out by homologous 
recombination (HR). This process uses the intact sister chromatid as a template 
for repair and is thought to be relatively error-free because it is able to use this 
DNA as a template. HR takes place during the S and G2 stages of the cell cycle, this 
is due to the requirement of the sister chromatid. HR is initiated by the resection 
of DNA, which is followed by invasion of the homologous sequence and 
subsequent resolution of these intermediate structures. Crossover between the 
homologous DNA sequences is determined by how these intermediate structures 
are resolved, resulting in crossover or non-crossover products (Figure 1.6).  
The MRN complex plays a key role in the early response to DSBs by recognising 
the break and recruiting ataxia telangiectasia mutated (ATM), a protein kinase, to 
the site of damage and activating its catalytic activity via its direct interaction 
with ATM and Nbs1 (Lee and Paull 2004, Lee and Paull 2005, Hartlerode and 
Scully 2009). In the DNA damage response there are many substrates that are 
phosphorylated by ATM, for example the H2A histone variant, H2AX. Therefore, 
phosphorylation of H2AX is frequently used as an early indication of DSB 
formation on chromatin (Matsuoka, Ballif et al. 2007, Hartlerode and Scully 2009, 
Savic, Yin et al. 2009). CtIP, BRCA1 and BARD1 work together with the MRN 
complex to facilitate resection and subsequent processing of the 5’-ends of the 
DSB, thus leaving a 3’-overhang for invasion of the sister chromatid template 
(Sartori, Lukas et al. 2007, Yun and Hiom 2009). The exposed overhang of ssDNA 
is bound by the large subunit of RPA and is subsequently displaced by Rad51, 
which is recruited by factors including BRCA2. The formation and stabilisation of 
Rad51 filaments stimulates the invasion and displacement of the homologous 
strand. This displacement results in Rad54 promoting D-loop formation, which 
can be extended by DNA pol δ or ε via the 3’ strand (Holmes and Haber 1999, 
Krejci, Altmannova et al. 2012).  
Double Holliday junction formation occurs when the 3’-overhang is ‘captured’ on 
the other side of the break, these junctions must be resolved by endonucleases. It 
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Figure 1.6. The homologous recombination pathway. DNA double strand 




1.2. Chromatin Structure and Remodelling 
 
In eukaryotes, genomic DNA is tightly packed together in a protein-DNA complex 
structure known as chromatin. The nucleosome is the basic unit of chromatin, 
where 147bp of DNA is tightly wrapped in left-handed ~1.7 superhelical turns 
around an octomer of histone proteins, comprised of a heterodimer (two copies) 
of histone proteins H2A and H2B, and a tetramer of histones H3 and H4 (Luger, 
Mader et al. 1997, Richmond and Davey 2003). One molecule of the linker histone 
H1 associates with the external interface of the nucleosome, sealing the ~1.7 
turns of DNA, where the DNA enters and exits the nucleosome (Kamakaka and 
Biggins 2005).  
The condensation and organisation of the genome is regulated by the packaging 
of DNA by nucleosomes. Chromatin actively participates in numerous DNA 
transactions including transcription, chromosome segregation, replication, 
recombination, DNA repair and the maintenance of genome integrity. This 
section will introduce chromatin structure, histone variants and the post-
translational modification of histones as well as chromatin remodelling families 
and how mutations found in these families is strikingly linked to cancer formation. 
 
1.2.1. Chromatin Structure 
 
As mentioned, the nucleosome is formed from the four core histones H2A, H2B, 
H3 and H4, created in a ‘hand-shake motif’ due to the interaction of electrostatic, 
hydrophobic and hydrogen bonds between the histone pairs (Kamakaka and 
Biggins 2005). The core histones share a conserved C-terminal histone fold 
domain and N-terminal tails that are directly involved in the interaction with 
other proteins and nucleosomes (Kamakaka and Biggins 2005). 
The extremely recognisable ‘beads on a string’ structure represents chromatin in 
its most basic form, a linear arrangement of nucleosomes that can be bound to a 
number of structural and/or functional proteins, for example, linker histones, 


























Figure 1.7. The packaging of DNA in to chromatin. Image taken from 
(Weier 2001). DNA molecules are tightly wound around histone proteins that 
compact themselves in to 30 nm chromatin fibres. Additional packaging 




The folding of nucleosomes into its secondary three-dimensional structure, 
known as a 30 nm fibre, is driven by interactions between nucleosomes. The 30 
nm fibre associates with linker histones, for example H1 or H5 to stabilise this 
secondary structure. Self-association of these 30 nm fibers into 100 to 400 nm 
filaments forms the tertiary structure organisation (Belmont and Bruce 1994, 
Gordon, Luger et al. 2005). Additional levels of packaging allow for the eventual 
formation of chromatids by chromosomes.   
A three-helix bundle of histones is denoted a histone fold motif (or domain) and 
it is these that mediate a histone’s interaction with other histones (histone-
histone interaction) as well as with DNA (histone-DNA interaction) (Peterson and 
Almouzni 2013). The modulation of chromatin for the facilitation of multiple 
cellular processes is carried out in various ways. For example, histones are 
subject to various post-translational modifications, for example phosphorylation, 
methylation, acetylation and ubiquitylation, modifications which can alter 
histone properties (Iizuka and Smith 2003, Kamakaka and Biggins 2005). The use 
of chromatin remodelling complexes and their catalytic ATP core subunit, which 
will be further introduced in section 1.2.4, also facilitates the movement of 
chromatin by nucleosome sliding, ejection and the repositioning of histones etc. 
The incorporation of histone variants is also important in the modulation of 
chromatin. 
 
1.2.2. Histone Variants 
 
Canonical replicative histones H2A, H2B, H3 and H4 are mostly restricted to being 
produced during S phase of the cell cycle (Peterson and Almouzni 2013). These 
canonical histones make up the dominant proportion of cellular histones, 
however nonallelic variants of these core histones also exist, exhibiting very 
different biophysical characteristics (Kamakaka and Biggins 2005). These non-
canonical histone variants are not restricted to expression during S phase, and 
are therefore expressed throughout the cell cycle (Peterson and Almouzni 2013). 
Histone variants are thought to have specialised functions in the regulation of 
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chromatin dynamics, this could be due to a multitude of factors, for example, in 
contrast to canonical histones, variants contain introns and are often 
polyadenylated, suggesting an importance for the post-translational regulation of 
these proteins (Old and Woodland 1984, Kamakaka and Biggins 2005). The 
exchange of histones for histone variants, which then become preferentially 
expressed, also suggests a specialised function with regards to the dynamics of 
chromatin (Wunsch, Reinhardt et al. 1991). Below I will briefly introduce a subset 
of the different histone variants.  
 
1.2.2.1. Histone H1 
 
Eleven sequence variants such as H10, H5 and the spermand testis-specific 
variant all belong to the histone H1 variants, with the N and C-terminal tail 
domains being the sites of sequence variation from canonical H1 (Kamakaka and 
Biggins 2005, Millan-Arino, Islam et al. 2014). The histone H1 family is the most 
diverse in comparison to the core histones H2A, H2B, H3 and H4, having the most 
variants or subtypes (Happel and Doenecke 2009, Millan-Arino, Islam et al. 2014).  
 
1.2.2.2. The histone variants of H2A and H2B 
 
Of the core histones H2A, H2B, H3 and H4, it is known that H2A has the most 
diverse range of histone variants, including the very important H2A.Z and H2A.X 
(Redon, Pilch et al. 2002). The H2A variants are distinguishable from canonical 
H2A by their C-terminal tails that vary in length and sequence and have a 
divergent genome distribution. Broadly, H2A.Z has been linked to both 
transcriptional repression and activation and is ~60% identical to canonical H2A 
(Jackson and Gorovsky 2000). H2AX has important roles in DNA double strand 
break induction. At DNA DSBs H2AX becomes rapidly phosphorylated at serine 
139, gaining the nomenclature γ-H2AX and serving as a sensitive indicator of 
DSBs (for reviews of both H2A.Z and H2AX see (Redon, Pilch et al. 2002, Zlatanova 
and Thakar 2008, Bonisch and Hake 2012, Tsabar and Haber 2013)). H2B has 
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very few variants, however the ones that have been documented have specialised 
functions in chromatin compaction and transcription repression, particularly 
during gametogenesis (For review see (Poccia and Green 1992, Green, Collas et 
al. 1995)). 
 
1.2.2.3. The centromeric histone H3 variant, CENP-A 
 
There are two major histone H3 variants, H3.3 and centromeric H3, known as 
CENP-A in mammalian cells.  CENP-A is a conserved essential protein that binds 
to centromeres, is expressed throughout the cell cycle and often localizes to 
transcriptionally active regions of the chromosome (Ahmad and Henikoff 2002, 
Kamakaka and Biggins 2005). CENP-A shares similarity in histone-fold domain 
with canonical H3, but has highly divergent N-terminal tails (Kamakaka and 
Biggins 2005). 
 
1.2.2.4. Histone H4 
 
Histone H4, to date, has no known variants, with some suggesting that it is a 
slowly evolving protein (Malik and Henikoff 2003, Kamakaka and Biggins 2005). 
It is not clear why this core histone isn’t represented by multiple variants or 
subtypes. 
 
1.2.3. Post-translational Modification of Histones 
 
For the regulation of chromatin structure and function, histones are subject to a 
diverse set of post-translational modifications (PMTs). These PMTs include lysine 
acetylation, methylation, SUMOylation and ubiquitination, serine/threonine 
phosphorylation, proline isomerization, argenine methylation and ribosylation 
(Peterson and Almouzni 2013). PMTs can occur in the nucleosomal core, but the 
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majority of events affect the N- and C-terminal tail regions(Peterson and 
Almouzni 2013). Two broad mechanisms can explain how chromatin dynamics 
are regulated by post-translational modification. Firstly the creation or 
elimination of binding sites for non-histone proteins by PMTs can affect the 
structure and function of chromatin. Secondly, the stability of nucleosomes 
individually as well as the ability of chromatin fibres to fold into higher order 
structures is directly influenced by histone PMTs (Peterson and Almouzni 2013). 
The formation of a DNA double strand break can rapidly induce post-
translational modifications and the modification of histones in this way is thought 
to have a key role in the DNA damage response (DDR) (Figure 1.8) (Peterson and 
Almouzni 2013). An example of this role in the DDR can be seen in the 
phosphorylation of the histone variant H2A.X at S139 by ATM, ATR and DNA-PK. 
This phosphorylation of H2A.X (termed γH2AX) is an early event in the response 
to DNA DSBs and affects around a megabase of chromatin either side of the break, 
promoting the binding of DNA damage checkpoint mediators like MDC1, thus 
pausing the cell cycle and therefore mediating the repair of the damaged DNA 
(Rogakou, Boon et al. 1999, Stucki, Clapperton et al. 2005, Peterson and Almouzni 
2013). Below I will briefly introduce the most well-known PMTs: acetylation, 





































Figure 1.8. The effect of histone modifications in chromatin on the DDR 
response. (A) Histone modifications that occur on chromatin with a DSB and 
the proteins that are associated. (B) The binding partners or regulators of 
histone modifications. Taken from (Peterson and Almouzni 2013). 
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1.2.3.1. Acetylation  
 
Lysine residues are able to undergo many post-translational modifications. The 
acetylation of lysine residues, meaning the transfer of an acetyl functional group 
from one molecule to another, at the ε-amino group neutralises the charge of the 
lysine and results in a change of the histone’s electrostatic properties. This 
change results in a weakened interaction with the negatively charged DNA, 
forming a more relaxed chromatin structure that is typically associated with a 
transcriptionally active state (Musselman, Lalonde et al. 2012).  Lysine residue 
acetylation can occur on H3 (K4, K9, K14, K18, K23, K27, K36 and K56), H4 (K5, 
K8, K12, K16, K20 and K91), H2A (K5 and K9) and H2B (K5, K12, K15, K16, K20 
and K120) (Musselman, Lalonde et al. 2012). Histone acetylation or deacetylation 
can be carried out by enzymes known as Histone/Lysine Acetyltransferases 
(HATs/KATs) or Histone/Lysine Deacetylases (HDACs/KDACs), for example the 
transcriptional activator lysine acetyltransferase 2A (KAT2A aka. GCN5), which I 
will introduce further in Chapter 3. The relaxed chromatin structure created by 
lysine acetylation can be reversed by a de-acetylation event. Relaxed DNA that is 
transcriptionally active can be referred to as euchromatin and the corresponding 
condensed version of chromatin is referred to as heterochromatin (Grunstein 
1997).  
Acetylated lysines are recognised by three types of histone effectors; the 
bromodomain, PHD fingers and PH domains. Bromodomains are well 
characterised as acetyl-lysine readers(Dhalluin, Carlson et al. 1999, Sanchez and 
Zhou 2009). A well conserved four-helix bundle structure, comprised of αA, αB, 
αC, and αZ helices, folds together to form the typical bromodomain’s structure. A 
deep hydrophobic cavity is created by inter-helical ZA and BC loops and it is 
within this cavity where the acetyllysine residue is inserted and have contact with 
several hydrophobic residues, for example two conserved tyrosines or the 
hydrogen bonding of a conserved asparagine which leads to stabilization 
(Musselman, Lalonde et al. 2012). Typically single bromodomains bind to 
acetylated lysines very weakly, however, binding can be substantially enhanced 
by a single bromodomains interaction with multiple acetylated sequences or the 
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recognition of the acetylated lysine by covalently linked tandem bromodomains 
(Musselman, Lalonde et al. 2012). 
PHD domains, such as the double PHD finger (DPF) of DPF3b, a key epigenetic 
factor for the development of heart and muscle that is associated with the 
SWI/SNF chromatin remodelling complex BAF, have also been found to recognise 
acetylated lysines at histones H3 and H4 (Lange, Kaynak et al. 2008, Zeng, Zhang 
et al. 2010). PH (pleckstrin homology) domains, such as the double PH domain of 
Rtt106, a histone chaperone has specifically be linked to the binding of H3K56-
acetylated histone H3-H4, implicating it in the regulation of nucleosome assembly 
during DNA replication and repair and disassembly during gene transcription (Su, 
Hu et al. 2012). 
Histone deacetylase 1 and 4 (HDAC1 and HDAC4) are responsible for the 
deacetylation of N-terminal lysine residues of the core histones (H2A, H2B, H3 
and H4). Epigenetic repression is marked by the deacetylation of histones, which 
play a key role in the progression of the cell cycle and developmental events as 
well as transcriptional regulation. HDACs can interact with a diverse range of 
non-histone proteins, thus making the terminology lysine de-acetyltransferases 
or KDACs more encompassing of the roles they actually carry out in vivo, although 
typically they are mostly referred to by their original nomenclature (Kadiyala and 
Smith 2014). There are currently eighteen mammalian HDACs that can be 
subdivided in to different families, decided by their homology with yeast HDACs 
(Bhaskara 2015). HDAC1 belongs to Class I HDACs, which is homologous to Rpd3 
in yeast, this class also contains HDACs 2, 3, and 8. HDAC4 belongs to Class IIa 
HDACs, which also contains HDAC 7 and 9 and is homologous to Hda1 in yeast 
(Ropero and Esteller 2007). 
HDAC1 is specifically recruited to sites of DNA damage during DNA repair as well 
as to chromatin around replication forks (Bhaskara 2015). HDAC1 is also 
involved with transcriptional repression that is regulated by the retinoblastoma 
protein Rb (Robertson, Ait-Si-Ali et al. 2000), as well as interacting with the 
nuclear receptor Estrogen receptor-α (ER-α), via its DNA-binding domain and 
activation function-2 (AF-2) domain (Kawai, Li et al. 2003).  
As well as having the broad HDAC activity, HDAC4 is also involved in muscle 
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maturation though its physical and functional interaction with the transcription 
factor MEF2C. MEF2C can recruit HDAC4 via its N-terminal domain to aid 
transcriptional repression (Wang, Bertos et al. 1999). HDAC4 is also known to 
associate and co-localize with a protein that causes Huntington’s disease, the 
aggregation-prone mutant huntingtin protein (mHTT) through its interaction 
with MAP1S (Yue, Li et al. 2015). 
HDACs make an attractive group of synthetic lethal candidates as there are 
currently several small molecule histone deacetylase inhibitors (HDIs) that 
inhibit various HDACs already in clinical studies. These HDIs are potent anti-





Methylation can occur on two residues, lysine and arginine, and each has three 
possible methylation states (Musselman, Lalonde et al. 2012). Unlike other 
modifications, methylation does not affect overall charge, however it does alter 
the hydrophobic character and size of the modified residue (Musselman, Lalonde 
et al. 2012). Lysine can be mono-, di- and trimethylated on its ε-amino group. For 
histone H3 methylation sites typically occur at K4, K9, K26, K27, K36 and K79, for 
histone H4 at K20 and for histone H1 at K26. Excluding H3K79, these are all 
located in the N-terminal tails of the histone proteins. Readers of lysine 
methylation include ADD (ATRX-DNMT3-DNMT3L), ankyrin, bromo-adjacent 
homology (BAH), chromo-barrel, chromodomain, double chromodomain (DCD), 
MBT (malignant brain tumour), PHD (plant homeodomain), PWWP (Pro-Trp-
Trp-Pro), Tandem Tudor domain (TTD), Tudor, WD40 and the zinc finger CW (zf-
CW) (Musselman, Lalonde et al. 2012).  
In the context of cellular functions, methylation of lysine residues is the best 
characterised, with a defining role in transcriptional regulation. Methylation of 
H3K4 (H3K4me) is thought to be a gene-activation mark on global chromatin, 
with H3K4me1 distinguishing active enhancer elements, H3K4me2 being 
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associated with active or potentially active ‘permissive’ chromatin states and 
H3K4me3 occurring within active transcription (Bernstein, Humphrey et al. 2002, 
Schneider, Bannister et al. 2004, Jeong, Kim et al. 2011, Musselman, Lalonde et al. 
2012).  
H3K36me is also thought to have a role in transcription. A progressive shift from 
monomethylation to trimethylation of K36 between the 5’ and 3’ ends of genes 
was found by genome wide profiling (Bannister and Kouzarides 2005). H3K36me 
also has an additional roles in DNA damage response, DNA replication and mRNA 
alternative splicing (Musselman, Lalonde et al. 2012). H3K20me2 is a 
methylation mark that also has a role in the DNA damage response, being 
targeted by the TTD (Tandem Tudor Domain) of 53BP1 (Botuyan, Lee et al. 2006).  
H3K9 and H3K27 are typically associated with the formation of constitutive and 
facultative heterochromatin and gene silencing. At pericentromeric 
heterochromatin regions the methylation marks H3K27me1 and H3K9me3 are 
found, conversely H3K27me3 and H3K9me2 are found in repressed euchromatin 
regions (Peters, Kubicek et al. 2003, Rice, Briggs et al. 2003).  
Arginine can be monomethylated or dimethylated symmetrically or 
asymmetrically. It has been reported that arginine methylation can occur at H3R2, 
H3R8, H3R17, H3R26, H4R3, H2AR11 and H2AR29 (Musselman, Lalonde et al. 
2012). Functionally, very little is known about the significance of methylarginine 
readout in histone proteins, but it is thought that the recognition of these 
methylated residues can influence transcription processes (Musselman, Lalonde 




Phosphorylation occurs at serine or threonine residues. Bulky, negatively 
charged groups are added to the modified residues, altering the electrostatic and 
topographic properties of histones. Histones are phosphorylated on histone H3 
at T3, T6, S10, T11, S28 and T45, on histone H4 at S1, on histone H2A at S1 and 
T120, on H2AX at S139 and on histone H2B at S14. Phosphorylation at these 
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residues is important in the DNA damage response pathways, mitosis and 
transcriptional regulation (Musselman, Lalonde et al. 2012).  
 
1.2.4. Chromatin Remodelling Families 
 
As described, DNA is packaged in to chromatin and access to this tightly bound 
structure is integral to allow the participation of chromatin in roles such as the 
regulation of transcription and DNA repair to name a few. Specialised chromatin 
remodelling complexes have evolved to facilitate this access by dynamically 
mediating nucleosome composition in chromosomal regions (Clapier and Cairns 
2009). The energy from ATP hydrolysis is utilised by chromatin remodelling 
complexes to aid the sliding, ejection and repositioning of nucleosomes as well as 
mediating the exchange of histone variants. Other chromatin related factors work 
with these ATPase remodelers to guide the packaging and un-packaging of DNA, 
with a view to controlling not only the tightly bound structure of chromatin, but 
the regulation of essential processes, including DNA repair (Clapier and Cairns 
2009).  
Four different chromatin remodelling families are currently known, including the 
ISWI family, the CHD family, the INO80 family and the SWI/SNF family of 
remodelers. All families give rise to multi-subunit complexes that share a similar 
core catalytic ATPase domain, surrounded by uniquely associated subunits 
(Clapier and Cairns 2009). Strong affinity for nucleosomes, the recognition of 
histone modifications, similar ATPase domains, proteins that regulate these 
ATPase domains and subunits that interact with other chromatin or transcription 
factors are the five essential properties shared by all four families of remodelers 
(Clapier and Cairns 2009). Though the families of remodelers share properties, 
they also serve different purposes and act in very different biological contexts. 
The subject of this thesis is the SWI/SNF family of remodelers, specifically the 
PBAF complex, and so a thorough introduction of this family is described in 




1.2.5. Chromatin Remodelling Complexes and Cancer 
 
Dysregulation of processes mediated by chromatin remodelling complexes 
including transcriptional regulation and DNA-damage repair have been 
implicated in cancer development. Genome-wide sequencing of human cancers 
in recent years have identified multiple genes involved in cancer progression. In 
those identified, somatic mutations affected multiple epigenetic processes such 
as DNA methylation or hydroxylation, as well as mutations being found in 
histone-modifying enzymes like EZH2 or SUZ12 (Masliah-Planchon, Bieche et al. 
2015).  ATP chromatin remodelling complexes, like epigenetic changes, are 
implicated in cancer formation. Most notably, mutations in subunits of the 
SWI/SNF family of remodelers have been found in a striking  19% of all human 
tumours, rivalling the frequency of TP53 mutations, which is found in 26% of all 
human cancers (Shain and Pollack 2013). I will discuss specific SWI/SNF subunits 
and their involvement in cancer in section 1.4.    
Other chromatin remodelling families have been implicated as having roles in 
cancer, for example the NuRD complex , which belongs to the CHD family of 
remodelers. The NuRD complex components, MTA1-3, have been associated with 
metastasis when overexpressed in cells and is thought to be linked with the 
invasive behaviour in several cancers (Denslow and Wade 2007). To give one 
example, in breast cancer, estrogen receptors (ERs) are regulators of 
proliferation and differentiation, and expression of these receptors can be used 
as a prognostic tool as well as a therapeutic target. MTA3 expression has been 
found to correlate with ER expression, and it has been suggested that this MTA3 
subunit is responsible for the regulation of invasive growth pathways and that 
mutations within this gene can lead to breast cancer development via direct 
inhibition of the transcriptional repressor Snail (Fujita, Jaye et al. 2003).
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1.3. The Genetics of Renal Cell Carcinoma 
 
Renal cell carcinomas (RCC) are a complex set of diseases that have a major 
socioeconomic impact and are seen to be rising in incidence throughout the world 
(Jonasch, Futreal et al. 2012). 338,000 new cases were diagnosed worldwide in 
2012 and there is thought to be a five-year survival rate of just ~12% when 
advanced in stage. Affecting both men and women alike, it is biologically distinct 
from kidney cancer, in that it doesn’t involve the renal pelvis or renal medulla and 
isn’t a single entity, but instead is a class of tumours of renal epithelial origin, for 
example the renal tubules. RCC mostly tends to arise sporadically, but can also be 
heritable, accounting for 1-4% of cases, with genetic mutations being the cause 
of some RCC cancer-prone families (Pavlovich and Schmidt 2004). Four major 
autosomal dominantly inherited RCC syndromes have been identified as; von 
Hippel-Lindau syndrome (VHL), which is also mutated in sporadic RCC, 
Hereditary leiomyomatosis and renal cell cancer (HLRCC), Hereditary papillary 
renal cancer (HPRC) and Birt-Hogg-Dube syndrome (BHD). We know that VHL is 
the gene mutated in von Hippel-Lindau disease (Latif, Tory et al. 1993), MET 
mutations are drivers in familial papillary renal cancer (Schmidt, Duh et al. 1997), 
fumarate hydratase (FH) mutations are found in hereditary leiomyomatosis and 
renal cell cancer (Tomlinson, Alam et al. 2002), as well as folliculin (FLCN) 
mutations in Birt-Hogg-Dubé syndrome (Nickerson, Warren et al. 2002). 
Clear cell renal cell carcinoma (ccRCC) accounts for about 80% of sporadic RCC 
(Shenoy and Pagliaro 2016). This major subtype of kidney cancer is characterised 
by 80-90% of these tumours having a frequent inactivation of the von Hippel-
Lindau (VHL) gene (Liao 2015) and the aberrant signalling of the hypoxia 
inducible factor (HIF) that subsequently ensues (Jonasch, Futreal et al. 2012). It 
is interesting to note that VHL can be considered as both a germline cancer 
susceptibility gene as well as one that can be somatically mutated. Most of these 
VHL mutations cause loss of the wild type (WT) allele via large-scale loss of 
heterozygosity of chromosome 3p, resulting in a loss of protein (Jonasch, Futreal 
et al. 2012). It is known that ccRCC tumours exhibit extremely diverse mutational 
heterogeneity and as well as VHL, there are known to be three other genes that 
are frequently mutated in ccRCC; PBRM1 (mutated in ~50%), BAP1 (~15%) and 
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SETD2 (~15%). These genes all cluster with VHL in a 43Mb region on 
chromosome 3p, a region that is deleted in over 90% of tumours due to the loss 
of one or more of these tumour suppressor genes (Pena-Llopis, Christie et al. 
2013). Loss of these genes are oncogenic drivers, which are distinct from 
passenger mutations in that they occur at mutation frequencies that are higher 
than expected by chance alone (Pena-Llopis, Christie et al. 2013).  
The genes frequently mutated in RCC are biologically very diverse and therefore 
multiple mechanisms and biological pathways can be implicated in the 
tumorigenesis of RCC (Pavlovich and Schmidt 2004). Currently it is not well 
understood how driver mutations in cancer genes can work together in the 
progression of tumorigenesis and RCC is a good example of the complex 
relationships that can arise between cancer genes (Pena-Llopis, Christie et al. 
2013). The most commonly mutated genes in ccRCC have strong links to 
chromatin (Figure 1.9) and ccRCC tumours are known to lack the hallmark 
genetic features of solid tumours, such as KRAS and TP53 mutations and are 
unresponsive to angiogenesis inhibitors, traditional chemotherapies, as well as 
highly resistant to radiation (Jonasch, Futreal et al. 2012). Thus, the study of the 
identified key tumour suppressors is vital, not only for the understanding of the 
mechanism behind ccRCC tumorigenesis, but also to exploit these known 
mutations to develop novel therapeutic treatments for a cancer that has a clear 
































Figure 1.9. Genes involved in ccRCC interact with chromatin. Adapted 
from (Liao, Testa et al. 2015). 
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1.3.1. VHL is the most frequently mutated gene in ccRCC 
 
Inactivation of the VHL tumour suppressor gene is the most significant driver of 
ccRCC, with 70-80% of all ccRCC tumours harbouring a biallelic inactivation of 
VHL through mutation, deletion, or hypermethylation of its promoter resulting in 
the loss of expression (Liao, Testa et al. 2015). Although loss of VHL is a key driver 
in the tumorigenesis of ccRCC, inactivation of this gene alone is not sufficient to 
cause ccRCC (Mandriota, Turner et al. 2002, Rankin, Tomaszewski et al. 2006). 
The VHL gene maps to chromosome 3p25 and is an established two-hit tumour 
suppressor gene, meaning that one allele is inactivated by mutation or promoter 
methylation and the other is inactivated through a large deletion resulting in loss 
of heterozygosity (LOH) (Gnarra, Tory et al. 1994, Gossage, Murtaza et al. 2014). 
Von Hippel-Lindau (VHL) gene mutations are associated with the development of 
both hereditary and sporadic clear cell renal carcinoma. The protein product of 
VHL (pVHL) forms an E3 ubiquitin ligase complex with Cul2 and Rbx1 that is able 
to regulate the hypoxia-inducible factor-1 (HIF-1), however the relationship 
between this function and ccRCC development is not clear (Mandriota, Turner et 
al. 2002, Liao, Testa et al. 2015). It has been demonstrated that in the kidneys of 
patients with VHL disease, HIF activation is an early event occurring in 
morphologically normal single cells within the renal tubules (Mandriota, Turner 
et al. 2002).  
 
1.3.1.1. The role of Hypoxia Inducible Factor (HIF) in ccRCC 
 
VHL is mutated in both hereditary kidney cancer as well as spontaneous clear cell 
renal cell carcinoma (Liao, Testa et al. 2015). The heterodimeric transcription 
factor hypoxia-inducible factor (HIF) contains α-subunits that are targeted by the 
VHL containing E3 ubiquitin ligase complex, resulting in poly-ubiquitination and 
proteosomal destruction (Liao, Testa et al. 2015). When HIFα is hydroxylated on 
either of the two prolyl residues by members of the Egl nine homolog family 
(otherwise known as either prolyl hydroxylase domain-containing proteins or 
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HIF prolyl hydroxylases), it can then be recognised by pVHL (Liao, Testa et al. 
2015). A loss or inactivation of pVHL promotes the synthesis and accumulation 
of HIFα proteins, which then form a complex with HIF1β protein, resulting in the 
activation of a transcriptional response to hypoxia in the nucleus (Liao, Testa et 
al. 2015). Not all HIF-induced genes result in tumour development (Niu, Zhang et 
al. 2012), however constituently active HIF activity is known to promote 
tumourigenesis and stimulate growth in ccRCC tumours (Kaelin 2005). 
Activation of HIF is thought to be an important step in the development of VHL 
mutant ccRCC. Development of VHL mutant ccRCC has been described as a 
sequence of events, starting with the loss of VHL activity, followed by the 
consequential activation of the HIF pathway, followed by interaction of the HIF 
pathway with other oncogenic pathways, resulting in genome-wide epigenetic 
changes and further inhibition of multiple tumour suppressor genes, finally 
ending with immune evasion (Shenoy and Pagliaro 2016). 
 
1.3.2. Intratumour heterogeneity and branched evolution 
 
Vast heterogeneity within individual tumours has been identified by large-scale 
sequencing analysis of solid tumours (Parsons, Jones et al. 2008, Varela, Tarpey 
et al. 2011). Intratumour heterogeneity (ITH) is a phenotype expressed in ccRCC. 
Sequencing analysis of ccRCC recently identified multiple genetically distinct 
subclones within primary tumours and their metastases (Gerlinger, Rowan et al. 
2012), revealing that the evolution of ccRCC was branched, rather than occurring 
in a linear fashion (Figure 1.10) (Gerlinger, Horswell et al. 2014). Genetic 
complexity of a tumour identified by single-biopsy may be therefore 
underestimated if ITH is not taken in to consideration. In ccRCC, mutations in VHL 
or PBRM1 are thought to be the main drivers or truncal mutations, however the 
clinical outcomes for patients with ccRCC can differ greatly from patient to 
patient. This is likely due to subclonal driver mutations acquired by tumours 
during progression (Gerlinger, Horswell et al. 2014). Subclonal driver events 
present in solid tumours may provide an explanation for the acquired resistance 
to targeted therapeutics in late stages of disease (Gerlinger, Horswell et al. 2014). 
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Greater knowledge of the evolution of truncal mutations and the consequential 
subclonal branches they form in ccRCC may be useful in future prediction of 
tumour evolution in patients and ultimately may be able to identify new targets 








































Figure 1.10. Phylogenetic tree for tumour analysis. Adapted from 
(Gerlinger, Rowan et al. 2012). Normal tissue that acquires a ubiquitous 
driver mutation forming the ‘trunk’, the ‘branches’ that arise from this driver 
mutation represent the intratumour heterogeneity displayed in ccRCC. 
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1.3.3. PBRM1 is another key tumour suppressor in kidney cancer 
 
Whole exome sequencing of ccRCC tumours has revealed that PBRM1, the gene 
that encodes BAF180, is mutated in over 40-50% of cases (Varela, Tarpey et al. 
2011). Found on chromosome 3p21, PBRM1 mutations lead to loss of protein and 
are typically associated with gross chromosomal aberrations, such as loss of 
heterozygosity (LOH) (Varela, Tarpey et al. 2011). While we know that PBRM1 is 
frequently mutated in ccRCC and is known to be a driver of this cancer, we still 
require a greater understanding of the molecular mechanism of how this gene 
acts as a tumour suppressor, before we can fully exploit it for the development of 
cancer therapies.  
PBRM1has multiple cellular functions that could contribute to tumorigenesis. 
This is the focus of our study and so will be discussed in much greater detail in 
Section 1.5, 
 
1.3.4. BAP mutations in cancer and its tumour suppressor role in 
ccRCC 
 
BRCA1- associated protein-1 (BAP1) is mutated in ccRCC at a frequency of around 
15% (Liao, Testa et al. 2015). It was first identified as a protein that interacted 
with BRCA1’s RING finger in a yeast two-hybrid screen (Jensen, Proctor et al. 
1998). In the study from Jensen et al, BAP1 was found to enhance BRCA1-
mediated inhibition of breast cancer cell growth and was suggested to be a new 
tumour suppressor gene that functions within the BRCA1 growth control 
pathway (Jensen, Proctor et al. 1998). BAP1 shares homology with the ubiquitin 
C-terminal hydrolases (UCH) family of deubiquitases and has deubiquitinase 
activity (Jensen, Proctor et al. 1998). As well as harbouring its deubiquitinase 
activity in its N-terminal domain, BAP1 also has a BARD1 interaction domain (BA), 
a UCH37 domain located in the C-terminus, a YY1-binding domain, two nuclear 
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localisation signals and its interaction with host cell factor-1 (HCF-1) requires its 
NHNY sequence (Liao, Testa et al. 2015).  
BAP1’s role in the BRCA1 growth control pathway is complex and not fully 
understood, however it is thought that BAP1, under circumstances such as in 
response to DNA damage, can then interact with BRCA1 (Yu, Pak et al. 2014).  
BAP1 has key roles not only in the DNA damage response (DDR), but in the 
control of cell cycle, cellular growth and regulation of chromatin architecture by 
de-ubiquitination of histone H2A (Piva, Santoni et al. 2015), and these 
subsequently allow for the promoters of several target genes to become 
accessible to transcription factors. It is interesting to note that BAP1 
deubiquitinates the mono-ubiquitinated K119 residue on histone H2A, however 
this does not seem to associate with its ability to repress cell growth (Liao, Testa 
et al. 2015). 
Mutations in BAP1 result in the development of metastases in uveal melanoma 
(UM) (Harbour, Onken et al. 2010) as well as other malignancies such as 
malignant pleural mesotheliomas (Bott, Brevet et al. 2011). BAP1 mutations have 
conflicting implications in cancer. They present as a paradox in which, both 
overexpression (Jensen, Proctor et al. 1998, Ventii, Devi et al. 2008), as well as 
knockdown (Pan, Jia et al. 2015), result in growth suppression and the down 
regulation of E2F-responsive growth-related genes. It has been postulated that 
this BAP1 paradox could be explained by BAP1 contributing to a delayed but 
more permissive G1/S checkpoint, where cells may in fact grow more slowly, but 
still in an uncontrollable manner (Bott, Brevet et al. 2011).  
As previously mentioned, BAP1 is mutated in uveal melanoma metastases, the 
most important cytogenetic predictor of this being the loss of chromosome 3. 
BAP1, like VHL and SETD2, is located on chromosome 3, specifically on the short 
(p) arm of chromosome 3, at band location 3p21, which is extremely close to the 
PBRM1 gene. Like VHL, BAP1 is modelled as a two-hit tumour suppressor in 
ccRCC, where the wild type allele compensates for the mutated allele (Piva, 
Santoni et al. 2015).  
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Mutations of BAP1 in ccRCC are mostly inactivating mutations and that in a large 
portion of tumours studied, were subclonal rather than ubiquitous.  
In almost all tumours where BAP1 is mutated, VHL is also inactivated. Mutation 
of VHL results in high allelic burden with mutations typically resulting in loss of 
heterozygosity (LOH), however tumours with subsequent mutations in BAP1 
tended to show this burden as being significantly lower. BAP1 mutations may be 
more likely to be acquired in tumours with pre-existing VHL mutations and 
therefore subsequently contribute to tumour progression because of selection 
pressure (Sato, Yoshizato et al. 2013).  
BAP1 mutations in ccRCC are associated with poor outcome, tumour 
aggressiveness and high Fuhrman grade, with more than 50% of tumours with 
mutant BAP1 exhibiting coagulative necrosis (Pena-Llopis, Vega-Rubin-de-Celis 
et al. 2012, Kapur, Pena-Llopis et al. 2013). 
As mentioned, BAP1 is frequently mutated in tumours with a driver mutation in 
VHL. BAP1 and PBRM1 mutations, however, appear to be mutually exclusive 
(Pena-Llopis, Vega-Rubin-de-Celis et al. 2012, Kapur, Pena-Llopis et al. 2013). 
When two genes function within the same pathway, they are often thought to 
have mutation exclusivity, however BAP1 and PBRM1 have been suggested to be 
involved in two separate processes as they are mutually exclusive in ccRCC 
(Brugarolas 2013). Evidence supporting this is first seen in the parallels in 
outcome prognosis after mutation in each gene. BAP1 mutations are associated 
with poor outcome and high Fuhrman grade as well as activation of mTORC1, 
however, PBRM1 mutant ccRCC’s are thought to be low grade, have a lack of 
mTORC1 activation and have a markedly better outcome (Pena-Llopis, Vega-
Rubin-de-Celis et al. 2012, Kapur, Pena-Llopis et al. 2013). Secondly, the gene 
expression signatures of BAP1-mutant and PBRM1-mutant tumours are highly 
specific and quite distinct from one another, which typically suggests tumours 
with different pathological features and different patient outcomes (Kapur, Pena-
Llopis et al. 2013). Therefore, it would not infer that BAP1 and PBRM1 mutations 
are mutually exclusive because they act in the same pathway, in fact, it would 
suggests that the mutations define two different molecular subtypes of ccRCC, 
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which have different biology, act in different pathways and result in markedly 
different outcomes (Brugarolas 2013). The mutual exclusive relationship 
between BAP1 and BAF180 could be exploited therapeutically by harnessing 
synthetic lethality, which will be further discussed in section (3.8.4). 
 
1.3.5. SETD2 in renal cancer 
 
Set domain-containing 2 (SETD2), a gene known to produce at least three 
alternative splicing transcripts that produce histone methyltransferases, is 
known to trimethylate histone H3 at lysine 36 (H3K36me3) (Piva, Santoni et al. 
2015). It is mutated in multiple cancers, including breast cancer and leukemias 
(Al Sarakbi, Sasi et al. 2009, Zhang, Ding et al. 2012), but first being identified as 
inactivating mutations in ccRCC in 2010 (Dalgliesh, Furge et al. 2010). It is now 
known to be mutated in 3-16% of all human ccRCC tumours (Wang, Liu et al. 2016) 
and is associated with loss of DNA methylation at non-promoter regions (Piva, 
Santoni et al. 2015). Most cases of ccRCC with a SETD2 mutation were found to 
have either a VHL or PBRM1 mutation also, and as previously mentioned, all three 
genes map to chromosome 3p. This suggests that the mutations are functionally 
non-redundant and that physical linkage of these three genes may be the driver 
for the loss of fitness and the large scale 3p loss of heterozygosity (LOH) seen in 
over 90% of ccRCC cases, perhaps due to haploinsufficiency (Varela, Tarpey et al. 
2011).  
It has been hypothesised that there may be high selection pressure for mutations 
of SETD2 after analysis of different SETD2 mutations in a panel of multiple ccRCC, 
show a tendency to be subclonal and showed that different regions of the same 
tumour could harbour different SETD2 mutations(Gerlinger, Rowan et al. 2012). 
In one example given by Gerlinger et al, the same tumour was biopsied in multiple 
sites and within these sites three different SETD2 mutations were found, 
including a missense mutation, a splice-site mutation, and a frameshift deletion 
(Gerlinger, Rowan et al. 2012). It is interesting to note that the ubiquitous loss of 
one gene allele could provide a foundation for the subsequent loss of protein 
function, driven by different mutations that are regionally separated. Tumours 
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that harbour missense or frameshift mutations of SETD2 have notably down-
regulated trimethylation of H3K36 (Gerlinger, Rowan et al. 2012), which would 
suggest active transcription would not be carried out in these regions, however 
the H3K36me3 signature has also been linked with alternative splicing as well as 
transcriptional repression (Wagner and Carpenter 2012), making it unclear what 
role this down-regulation of H3K36me3 by SETD2 mutation plays in the biology 
of ccRCC.  
In context of the DNA damage response, SETD2 is known to play an important 
role. It is thought to act in a similar way to RAD51, in that it promotes the repair 
of DNA DSB’s through homologous recombination, by facilitating the recruitment 
of repair proteins (Pfister, Ahrabi et al. 2014). SETD2 mutated cancers are also 
thought to be unable to activate p53-mediated checkpoints, without the need for 
additional mutations in TP53, a known guardian of the genome that is very rarely 
mutated in ccRCC (Carvalho, Vitor et al. 2014).  
SETD2 plays a significant role in ccRCC disease progression and like BAP1 
mutations, is typically associated with poorer cancer-specific survival (CSS) 
(Hakimi, Ostrovnaya et al. 2013). However, unlike BAP1 mutations that are 
typically mutually exclusive with PBRM1 mutations, SETD2 mutations are often 
found to occur in tumours where PBRM1 was mutated more frequently that 
would be expected by chance alone, suggesting some level of cooperation 
between the loss of these two genes in the tumorigenesis of ccRCC (Pena-Llopis, 
Christie et al. 2013). While this study focuses on mutant PBRM1 ccRCCs, it is still 
important to note that study of SETD2 mutant cancers could too have 
translational potential in the clinic.  
 
1.3.6. JARID1C/KDM5C mutation in ccRCC 
 
Trimetylation of Histone H3 at Lysine 4 (H3K4me3) is an epigenetic modification, 
which identifies the transcription start sites (promoters) of active genes 
(Benayoun, Pollina et al. 2014). The methylation state of the lysine residues of 
histone H3 and the modification that takes place here is implicated in 
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transcriptional control by its regulation of chromatin structure (Varela, Tarpey et 
al. 2011). JARID1C, also known as KDM5A, is a histone demethylase that removes 
a methyl group from lysine 4 on histone H3 (H3K4Me3) and is mutated in 3-7% 
of ccRCC tumours, most of which are subclonal mutations (Dalgliesh, Furge et al. 
2010, Liao, Testa et al. 2015). JARID1C mutation is linked with poor prognosis of 
ccRCC patients, having an association with advanced tumour stage and grade as 
well as overall tumour invasiveness (Sankin, Hakimi et al. 2014). Amplification or 
mutation of JARID1C can also be observed in other urological malignancies, such 
as prostate adenocarcinoma and papillary RCC to name a few (Liao, Testa et al. 
2015). As mentioned previously, HIF’s are known to increase the transcription of 
histone demethylases and so, unsurprisingly, JARID1C mRNA and protein 
expression are HIF-dependent (Niu, Zhang et al. 2012). VHL negative cells have 
low levels of H3K4me3 and this could be due to reduced methyltransferase 
activity or increased demethylase activity, or both. It has been suggested that 
there could be a HIF-induced JARID1C negative feedback loop that could be linked 
to tumour size. This model would see a loss of JARD1C leading to an increase in 
H3K4me3 in VHL-defective kidney cancer and would therefore form larger 
tumours (Niu, Zhang et al. 2012) 
 
1.3.7. UTX/KDM6A mutation in ccRCC 
 
The trimethylation of histone H3 at lysine 27 is the most prominent histone 
modification that is associated with transcriptional repression. Enzymes that 
modify this site, such as EZH2, are frequently mutated in cancer (Yamaguchi and 
Hung 2014). UTX, otherwise known as KDM6A, is a H3K27 demethylase that is 
mutated at low frequencies in ccRCC and at higher levels in bladder cancer and 
others (van Haaften, Dalgliesh et al. 2009, Dalgliesh, Furge et al. 2010, Liao, Testa 
et al. 2015). UTX mutations in a study of ccRCC samples, were found in a subset 
of cancer cells within a tumour, meaning these mutations are subclonal rather 
than driver mutations, although little is known about them and how they impact 
ccRCC tumorigenesis at present (Liao, Testa et al. 2015).  
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1.4. SWI/SNF Remodelling Family 
 
Originally identified in S. cerevisiae by both genetic screens and biochemical 
purification, the SWI/SNF (switching defective/sucrose nonfermenting) family of 
chromatin remodelers are typically composed of 8 to 14 subunits (Clapier and 
Cairns 2009). The SWI/SNF subfamily of complexes work to remodel chromatin 
by moving or ejecting nucleosomes, allowing for the proper frequency and 
positioning of nucleosomes at genes and other loci (Kasten, Clapier et al. 2011). 
The complex, in most eukaryotes, centres around two variant catalytic subunits, 
which subsequently form two well-defined members of this sub-family of 
chromatin remodelers, BAF and PBAF (Brownlee, Meisenberg et al. 2015). The 
BRG1 catalytic subunit belongs to the PBAF complex, whereas the BAF complex 
can contain either BRG1 or BRM (Table 1) (Brownlee, Meisenberg et al. 2015).  
BRG1 and BRM are both catalytic ATPase subunits, comprised of an N-terminal 
HSA (helicase-SANT) domain, a post-HSA domain that is split in to two areas 
separated by a linker, called DExx and HELICc, as well as a C-terminal 
bromodomains (Clapier and Cairns 2009). Both BAF and PBAF share a number of 
core and accessory subunits and have additional subunits that are unique to each 
complex (Figure 1.11). As mentioned previously, the genes that encode these 
subunits are frequently mutated in human cancers, earning their title as tumour 
suppressor genes (Shain and Pollack 2013). SWI/SNF complexes have a well-
described role in the regulation of gene expression (Wilson and Roberts 2011, 
Romero and Sanchez-Cespedes 2014, Masliah-Planchon, Bieche et al. 2015). 
More recently, SWI/SNF has been found to play a vital role in transcription-
independent pathways, contributing to genome stability via DNA repair, sister 
chromatid cohesion and the DNA damage response (Brownlee, Meisenberg et al. 
2015).  
 
1.4.1. Discovery of the RSC chromatin remodelling complex 
 
The SWI/SNF-family of chromatin remodelers exists as SWI/SNF and RSC 
(remodels the structure of chromatin) in budding yeast, with RSC being ten times 
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more abundant than SWI/SNF (Cairns, Lorch et al. 1996). The yeast SWI/SNF 
(ySWI/SNF) was first identified by genetic screening in 1984, where yeast 
mutants defective in either mating-type switching (swi mutants) or sucrose 
fermentation (snf mutants) were screened together (Neigeborn and Carlson 1984, 
Stern, Jensen et al. 1984, Breeden and Nasmyth 1987). The identification of RSC 
came slightly later, being isolated by mass spectrometry and limited sequence 
analysis based on the homology to the ySWI/SNF complex (Cairns, Lorch et al. 
1996). The RSC subunits known to date are; Sth1, Rsc1, Rsc2, Rsc3, Rsc4, Rsc5, 
Rsc6, Rsc7, Rsc8/Swh3, Rsc9, Rsc10/Rsc56, Rsc14/Ldb7, Htl1, Sfh1, Arp7, Arp9 
and Rtt102 (Kasten, Clapier et al. 2011), at least three of which are homologous 
to the ySWI/SNF components (Cairns, Lorch et al. 1996). The catalytic ATPase 
‘core’ subunit of RSC, Sth1, closely resembles the ySWI/SNF catalytic subunit 
Swi2/Snf2, both being activated by single-strand, double-strand and nucleosomal 
DNA (Cairns, Lorch et al. 1996). As well as having similarities within the ATPase 
catalytic subunits, there is an extended conservation of four core subunits, 
Swi2/Snf2, Swp73, Swi3 and Snf5 in ySWI/SNF and their RSC homologs Sth1, 
Rsc6, Rsc8 and Sfh1 (Figure 1.11). This homology extends to higher eukaryotes, 
such as human SWI/SNF (hSWI/SNF), suggesting that conservation of the core 
proteins is functionally important (Cairns, Lorch et al. 1996), either to maintain 
the complex integrity or to preserve remodelling activity (Tang, Nogales et al. 
2010). RSC and ySWI/SNF have many similarities, however, they are thought to 
regulate different regions of chromatin and the function of RSC is vital for cell 
survival (Tang, Nogales et al. 2010). It is plausible that the addition/subtraction 
of accessory subunits allows for this more specialised function of RSC, just as the 
addition of novel subunits to mammalian BAF and PBAF (Figure 1.11), for 
example, can allow for selective regulation of certain genes and functional 





















































































































































1.4.2. The RSC complex can exist as two distinct isoforms 
 
It is known that in budding yeast, the RSC complex can exist as two related 
complexes containing either Rsc1 or Rsc2 (Cairns, Schlichter et al. 1999). The RSC 
complex, as previously described, was identified from yeast extracts in 1996 
(Cairns, Lorch et al. 1996). Rsc1 and Rsc2 are similar in domain architecture, 
being composed of two bromodomains, an AT hook motif, a bromo-adjacent 
homology (BAH) domain and two regions in the carboxyl termini (C-terminal) of 
high and moderate identity respectively, CT1 and CT2 (Figure 1.12) (Cairns, 
Schlichter et al. 1999). The mammalian PBAF complex, interestingly carries a 
subunit, BAF180, which consists of six bromodomains, two BAH domains and a 
high-mobility group (HMG), therefore appearing to be a fusion of the yeast Rsc1, 
Rsc2 and Rsc4 (Figure 1.13) (Goodwin and Nicolas 2001, Mohrmann and 
Verrijzer 2005, Chambers, Pearl et al. 2013).  
 
1.4.2.1. Bromodomains and AT hook functionality in RSC 
 
Bromodomains, such as the ones found in the Rsc components as well as in many 
other proteins, are important for the regulation of transcription and the 
structural integrity of chromatin (Cairns, Schlichter et al. 1999). They exist as 
110-amino acid acetyl-lysine binding motifs (Dhalluin, Carlson et al. 1999), 
binding to the amino-terminal tails of histones H3 and H4 (Ornaghi, Ballario et al. 
1999). The second bromodomain (BD2) of Rsc1 and Rsc2 (Figure 1.12), with the 
BAH and C-terminal domain, are entirely required for function, where loss or 
mutation of these areas results in null phenotypes (Cairns, Schlichter et al. 1999). 
However, the first bromodomain (BD1) and the AT hook are only required in a 
subset of functions. Rsc1 can lose BD1 without impeding any function, however 
in Rsc2, BD1 was found to be required for its function in media supplemented 
with caffeine (effecting osmotic stability and cAMP signalling), a demonstration 
that Rsc1 and Rsc2 bromodomains are functionally distinct (Cairns, Schlichter et 
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al. 1999). The bromodomains found in the Rsc4 subunit of RSC, appear in tandem 
and both preferentially bind at different sites. It is thought that the BD1 domain 
binds directly to Rsc4 itself at the acetylated lysine K25, whereas the BD2 domain 
binds the acetylated lysine at K14 of histone H3 (H3K14ac) (VanDemark, Kasten 
et al. 2007). Gcn5 has activating and inhibitory roles with Rsc4, it is known that 
Gcn5 acetylates the ligands for BD1 and BD2, K25 and H3K14 respectively. These 
acetylated ligands are then thought to compete for binding to Rsc4, however it is 
known that Rsc4 K25 acetylation directly inhibits Rsc4 binding to acetylated 
H3K14. It has therefore been postulated that there is an auto-regulatory 
mechanism, with Gcn5 acting as a switch for RSC at sites of remodelling. In this 
model, Gcn5 would promote RSC-nucleosome binding by acetylation of H3K14, 
therefore enabling remodelling, with the subsequent acetylation of K25, releasing 
RSC from the interaction (VanDemark, Kasten et al. 2007).   
 
AT hooks (Figure 1.12) associate preferentially with the minor groove of AT-rich 
DNA and were first identified as short DNA-binding motifs in the high-mobility 
group chromosomal protein HMG-I (Reeves and Nissen 1990, Aravind and 
Landsman 1998). The functional domains of chromatin proteins and DNA-
binding proteins, such as histone folds and zinc fingers, are known to associate 
with AT hooks and they are commonly found preceding bromodomains by 20-40 
amino acids (Cairns, Schlichter et al. 1999). It is thought that these AT hooks can 
facilitate changes in the structure of DNA either cooperating as part of a protein 
with multiple domains, like Swi2 in yeast, or as a single polypeptide, as in HMG-I 
(Aravind and Landsman 1998). In RSC, it is thought that the AT hook is only 
required for Rsc1, but not Rsc2 functions. The cooperation between AT hooks and 
bromodomains may facilitate specific interactions with defined nucleosomes. For 
example the AT hook in the catalytic subunit BRM of the BAF mammalian 
SWI/SNF complex has been found to bind DNA as well affecting the complexes 
association with chromatin (Bourachot, Yaniv et al. 1999). In contrast, the RSC 
catalytic subunit Sth1, does not contain an AT hook, therefore these specific 




























Figure 1.12. Rsc1, Rsc2 and Rsc4 are bromodomain containing 
members of RSC. Adapted from (Cairns, Schlichter et al. 1999). 
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1.4.2.2. BAH domain function in RSC  
 
First identified in the chicken polybromo (BAF180) protein (gPB) (Nicolas and 
Goodwin 1996), Bromo-adjacent homology (BAH) domains are often associated 
with chromatin proteins, protein complexes and proteins that facilitate gene 
transcription and repression and are thought to be involved in protein-protein 
interactions (Goodwin and Nicolas 2001). BAH domains interact with 
nucleosomes and can be classified in two ways, the first being, ‘Remodels the 
Structure of Chromatin (RSC)-like’, which can be found in the yeast Rsc1 and Rsc2 
and their mammalian homologue BAF180 (Chambers, Pearl et al. 2013). RSC-like 
BAH domains can also be found in transcription factors, such as Ash1, as well as 
the CpG-DNA methylase DNMT1 (Oliver, Jones et al. 2005). Secondly, BAH 
domains can be classified as ‘Silent information regulator 3 (Sir3)-like’ and this 
classification includes Orc1 homologues and the Sir3 protein found in budding 
yeast (Chambers, Pearl et al. 2013).  
The BAH domains of Orc1 and Sir3 have a key role in the mediation of 
transcriptional silencing at telomeres (Norris and Boeke 2010) and can both bind 
nucleosomes (Noguchi, Vassilev et al. 2006, Onishi, Liou et al. 2007, Norris, 
Bianchet et al. 2008, Muller, Park et al. 2010). Interestingly Orc1 BAH domain 
nucleosome binding in mammals is determined by an interaction with the tail of 
histone H4 dimethylated at lysine 20, whereas the Sir3 BAH domain interacts 
with both H3 and H4, by binding nucleosomes at the Loss of Ribosomal Silencing 
(LRS) region of the nucleosome. As well as being able to bind nucleosomes, the 
Orc1 BAH domain can interact with the silent information regulator Sir1 and the 
heterochromatin-associated protein HP1 in yeast and higher eukaryotes 
respectively.  
In the context of RSC, it is known that the BAH domains of both Rsc1 and Rsc2 are 
required for function and viability, but have no role in the assembly of the 
complex and relatively little is known about their binding partners (Cairns, 
Schlichter et al. 1999). However, recently in our lab, it was found that the Rsc2 
BAH domain is able to bind specifically with histone H3 as well as being important 




1.4.2.3. Structural conformation of RSC 
 
The structure of the RSC complex has been determined using cryo-electron 
microscopy, revealing a ring of protein densities around a large central cavity 
with the size and shape that would be appropriate for nucleosome binding 
(Asturias, Chung et al. 2002). It has been suggested that this cavity acts as a 
nucleosome binding pocket, due to the observation that addition of nucleosomes 
to the complex experimentally leading to an increase in density in this region 
(Lorch, Cairns et al. 1998, Asturias, Chung et al. 2002, Skiniotis, Moazed et al. 
2007). To accommodate a nucleosome in this binding pocket, RSC can exist in two 
conformations, ‘open’ and ‘closed’, which were determined when Rsc2-RSC 
(Leschziner, Saha et al. 2007) as well as the mixture of Rsc1-RSC and Rsc2-RSC 
were analysed (Skiniotis, Moazed et al. 2007, Chaban, Ezeokonkwo et al. 2008). 
The open conformation is thought to allow the entrance or release of a 
nucleosome, whereas in the closed conformation the movement/conformation of 
the distal portion of the bottom domain or ‘arm’, which becomes very close in 
proximity, is the most important for enveloping the docked nucleosome (Chaban, 
Ezeokonkwo et al. 2008). The dynamically mobile distal portion of RSC is thought 
to be stabilised by the presence of acetylated histone H3 N-terminal tail peptides 
(Skiniotis, Moazed et al. 2007). A portion of the complexes formed by the mixture 
of both Rsc1-RSC and Rsc2-RSC isoforms were found to appear in a third 
conformation, where ~16% of the complexes had either a reduced density or 
were completely lacking part of the distal arm, a conformation that could be 
attributed to Rsc1 isoform specificity (Skiniotis, Moazed et al. 2007, Chambers 
and Downs 2012).  
 
1.4.2.4. Biochemical activity of RSC 
 
In vitro assays have been carried out on mixed populations of Rsc1 and Rsc2-
containing complexes as well as Rsc2 only containing complexes to establish the 
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biochemical activity of these chromatin remodelers. From these studies, the RSC 
complex is known to be involved in nucleosome remodelling, repositioning, 
disassembly and histone octamer transfer. DNA of at least 25bp in length is 
thought to be able to stimulate the ATPase activity of the RSC complex, at a rate 
of ~7.5 molecules ATP/second under optimal conditions, which is not further 
stimulated by the addition of nucleosomes (Cairns, Lorch et al. 1996, Boyer, Logie 
et al. 2000, Saha, Wittmeyer et al. 2002). The catalytic Sth1 subunit, when 
compared to the intact Rsc2-RSC complex, is thought to have approximately 2.5 
times lower ATPase activity, suggesting that the cooperation of the other RSC 
subunits is necessary for maximal complex activity (Saha, Wittmeyer et al. 2002). 
Using atomic force microscopy, RSC was found to form relaxed supercoiled loops 
of around 400-700bp or 20-1200bp respectively on DNA that was tethered and 
stretched at low forces as well as on nucleosomal templates (Lia, Praly et al. 2006, 
Zhang, Smith et al. 2006). The loops formed in an ATP-dependent manner and 
slippage was observed in both templates. However, a greater translocation 
rate, >500bp/s compared to 12bp/s, was seen in the naked DNA, rather than the 
nucleosome-bound DNA template. The loops formed may provide a molecular 
basis for the functions of chromatin remodelling complexes (Zhang, Smith et al. 
2006). It has been suggested that these loops may cause the formation of a bulge 
of DNA on the nucleosome surface that has the capability of forming a larger loop 
by translocation and on dissolution of this large loop can facilitate remodelling 
activities such as reverse translocation, nucleosome position jump or nucleosome 
sliding (Chambers and Downs 2012). 
 
1.4.2.5. In vivo functions of RSC 
 
It has been well established that the RSC complex is important for the activation 
and repression of transcription of multiple genes in S. cerevisiae and is found to 
be co-immunoprecipitated with all three RNA polymerases (Angus-Hill, 
Schlichter et al. 2001, Ng, Robert et al. 2002, Soutourina, Bordas-Le Floch et al. 
2006). The RSC complexes role in vivo isn’t restricted to transcriptional control 
however, it is also thought to be important for proper kinetochore function (Hsu, 
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Huang et al. 2003), adaption to the spindle assembly checkpoint (Rossio, Galati et 
al. 2010), correct localisation of the nuclear pore complex (Titus, Dawson et al. 
2010), and sister chromatid cohesion (Baetz, Krogan et al. 2004) to name a few.  
 
1.4.3. Mammalian SWI/SNF exists as BAF and PBAF 
 
As previously described, mammalian SWI/SNF can exist as the BRG1- or hBRM-
associated factor (BAF or SWI/SNF-A) or the polybromo BRG1-associated factor 
(PBAF or SWI/SNF-B) complexes (Wilson and Roberts 2011). Two mutually 
exclusive catalytic ATPase subunits define each complex, either brahma 
homologue (BRM) or BRM/SWI2-related gene 1 (BRG1), with the BAF complex 
containing BRG1 or BRM and the PBAF complex containing only BRG1 (Table 1.1) 
(Wilson and Roberts 2011). Both complexes contain a set of highly conserved 
‘core’ subunits, SNF5, BAF155 and BAF170 (Table 1.1). Variant subunits associate 
with each complex and are thought to facilitate complex targeting, assembly and 
the regulation of lineage-specific functions of each complex (Wang, Cote et al. 
1996, Phelan, Sif et al. 1999, Wilson and Roberts 2011). Subunits unique to the 
BAF complex include, AT-rich interactive domain-containing protein 1A (ARID1A) 
and ARID1B and subunits that are unique to the PBAF complex include, BAF180, 
BAF200 and bromodomain-containing 7 (BRD7) (Wang, Cote et al. 1996, Wang, 
Nagl et al. 2004, Mohrmann and Verrijzer 2005, Kaeser, Aslanian et al. 2008). 
SWI/SNF complexes are able to remodel nucleosome structure by the 
mobilisation of nucleosomes by sliding and by catalysing the ejection and 
insertion of histone octamers (Saha, Wittmeyer et al. 2006, Wilson and Roberts 
2011).  The sequential steps of nucleosome sliding are thought to be initiated by 
SWI/SNF complex binding to a fixed position of nucleosome DNA, followed by the 
disruption of histone-DNA contacts, the ATPase subunit then can translocate DNA 
and DNA loop formation can then propagate around the nucleosome and 
subsequently generate sites that are accessible to DNA binding factors (Saha, 
Wittmeyer et al. 2006, Lorch, Maier-Davis et al. 2010, Wilson and Roberts 2011). 
Less is known about the mechanism employed for nucleosome ejection and 
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insertion, however it may be aided by histone chaperones. It has been suggested 
that histone ejection may not occur at nucleosomes directly bound by SWI/SNF 
complexes, but rather at adjacent nucleosomes as a consequence of repositioning 
the bound nucleosome (Dechassa, Sabri et al. 2010). SWI/SNF complexes may 
have effects on higher order chromatin structure other than nucleosome 
remodelling, which is the most studied, and this could be due to the complexes 



















Table 1.1. SWI/SNF subunits. Taken from (Brownlee, Meisenberg 
et al. 2015). 
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SWI/SNF complexes were originally identified in budding yeast because of their 
roles in transcriptional activation, but there is mounting evidence to suggest roles 
for mammalian SWI/SNF in transcriptional repression as well as activation. Some 
examples of the duality of the subunits in these complexes are highlighted below.  
For example, BRG1 and BAF57 are required for the reciprocal regulation of 
CD4/CD8 expression, acting to silence CD4 and to activate CD8 expression during 
mammalian T lymphocyte development (Chi, Wan et al. 2002). BRG1 is also 
thought to act as both a repressor that inhibits programs linked to differentiation 
and a facilitator of the expression of core pluripotency programmes in the BAF 
complex of embryonic stem cells (Ho, Jothi et al. 2009). 
It was discovered that SNF5 deletion in murine fibroblasts (MEFS) leads to 
transcriptional activation (Isakoff, Sansam et al. 2005). In gene expression arrays 
comparing SNF5 deleted MEFS to appropriate controls, significantly more genes 
were defined as being upregulated compared to those that were down regulated 
(Isakoff, Sansam et al. 2005). Conversely to this, SNF5 has also been implicated in 
the repression of transcription. It is known that histone deacetylases (HDACs) 
can be recruited by SWI/SNF complexes, to aid the removal of transcriptionally 
activating acetyl marks from histone tails. SNF5 was found to exert tumour 
suppressor activity by mediating cell cycle arrest by the direct recruitment of 
HDAC activity to the cyclin D1 (CCND1) promoter and therefore causing 
repression (Zhang, Davies et al. 2002). The PBAF complex is also thought to have 
a role in DNA induced transcriptional repression, which will be discussed further 
in section 1.5.  
These data suggest that mammalian SWI/SNF complexes have dynamic and 
essential roles in many gene expression programs by regulating both activation 






1.4.3.1. Epigenetic antagonism between Polycomb and SWI/SNF 
complexes 
 
The dynamic structure of chromatin is regulated by two classes of enzymes: those 
that mediate covalent modifications on either histone proteins or DNA, like the 
Polycomb (PcG) complex, and those that use energy created from ATP hydrolysis 
to remodel chromatin structure, like the SWI/SNF complexes.   
There are two main PcG complexes; polycomb repressive complex 1 (PRC1) and 
2 (PRC2). The catalytic subunit of the PRC2 complex is the protein 
methyltransferase, EZH2, and it is known to promote H3K27me3, a covalent 
chromatin modification associated with repressed heterochromatin. The 
H3K27me3 mark at PcG-regulated promoters facilitates PRC1 recruitment, 
subsequently repressing transcription by the BMI1-dependent promotion of H2A 
monoubiquitination at K119 (Cao, Tsukada et al. 2005). The catalytic activity of 
SWI/SNF complexes, mediated by either BRG1 or hBRM, results in a relaxed, open 
state of chromatin that is associated with active transcription. Epigenetic 
modifications, like those carried out by PcG and SWI/SNF complexes, can be 
defined as somatically heritable changes in gene expression that is derived from 
alterations in chromatin structure, rather than from DNA sequence changes. 
These modifications are important in cell fate decisions and have roles in 
oncogenic transformation (Jones and Baylin 2007, McKenna and Roberts 2009). 
However, unlike DNA mutations, epigenetic modifications are reversible and 
therefore are good targets for effective cancer therapy.  
The antagonistic relationship between PcG and SWI/SNF complexes toward their 
roles in development was first identified by analysis of Drosophila mutants 
(Kennison and Tamkun 1988). The mechanism by which this antagonism 
occurred was discovered to be that the PcG proteins maintain repression of Hox 
genes during embryogenesis, while the SWI/SNF complex promotes Hox gene 
activation (Kennison and Tamkun 1988).  
Mammalian complexes were also found to be antagonistic, due to PcG proteins 
counteracting the repositioning of nucleosomes and chromatin remodelling 
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carried out by the enzymatic activity of SWI/SNF (Shao, Raible et al. 1999, 
Francis, Saurin et al. 2001). A cancer based mechanistic relationship was 
identified between PcG and SWI/SNF when the SWI/SNF subunit, SNF5, was re-
expressed in a SNF5-deficient rhabdoid tumour cell line, resulting in increased 
activation of the tumour suppressor protein p16INK4a and removal of PcG proteins 
at the p16INK4a locus (Kia, Gorski et al. 2008). Additional evidence supporting a 
role for PcG and SWI/SNF complexes in cancer was seen when primary SNF5-
deficient tumours as well as primary cells with experimentally inactivated SNF5 
were found to have elevated EZH2 expression (Wilson, Wang et al. 2010). 
Elevation of EZH2 expression levels in both models infers that the effect is not a 
secondary consequence of oncogenic transformation. Wilson et al also showed 
that Polycomb targets are broadly H3K27-trimethylated and repressed in SNF5- 
deficient fibroblasts and cancers (Wilson, Wang et al. 2010). They also found that 
antagonism between the complexes is found in the regulation of stem-cell 
associated programs and that SNF5 loss activates those programs (Wilson, Wang 
et al. 2010). Furthermore in mouse models, inactivation of EZH2 blocks tumour 
formation that is driven by SNF5 loss (Wilson, Wang et al. 2010). 
An increase in EZH2 expression has also been reported in other types of cancer, 
some in which SWI/SNF mutations occur, for example ovarian and renal cell 
carcinomas (Wagener, Holland et al. 2008, Lu, Han et al. 2010). These data 
suggests there is an epigenetic antagonism between PcG and SWI/SNF complexes 
and this antagonism may be mechanistically important in the prevention of 
tumorigenesis. 
 
1.4.3.2. SWI/SNF and DNA repair 
 
As introduced in section 1.1.3, DNA double strand breaks can be repaired by HR 
or NHEJ. The choice between repair pathways after damaged DNA is recognised 
is thought to rely on the composition of chromatin that surrounds the break. 
Compaction of chromatin and the presence of active transcription prior to the 
induction of the break is thought to be important in the choice between repair 
pathways (Aymard, Bugler et al. 2014, Pfister, Ahrabi et al. 2014). 
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Both BAF and PBAF have been implicated in DNA double strand break repair via 
HR and NHEJ. Consistent with data from yeast, the SWI/SNF complex is recruited 
to sites of DNA DSBs and is thought to have a direct role at DNA lesions (Park, 
Park et al. 2006, Peng, Yim et al. 2009, Ogiwara, Ui et al. 2011). Several proteins 
and protein modifications have been implicated in the recruitment of SWI/SNF 
to damage. BRIT1 is known to interact with two subunits common to both BAF 
and PBAF, BAF170 and BAF155. It was found that globally and at DNA DSBs, 
BRG1 and hBRMs association with chromatin was impaired upon BRIT1 
depletion. Depletion of BRIT1 results in defects in both NHEJ and HR activity. 
Therefore BRIT1 may be important for the mediation of SWI/SNF complex 
recruitment to DSBs (Peng, Yim et al. 2009). Subunits of BAF, but interestingly 
not PBAF, were recently found to promote NHEJ in a model where I-SceI-induced 
DSBs, which require some end processing, were used to monitor NHEJ (Watanabe, 
Ui et al. 2014).  
In contrast, work in our lab identified that the PBAF, not BAF complex is required 
for the repair of a subset of DSBs in the area surrounding actively transcribed 
genes (Kakarougkas, Ismail et al. 2014). This is thought to reflect NHEJ activity as 
it was epistatic with LIGIV when repair was analysed following irradiation 
(Kakarougkas, Ismail et al. 2014). We have speculated that neither BAF or PBAF 
is essential for NHEJ, but perhaps that BAF might promote resection-mediated 
end joining, while PBAF may be required for NHEJ in the vicinity of actively 
transcribed genes (Jeggo and Downs 2014). 
Histone acetylation has also been implicated in mediating the recruitment of 
SWI/SNF to chromatin at sites of DNA damage (Lee, Park et al. 2010, Ogiwara, Ui 
et al. 2011). At DSBs, histones H3 and H4 are acetylated by the histone 
acetyltransferase (HAT), CBP/p300. hBRM recruitment to DNA DSBs is impaired 
when CBP/p300 was ablated (Ogiwara, Ui et al. 2011). Recent work in our lab has 
also identified a role for BAF180 in the replication of damaged DNA, by repriming 
stalled replication forks (Niimi, Chambers et al. 2012, Niimi, Hopkins et al. 2015). 




1.4.3.3. Mutation spectrum of SWI/SNF subunits 
 
SWI/SNF mutations are widespread across a diverse range of human cancers 
(Reisman, Glaros et al. 2009, Weissman and Knudsen 2009, Wilson and Roberts 
2011). SNF5 is a SWI/SNF subunit with a well characterised role as a tumour 
suppressor. It is known to be homozygously inactivated in nearly all rhabdoid 
tumours, a rare paediatric malignancy (Versteege, Sevenet et al. 1998). 
Consistent with this, SNF5 knockout mice are prone to forming similar tumours 
(Roberts, Galusha et al. 2000). SNF5 and other SWI/SNF subunit mutations, for 
example BRG1, have also been implicated in lung cancer (Medina, Carretero et al. 
2004, Medina, Romero et al. 2008). 
Whole exome sequencing surveys of human cancers have identified frequent 
mutations in SWI/SNF subunits in various single cancer types (Jones, Wang et al. 
2010, Wiegand, Shah et al. 2010, Birnbaum, Birnbaum et al. 2011, Li, Zhao et al. 
2011, Varela, Tarpey et al. 2011, Wang, Kan et al. 2011, Shain, Giacomini et al. 
2012). To appreciate the spectrum of human cancers with SWI/SNF subunit 
mutations on a larger scale, Shain and Pollack exploited whole-exome sequencing 
studies, mining 24 studies, representing 669 patient samples across 18 different 
cancer diagnosis (Shain and Pollack 2013) . Strikingly, SWI/SNF mutations rates 
were highest in ovarian clear cell carcinoma, with 75% of the samples harbouring 
a mutation. SWI/SNF mutations were also found in clear cell renal cell carcinoma 
(57%), hepatocellular carcinoma (40%), gastric cancer (36%), melanoma (34%) 
and pancreatic cancer (36%) (Shain and Pollack 2013). The overall rate of 
mutation across all tumour types for SWI/SNF subunits was 19%, rivalling that 
of TP53, comparatively mutated at 26% across all tumour samples (Shain and 
Pollack 2013). The authors show that SWI/SNF genes with mutations had an 
increased tendency to be deleterious mutations, i.e. frameshift, nonsense, 
rearrangement, splice-site and missense-damaging) at a frequency greater than 
predicted, compared to missense-benign and missense-damaging. Thus, 
SWI/SNF mutations are most likely driver mutations (Shain and Pollack 2013). 
Of the SWI/SNF mutations identified in this study, the majority appeared to 
preferentially effect the enzymatic and targeting subunits, inferring they may be 
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critical for SWI/SNF function. ARID1A (9%), PBRM1 (4%), SMARCA4 (3%), 
ARID1B (2%) and ARID2 (2%) were the five most frequently mutated SWI/SNF 
genes, with other mutations being found in scaffolding subunits at much lower 
rates (Shain and Pollack 2013). The main impact of mutations may be to 
compromise in part or whole the functional activity of SWI/SNF, reinforced by 
the fact that mutations were found across a varied range of SWI/SNF subunits 
(Shain and Pollack 2013). Assessing the frequency at which SWI/SNF gene 
mutations occur together with other mutations in known oncogenic or tumour 
suppressor pathways revealed that SWI/SNF and TP53 mutations are frequently 
mutually exclusive (Kadoch, Hargreaves et al. 2013). ARID1A and TP53 
mutations, for example, were found to be mutually exclusive, but coincided with 
PIK3CA and CTNNB1 mutations in clear-cell ovarian carcinoma (Kadoch, 
Hargreaves et al. 2013). 
SWI/SNF is known to control the expression and activity of specific genes and 
pathways including, Rb, TP53, Polycomb, sonic hedgehog, Myc, stem cell 
programs and nuclear hormone receptor signalling (Guan, Wang et al. 2011, 
Wilson and Roberts 2011). The regulation of these genes/pathways may be how 
SWI/SNF exerts its tumour suppressor activity. We also know that SWI/SNF, 
specifically PBAF, have roles in the DNA damage response as well as in correct 
sister chromatid cohesion. It is well known that defects in the DNA damage 
response and sister chromatid cohesion can contribute to tumorigenesis, 
therefore SWI/SNF complexes, namely PBAF, may exhibit their tumour 
suppressing function by the regulation of these factors. I will develop this theory 




1.5. The BAF180 subunit of PBAF  
 
BAF180 is a protein encoded for by the Polybromo-1 (PBRM1) gene and is one of 
three subunits that are unique to the PBAF (SWI/SNF-B) chromatin remodelling 
complex, with the other two being BRD7 and ARID2. These unique subunits 
distinguish the PBAF complex from the BAF (SWI/SNF-A) complex (Wilson and 
Roberts 2011).  
Little is known about the specific biological functions of BAF180, however its high 
mutation in cancer has suggested its role as a tumour suppressor gene. BAF180 
is mutated in a diverse range of cancers, for example in bladder cancer (Huang, 
Peng et al. 2015) and in breast cancer (Xia, Nagase et al. 2008, Mo, Li et al. 2015), 
but its strikingly high mutation frequency in clear cell renal cell carcinoma (ccRCC) 
has drawn the most attention.  
BAF180 is the second most frequently mutated gene in (ccRCC) and is thought to 
be mutated at a frequency of around 41% in all ccRCC (Varela, Tarpey et al. 2011), 
however this is reportedly higher in other studies, with some showing mutation 
frequency at ~50% (Brugarolas 2013). Mutation of BAF180 is believed to be an 
early event in carcinogenesis, but how it functions as a tumour suppressor is not 
well understood. As described previously, ccRCC is a disease that effects several 
thousands of people, with very limited treatment options and poor prognosis, 
therefore the continued study of BAF180 and its function as a tumour suppressor 
is important for the progression of new cancer therapeutics.  
 
1.5.1. BAF180 structure and domains 
 
BAF180 is conserved from yeast to humans, with BAF180 appearing to be a fusion 
of the budding yeast genes Rsc1, Rsc2 and Rsc4 (Figure 1.13) (Chambers, Pearl et 
al. 2013). BAF180 contains six tandem bromodomains responsible for binding 
acetylated histones, two bromo-adjacent homology (BAH) domains that can 
mediate protein-protein interactions and a high-mobility group (HMG) box that 
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can bind nucleosomal DNA (Figure 1.13) (Wilson and Roberts 2011, Brownlee, 
Chambers et al. 2012). The functional activity of these domains, in particular the 
bromodomains and their binding of acetylated histones, is thought to facilitate 
the recruitment, targeting, retention and orientation of the PBAF complex on 
chromatin (Brownlee, Chambers et al. 2012). The binding targets of BAF180’s 
bromodomains are yet to be conclusively identified. Two studies to date have 
examined the ability of BAF180’s bromodomains to bind acetylated histone 
peptides and they come to different conclusions. In one study they found that the 
first five bromodomains of BAF180 had binding affinity with different acetylated 
peptides, BD1-H3K4Ac, BD2-H3K9Ac, BD3-H3K9Ac, BD4-H3K23Ac and BD5-
H3K14Ac, with BD6 having no preference for any of the tested H3 peptides 
(Chandrasekaran and Thompson 2007). Contrary to this study, another found 
entirely different binding of BAF180s bromodomains to acetylated peptides, 
observing binding between BD1 and H3K36Ac, BD2 and K3K14Ac and 
H2BK116Ac, BD3 and H3K115Ac, H4K12Ac, H2BK15Ac and H2BK120Ac, BD4 
and H3K14Ac and H3K11Ac, BD5 and H3K36Ac and BD6 and H2BK24Ac and 
H2BK116Ac (Charlop-Powers, Zeng et al. 2010). It is unusual that these two 
studies come to such different conclusions as in each study all six bromodomains 
were individually expressed and purified before being used in in vitro binding 
assays, but perhaps the discrepancies could be accounted for in the different 
methodologies used by each lab (Brownlee, Chambers et al. 2012). This 
conflicting data does not help answer the question of what are the physiological 
targets of BAF180’s bromodomains. However, recent work in out lab has found 
that the BAH domain of Rsc2 and the homologous second BAH domain of 
mammalian BAF180 has the ability to bind to unmodified H3 (Chambers, Pearl et 
al. 2013). We can infer from this that the bromodomains of BAF180, like the BAH 
domains, may also have preference for histone H3, recognising acetylated lysine 
residues on this histone or neighbouring histones. 
It is unclear what role BAF180 plays in the prevention of tumorigenesis in cells, 
but what is known is that mutation within the bromodomains of BAF180 could 
lead to loss of function of the protein itself, potentially resulting in the onset of 






















































































































1.5.2. BAF180 and DNA damage 
 
It was shown recently that the yeast homolog of BAF180, Rsc2, has a role in 
repriming stalled replication forks at sites of damage (Niimi, Chambers et al. 
2012). DNA lesions, such as damaged bases, block DNA polymerases and in order 
to bypass the lesion, traditional DNA polymerases must be replaced for a group 
of specialised translesion synthesis (TLS) polymerases (Lehmann, Niimi et al. 
2007). Mono-ubiquitination of PCNA is required for this switching from 
replicative to TLS polymerases at stalled replication forks (Lehmann, Niimi et al. 
2007). RSC2 deletion, but not deletion of RSC1, results in a significant reduction 
in PCNA ubiquitination after DNA-damage caused by UV irradiation, or treatment 
with either HU or MMS (Niimi, Chambers et al. 2012). It was also found that siRNA 
depletion of BAF180 after DNA-damage with UV-irradiation, resulted in a 
reduction of PCNA ubiquitination as well as unmodified chromatin-associated 
PCNA and the STUbL E3 ligase that ubiquitinates PCNA, Rad18 (Niimi, Chambers 
et al. 2012). Interestingly, we recently found that specifically, the BAH domains 
of BAF180 are required for the ubiquitination of PCNA (Niimi, Hopkins et al. 
2015). 
Another role for BAF180 in the DNA damage response was shown by recent work 
in our lab. The PBAF complex, which uniquely harbours the BAF180 subunit, was 
identified as important for DSB-induced transcriptional silencing (Kakarougkas, 
Ismail et al. 2014). PBAF also promotes repair of a subset of DNA DSBs at early 
time points, which can be rescued by inhibiting transcription globally. 
Phosphorylation of BAF180 is required for both processes (Kakarougkas, Ismail 
et al. 2014). Transcription is repressed in response to a DSB in an ATM-
dependent manner and leads to H2A monoubiquitination at Lysine 119 (H2-
K119ub) (Shanbhag, Rafalska-Metcalf et al. 2010). H2A-K119ub levels are 
dependent on the PBAF complex and therefore could mediate the regulation of 
H2A-K119ub at both sites of damage as well as transcription repression 
(Kakarougkas, Ismail et al. 2014). Work from other members in our lab had 
previously identified two cancer-associated mutations of BAF180, which were 
found to not de-stabilise the protein (Brownlee, Chambers et al. 2014). In context 
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of transcriptional repression, these BAF180-mutants were unable to restore the 
ability of BAF180-depleted cells to repress transcription-flanking DSBs or 
promote efficient repair at early time points (Kakarougkas, Ismail et al. 2014). 
This data suggests that PBAFs role in repressing transcription near DSBs may 
contribute to its tumour suppressor activity. 
The yeast homologues of BAF180, Rsc1 and Rsc2, have been shown to have 
defects in HR-dependent DNA repair (Chai, Huang et al. 2005, Oum, Seong et al. 
2011). The RSC complex was found to physically interact with the recombination 
protein Rad59 and functions in HR (Oum, Seong et al. 2011). Studies have 
revealed that RSC is required for recombination between sister chromatids by its 
ability to promote sister chromatid cohesion by the recruitment of cohesin at 
DNA break sites (Oum, Seong et al. 2011). The defective sister chromatid HR at 
double strand break sites, in Rsc2 mutant cells specifically, is thought to be due 
to impaired accumulation of DSB-induced cohesin at the break (Oum, Seong et al. 
2011). It is possible that mammalian BAF180, like its yeast homologues, 
cooperates with cohesion factors to facilitate cohesin-dependent HR. 
Before this study, work in our laboratory had previously never directly looked at 
BAF180’s role in HR. However, BAF180 was found to be hypersensitive to 
mitomycin C (MMC), resulting in increased levels of structural chromosome 
aberrations after treatment. This mimics phenotypes seen in cells with defects in 
HR or cohesin subunits after MMC treatment (Brownlee, Chambers et al. 2012). 
We can infer from this that BAF180 may have a role in HR-dependent DNA repair. 
 
1.5.3. BAF180 and the PBAF complex have a role in sister chromatid 
cohesion 
 
Work in our lab has recently identified a transcription-independent role for 
BAF180 in promoting sister chromatid cohesion (Brownlee, Chambers et al. 
2014). Sister chromatid cohesion is dependent on the activity of several 
regulatory factors, including the cohesin loader components Scc2 and Scc4 and 
the cohesion establishment factors Eco1, Scc3, Pds5 and Wapl. In mammalian 
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cells, Scc3 homologs are SA1 (STAG1) and SA2 (STAG2), Eco1 homologs are 
ESCO1 and ESCO2 and Pds5, whose homologs are PDS5A and PDS5B. SA1, ESCO2 
and PDS5B are thought to promote cohesion, specifically at pericentromeric 
regions (Canudas and Smith 2009, Whelan, Kreidl et al. 2012, Carretero, Ruiz-
Torres et al. 2013). Chromosome biorientation and segregation is reliant on 
centromeric cohesion and defects here result in aneuploidy, defined as the 
presence of an abnormal number of chromosomes in a cell, a typical 
characteristic of cancer cells. 
In yeast, interactions have been found to occur between genes involved in sister 
chromatid cohesion and the Rsc2 gene (Chambers and Downs 2012). 
Furthermore, studies have shown that when looking at Rsc1 and Rsc2 deletion 
strains in G2 phase of the cell cycle, increased separation of sister chromatids can 
be observed as well as a greater tendency to lose chromosomes in comparison to 
a wild type strain (Chambers and Downs 2012). There is evidence showing an 
interaction between the cohesin complex and RSC, however it a matter of debate 
as to whether RSC’s role in sister chromatid cohesion is during loading of cohesin 
or the establishment of cohesion (Chambers and Downs 2012).  
Loss of BAF180 in mouse and human cells results in defective sister chromatid 
cohesion at the centromeric locus, as opposed to chromosome arms, implying 
that BAF180 specifically regulates centromere cohesion (Brownlee, Chambers et 
al. 2014). This study also found increased levels of micronuclei formation, 
abnormal anaphase events and aneuploidy associated with BAF180-depletion. 
This suggests both chromosome instability (CIN) and consequently genome 
instability after the loss of BAF180-mediated centromere cohesion (Brownlee, 
Chambers et al. 2014). 
BAF180 is known to localize to the kinetochores of mitotic chromosomes and it 
has been implied that BAF180 therefore plays a role there during mitosis (Xue, 
Canman et al. 2000). In yeast, there is evidence showing that chromosome 
kinetochores can promote cohesin loading by Scc2-Scc4 (Natsume, Muller et al. 
2013). We can hypothesise that PBAF, via BAF180s localisation to kinetochores, 
may in turn aid cohesin loading. 
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1.5.4. Transcriptional roles for BAF180 
 
BAF180 is thought to contribute to transcriptional regulation by altering 
chromatin structure and controlling the accessibility of DNA (Thompson 2009). 
p53 is a well characterised tumour suppressor protein whose normal activity 
prevents tumorigenesis. It is well known as a transcription factor that regulates 
the expression of many genes involved in apoptosis, genome stability and 
angiogenesis. Recently it was demonstrated that PBRM1 regulates p53 function 
by influencing p53 transcriptional activity and is required for p53-induced 
senescence and proper p21 expression (Xia, Nagase et al. 2008, Burrows, 
Smogorzewska et al. 2010, Macher-Goeppinger, Keith et al. 2015). It was 
suggested that BAF180 acts together with BRD7 to promote p53 transcriptional 
activity directed towards a plethora of target genes and that loss or disruption of 
the PBAF complex results in compromised p53 function (Burrows, 
Smogorzewska et al. 2010).  
Another transcriptional role for BAF180 is seen in association with p21, BAF180 
has been described as a physiological mediator of p21 expression (Xia, Nagase et 
al. 2008). 
BAF180 has also been found to interact with the bromodomain containing 1 
(BRD1) gene, which is implicated with transcriptional regulation, brain 
development and susceptibility to schizophrenia and bipolar disorder (Fryland, 
Christensen et al. 2016). 
 
1.5.5. BAF180 is frequently mutated in human cancers 
 
Truncating mutations in PBRM1 that abrogated protein expression, were first 
identified in breast cancer in a screen for novel breast cancer tumour suppressor 
genes (Xia, Nagase et al. 2008). They identified four truncating mutations in the 
bromodomains of BAF180 that were associated with loss of wild-type BAF180. 
Microsatellite markers that flank the locus of BAF180 on 3p21 were used to 
screen tumour samples and of the 52 samples tested, 48.1% (25 samples) had 
70 
 
BAF180 loss of heterozygosity, suggesting that BAF180 loss may contribute to 
tumour progression (Xia, Nagase et al. 2008). In addition to this study, further 
work has identified low PBRM1 expression in breast cancer tissues, correlating 
with more advanced tumour stage, lymph node metastasis and lower overall 
survival (OS) for patients compared to those with higher PBRM1 levels. This data 
strengthens the argument for BAF180 acting as a tumour suppressor in breast 
cancer and identifies the potential as a valuable prognostic marker (Mo, Li et al. 
2015). 
Although the first BAF180 cancer mutations were identified in breast cancer, 
arguably the most influential study in regards to BAF180 cancer mutations was 
carried out by Varela et al, identifying BAF180 truncating mutation in a striking 
41% of clear cell renal cell carcinoma (ccRCC) (Varela, Tarpey et al. 2011). In this 
study exome sequencing was used to elucidate the mutation spectrum of seven 
ccRCCs, in which four cases presented with truncating mutations in PBRM1, three 
of which were frame-shift insertions and the fourth being a nonsense mutation. 
They next sequenced a further 257 cases of RCC, which included 36 cases of 
papillary chromophobe and other non-ccRCC cancers, finding PBRM1 truncating 
mutations in 88/257 (34%) cases, all of which were from the 221 ccRCC tumour 
samples. In 38 tumours sequenced, PBRM1 mutations were all found in the 
context of chromosome 3p loss of heterozygosity (LOH). ccRCC tumours with 
PBRM1 mutations were also frequently found to have mutations in VHL (Varela, 
Tarpey et al. 2011). Of the 38 PBRM1-mutant tumours studied, 36 exhibited a 
hypoxia signature, which is often linked to loss of VHL, however this signature 
was found in cases that did not have a detectable VHL mutation (Varela, Tarpey 
et al. 2011). Increased proliferation was observed in four out of five RCC cell lines 
after PBRM1 siRNA knockdown. The cell line with the outlying result was found 
to have a homozygous truncating mutation in PBRM1 and had no PBRM1 protein 
expression (Varela, Tarpey et al. 2011), this was the RCC cell line A704, which we 
have subsequently used in our study. Knockdown of PBRM1 was also associated 
with increased colony formation potential in soft-agar and increased cell 




In a panel of 727 cancer cell lines, with various histologies, exome sequencing 
was carried out to elucidate PBRM1’s contribution in other cancers. Congruent to 
the study carried out by Xia et al, PBRM1 homozygous deletion was found in the 
HCC-1143 breast cancer cell line (Xia, Nagase et al. 2008). Five homozygous 
truncating mutations in PBRM1 were identified in this study, including a frame 
shift deletion in the RCC line, A704, the small-cell lung cancer cell line NCI-H2196 
and the gall bladder cancer cell line TGBC24TKB. Nonsense mutations were found 
in two lines, the squamous-cell lung cancer cell line NCI-H226 and the pancreatic 
adenocarcinoma line PANC-10-05 (Varela, Tarpey et al. 2011).  
In addition to the data put forward by Varela et al, multiple other studies have 
linked PBRM1 mutation with loss of tumour suppressor activities in multiple 
cancers.  
PBRM1 maps to chromosome 3p21, interestingly, structural abnormalities were 
also frequently detected in this region in bladder cancers (Abat, Demirhan et al. 
2014). In a study by Huang et al, PBRM1 was found to be downregulated in 
bladder cancer cell lines and was associated with shorter overall survival in 
bladder cancer patients (Huang, Peng et al. 2015). They also found that PBRM1 
induced G2 cell cycle arrest by repressing cyclin B1 and suggest that it is this 
PBRM1-dependent block of the G2/M transition that allows PBRM1 to function 
as a tumour suppressor in bladder cancer (Huang, Peng et al. 2015). 
Recently PBRM1 mutations were also identified in a study of 68 diffuse large B-
cell lymphomas (Morin, Mendez-Lago et al. 2011, Pasqualucci, Trifonov et al. 
2011, Lohr, Stojanov et al. 2012), as well as in a sample of head and neck cancers 
(Agrawal, Frederick et al. 2011, Stransky, Egloff et al. 2011). Truncating 
mutations in PBRM1 were also reported in a mutational screen of pancreatic 
cancers (Jones, Zhang et al. 2008).  
To conclude, while it is not known the exact mechanism by which BAF180 
functions in cell biology, we do know that loss of this protein impacts on repair, 
replication, cohesion, DNA-damage induced transcriptional silencing and 
regulation of gene expression. The impairment of these factors, together with the 
wide mutation spectrum of BAF180 in human cancers, solidifies the notion that 
BAF180 is an important tumour suppressor gene. In this work we will discuss 
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how we have tried to exploit BAF180’s mutational status, specifically in ccRCC, to 
identify novel opportunities for therapeutic intervention. 
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1.6. Synthetic Lethality and Cancer Therapy 
 
The identification of chemical compounds that will kill cancer cells has never 
been a barrier to the progression of medical oncology. The challenge we are faced 
with instead, is how to use these identified chemical compounds at 
concentrations that will specifically target cancer cells, without effecting healthy 
cells. Traditional chemotherapeutic drugs aim to damage rapidly dividing cells, 
which encompasses cancer cells rather than normal non-cancer cells. However, 
some normal cells such as skin, hair and the healthy lining of the digestive system, 
can also rapidly divide and be at risk of damage from these non-specific agents. 
Most clinically available chemotherapeutic agents have limited efficacy for late 
stage patients and are associated with toxic side effects, such as hair loss and 
severe sickness (Chan and Giaccia 2011). A challenge facing current 
chemotherapies is in finding the concentration of drug needed to produce a 
therapeutic effect, while also taking in to consideration that high drug 
concentrations cause unwanted toxicity. Finding this perfect balance is known as 
the therapeutic window, which is often very narrow in current 
chemotherapeutics. Thus, there is a clear unmet clinical need for the 
development of new anti-cancer agents and the concept of synthetic lethality 
could provide scaffolding for the development of new, more cancer-cell-specific, 
cytotoxic agents. 
 
1.6.1. Synthetic Lethality 
 
The concept of synthetic lethality was first described in the fruit fly Drosophila 
melanogaster by Dobzhansky in the 1940’s, where he found that mutations in two 
different genes could promote a synthetic lethal interaction (Dobzhansky 1946). 
Two genes are typically referred to as ‘synthetic lethal’ if a mutation in both leads 
to cellular death, but mutation in either of the genes alone is consistent with 
viability (Hartwell, Szankasi et al. 1997, Hartman, Garvik et al. 2001, Kaelin 2005, 
Boone, Bussey et al. 2007). This type of interaction can also exist in an 
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intermediate state, where mutation in two genes result in a non-lethal impaired 
growth phenotype, referred to as ‘synthetic sickness’ (Kaelin 2005). 
Identification of a synthetic sick interaction between two genes can further be 
enhanced by acquiring additional mutations in one or more non-essential genes 
(Canaani 2014). The terms synthetic lethality and synthetic sickness are 
generally grouped together to encompass a broader definition of synthetic 
lethality as a whole. Under this more general description of synthetic lethality an 
identified pair of synthetic lethal genes may actually only cause a partial, rather 
than a total decrease in viability. There are three different mechanisms in which 
synthetic lethal genes interact to cause cellular lethality. Firstly, mutation of two 
genes in one essential pathway can result in synthetic lethality. Secondly, 
synthetic lethality can occur if two genes that exist in parallel pathways were 
mutated, consequently hindering the formation of an essential product that 
would normally arise from both functional pathways. Finally, a mutation in two 
genes that are located on two independent survival pathways can also result in 
synthetic lethality (Canaani 2014).  
Synthetic lethality typically describes two genetic perturbations, however, a 
revolutionary hypothesis by Hartwell and Friend in the 1990’s has allowed us to 
broaden the scope of this phenomenon to include cellular synthetic lethality 
caused by a combination of a genetic mutation, for example loss of a tumour 
suppressor gene and chemical inhibition (Hartwell, Szankasi et al. 1997). It was 
this revelation that revealed the potential exploitation of chemical and genetic 
synthetic lethal screening for the development of new therapeutics/drug targets 
for cancer therapy.  To date, multiple synthetic lethal screens have been 
performed in various model organisms, such as Saccharomyces cerevisiae 
(Bender and Pringle 1991), Drosophila (Lucchesi 1968) and human cancer cell 
lines e.g. (Bryant, Schultz et al. 2005, Farmer, McCabe et al. 2005, Helleday 2011). 
The use of screens like these to identify new synthetic lethal interactions is on 
track to becoming advanced enough to identify interactions in specific cancer 
types and even individual tumours, a progression within the field that would be 




1.6.2.  Exploration of synthetic lethal interactions in Saccharomyces 
cerevisiae 
 
In the study of synthetic lethal gene interactions, a well characterised model 
organism is the budding yeast, S. cerevisiae, having been examined on a genome-
wide scale. This high-throughput survey of synthetic lethal interactions in S. 
cerevisiae has led to the discovery of multiple genetic interaction networks and 
allowed for a more diverse functional annotation of multiple genes (Pan, Ye et al. 
2006, Hillenmeyer, Fung et al. 2008, Lin, Qi et al. 2008, Costanzo, Baryshnikova 
et al. 2010, Nijman 2011). For example, RSC1, which is known to be an important 
factor in transcriptional regulation, was subsequently found to be required for 
chromosome stability (Measday, Baetz et al. 2005).  
In yeast, the evolution of high-throughput screening for synthetic lethality has 
been facilitated by the development of synthetic genetic array (SGA) analysis 
(Tong, Evangelista et al. 2001). Tong and Boone carried out the first example of 
SGA analysis of high-throughput synthetic lethal screening in 2001; they used 
two individually viable mutants and showed that when mutated together the 
result was a substantial fitness defect. It was found that genes were more likely 
to exhibit synthetic lethal phenotypes if the mutated genes were located in either 
the same essential pathway or two parallel non-essential pathways (Tong, 
Evangelista et al. 2001). They extrapolated data between two gene sets, 
identifying the number of genetic interactions and used statistical analysis to 
organise genetic interaction networks (Tong, Evangelista et al. 2001, Lin, Qi et al. 
2008). The evolvement of this type of screening and analysis has expanded our 
knowledge of DNA integrity and the understanding of functional relationships 
among different processes (Pan, Ye et al. 2006), as well as broadening our 
assessment of post-translational modifications of histones (Lin, Qi et al. 2008) to 
name a few contributions.  Whether using yeast gene interactions, as a prediction 
of synthetic lethality in higher eukaryotes is actually accurate and useful, remains 
unclear. There is debate to whether the general lack of conservation of synthetic 
lethal interactions is due to technical limitations, or the fact that some 
interactions may only be conserved in certain biological processes (Nijman 2011). 
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However, there are examples where yeast genetic interactions have been 
successfully translated in to mammalian cells (Yu, Lopez et al. 2008, Conde-Pueyo, 
Munteanu et al. 2009, McLellan, O'Neil et al. 2009, McManus, Barrett et al. 2009), 
so it suggests that even if it does come with limitations, there is some level of 
conservation between the two organisms. 
 
1.6.3.  Identification of human synthetic lethal interactions 
 
BRCA1/2 and PARP have a robust and reproducible synthetic lethal phenotype 
Hartwell and Friend’s proposal that exemplified the possibility of a synthetic 
lethal interaction between a genetic mutation and chemical inhibition facilitated 
a plethora of research in the mammalian model (Hartwell, Szankasi et al. 1997). 
The first model and to date the most striking example of this hypothesis coming 
to fruition lies in the synthetic lethal interaction found between BRCA1/2-
deficient tumours and Poly(ADP-Ribose) polymerase (PARP) inhibition (Bryant, 
Schultz et al. 2005, Farmer, McCabe et al. 2005, Helleday 2011).  
The tumour suppressor genes BRCA1 and BRCA2 are involved in the repair 
double strand breaks (DSB’s) by Homologous Recombination (HR) (Tutt and 
Ashworth 2002), mutation or loss of these genes in mammalian cells can lead to 
an increased incidence of breast, ovarian, prostate and other cancers (Canaani 
2014). PARP is an enzyme known to be involved in the repair single strand breaks 
(SSBs) (Strom, Johansson et al. 2011). If something goes awry in the repair of 
these SSBs, either naturally or by PARP inhibition, then at the point of DNA 
replication, the persistence of these unrepaired SSBs at replication forks will 
cause the fork to collapse and allow the SSBs to be converted to DSBs. The DSBs 
will subsequently be repaired by HR (Underhill, Toulmonde et al. 2011). It is 
thought that mechanistically, BRCA1/2-deficient tumours are synthetic lethal 
with PARP inhibition as a consequence of both the single strand break repair 
pathway and the HR pathway being compromised (Bryant, Schultz et al. 2005, 
Farmer, McCabe et al. 2005). After treatment with PARP inhibitors in BRCA1/2-
deficient tumours, it is postulated that the DSBs that arise aren’t able to be 
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repaired by HR and instead are repaired, for example via NHEJ, a process by 
which several chromatid aberrations are gained, ultimately resulting in cell death 
(Underhill, Toulmonde et al. 2011). Pre-clinically, as a ‘proof of principle’ 
different examples of BRCA-deficient cell lines and even mouse xenografts have 
been demonstrated to be sensitive to PARP inhibition (Bryant, Schultz et al. 2005, 
Farmer, McCabe et al. 2005). Consequently, the synthetic lethal relationship 
between BRCA1/2 and PARP was the first to be determined in mammalian cells 
and exploited clinically for cancer therapy as both a PARP1-inhibitor single agent 
or in combination with classical chemotherapies.  
 
Other examples of synthetic lethality  
Like BRCA1/2, other genes involved in HR or the DNA damage response (DDR) 
have been identified as sensitive to treatment with PARP inhibitors. For example; 
RAD51, ATM, ATR, ATRX, NBN, CHK1, CHK2, SHFM1, RPA1, mir-182, SWI5-SFR1, 
USP1/UAF1, CDK1, PTEN1, TMPRSS2-ERG fusion, PDS5B, as well as several 
Fanconi anemia proteins (Xia, Sheng et al. 2006, Lord and Ashworth 2012, Papeo, 
Casale et al. 2013, Canaani 2014).  
The term ‘BRCAness’ has been adopted to describe some genes that have 
phenotypic traits mimicking tumours with BRCA1 and BRCA2 mutations and can 
be defined as a defect in double strand break repair by HR. This state of BRCAness 
can be induced by various tumour-specific genetic or epigenetic signatures, for 
example blocking sites of ubiquitination at DNA damage contributes to the 
proapoptotic phenotype induced by proteasome inhibitors. Proteasome 
inhibitors can decrease nuclear foci formation of DNA damage response 
molecules like RAD51, due to defective ubiquitination. These changes together 
can inforce this state of BRCAness (Jacquemont and Taniguchi 2007). 
Oncogenic drivers, such as KRAS and MYC can also be targeted by synthetic-
lethality approaches, where previously they were not thought to be ‘druggable’. 
In a recent study, oncogenic mutations in KRAS were shown to exhibit synthetic 
lethality after topoisomerase inhibition (Steckel, Molina-Arcas et al. 2012) and 
Myc-driven cancers are found to have a synthetic lethal interaction with 
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mammalian target of rapamycin (mTOR)-dependent phosphorylation of 
eukaryotic translation initiation factor 4E binding protein-1 (4EBP1) 
(Pourdehnad, Truitt et al. 2013). These unique identifications are providing novel 
therapeutic approaches to make these commonly deregulated oncogenes 
druggable in the clinic. 
Interestingly, synthetic lethal gene targets for VHL-mutant cancers have been 
identified recently in a shRNA synthetic lethal screen. As mentioned previously, 
VHL is the most frequently mutated gene in ccRCC, with BAF180 (PBRM1) being 
the second. A screen of 100 shRNA vectors, targeting 88 kinases, was performed 
to identify synthetic lethal ‘hits’ that inhibit viability of VHL-/- renal carcinoma 
cells. This screen identified multiple hits including CDK6, MET and MAP2K1 
(MEK1) and found that small molecule inhibition of Cdk4/6 had preferential 
activity against VHL-/- renal carcinoma cells (Bommi-Reddy, Almeciga et al. 
2008). This suggests that shRNA screening for synthetic lethality has the 
potential to identify novel therapeutic targets. 
 
1.6.4.  Limitations and translational challenges 
 
Excluding the translation of the BRCA/PARP interaction from hypothesis to 
clinical therapy, there have been very few other interactions that have 
successfully progressed from discovery to the clinic. For several years we have 
had extensive knowledge of synthetic lethal interactions in mammalian cells, and 
though progress has been relatively slow, there are still endless interactions to 
be exploited and great potential for valuable therapeutic elucidation of these 
relationships. 
One of the contributing factors to this slow progression is the lack of potent 
inhibitors that are specific to a single target and that are cell permeable (Fece de 
la Cruz, Gapp et al. 2015). Most chemical inhibitors have a broad spectrum of 
potential cellular targets (Lehar, Stockwell et al. 2008), so regardless of an 
impartial, systematic approach to identifying targets, actually targeting them 
with available inhibitors in a gene-specific manner is a challenge. There is a very 
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real concern that genetic synthetic lethal interactions may never have 
pharmacological representation (Nijman and Friend 2013).  
Another factor that hinders the translation of synthetic lethal interactions is our 
restricted understanding of how they are influenced by the tumour 
microenvironment, along with genetic and epigenetic variation (Nijman and 
Friend 2013). Most cancers do not harbour just one mutation, there are generally 
multiple driver and passenger mutations that contribute to tumour progression 
(Pon and Marra 2015) and therefore it is important to take in to account the 
context of the molecular heterogeneity that is exhibited in individual cancers 
when treating therapeutically. A good example of where looking at the overall 
context of the tumour has paid off in the clinic is in colon cancer cells that harbour 
mutations in the BRAF gene. These cancers do not respond to BRAF inhibitors 
and are not targetable by chemical inhibition. However, it was found that these 
cancers deterred the effects of BRAF inhibition by a feedback mechanism that 
promotes signalling by the epidermal growth factors and therefore could be 
successfully treated with a combination of BRAF and epidermal growth factor 
inhibitors (Corcoran, Ebi et al. 2012, Prahallad, Sun et al. 2012, Nijman and Friend 
2013).  
It will be advantageous to develop a broader understanding of how synthetic 
lethal interactions are influenced by multiple factors, rather than to just rule out 
interactions because they do not immediately validate with a single drug. In turn, 
this gained knowledge of tumour context should progress target validation as 





1.7. PolyADP-Ribose Polymerase (PARP) 
 
When a target protein is modified with monomeric, short chains, or long 
branching chains of ADP-ribose (ADPR), it is a post-translational modification 
known as ADP-ribosylation, which can be carried out by various ADP-
ribosyltransferases and polymerases (ADP-RTs and PARPs.  
Poly(ADP-ribose) polymerases (PARPs) are enzymes that can transfer these 
poly(ADP-ribose) (PAR) groups to themselves as well as to target proteins and 
function within the DNA damage network (Dantzer and Santoro 2013). When 
DNA damage occurs, poly(ADP)ribosylation is rapidly catalysed by poly(ADP-
ribose) polymerases (PARPs) at DNA lesions and it is this which subsequently 
facilitates DNA damage repair (Li and Yu 2015). The modifications formed by 
PARPs are known to be involved in a number of functions in the DNA damage 
response, such as detection and signalling of DNA damage, chromatin relaxation, 
recruitment of DNA repair factors, repair of the lesion and restoration of 






































Figure 1.14. PARP affects many cellular processes. The DNA repair 
process is affected by the post-translational modification of PARPs and other 




1.7.1. The PARP superfamily 
 
Members of the PARP family can be found across a wide range of species and 
domains and have a conserved function as essential molecules from lower to 
higher eukaryotes. ADP-ribosyltransferases (ARTs) possess the ability to transfer 
ADP ribose groups from nicotine adenine dinucleotide (NAD+) on to a single or 
multiple charged amino acids found on target proteins (Curtin and Sharma 2015). 
Specifically poly(ADP-ribosyl)ation of nuclear proteins can establish a molecular 
link between DNA damage and chromatin modification after DNA damage. 
Advancements in genome sequencing and improved genetic approaches 
illuminated the possibility that there was more than one enzyme involved in the 
conversion of NAD+ to ADP-ribose polymers. To date there are at least eighteen 
proteins that contain PARP domains (Ame, Spenlehauer et al. 2004), however 
only 6 of these are known to have predicted or confirmed PARP activity, in which 
they are able to form short (oligomers) or long chains (polymers) of poly ADP-
ribose (PAR) extending from the surface of the target protein (Curtin and Sharma 
2015). Differences found in core motifs of the catalytic domains of these proteins 
account for the differences in catalytic activity (Kleine, Poreba et al. 2008).  
Polymerase activity is initiated when a PARP protein binds to a free end of DNA, 
this allows PARP to auto-ribosylate itself and/or trans-ribosylate target proteins, 
which includes histones and DNA repair factors that are in close proximity to the 
break (Curtin and Sharma 2015). Of the six PARP proteins that are thought to 
have PARP activity, only three are able to bind DNA, PARP1, PARP2 and PARP3 
(Curtin and Sharma 2015). The DNA binding capability of these three proteins 
comes from their N-terminal DNA binding domains and WGR domains that reside 
close to their catalytic domains (Langelier, Planck et al. 2012). 
The catalytic core domain of PARPs 1, 2 and 3, which is comprised of a triad of 
histidine, tyrosine and glutamate residues is conserved (Johansson 1999, Kleine, 
Poreba et al. 2008, Langelier, Planck et al. 2012). This conservation is particularly 
strong in the pocket within the catalytic core that coordinates the NAD+ substrate 
and it is this that is targeted by many PARP inhibitors, which act by providing a 
block for NAD+ binding (Clark, Ferris et al. 1971, Johansson 1999). 
83 
 
Although there is strong conservation between PARPs 1, 2 and 3, there is also 
notable variations found in the sequences of the N-terminal binding domains, 
which subsequently allows each PARP to react differently to stimulation from 
different substrates (Johansson 1999).  
As well as variations in the N-terminal domains, the length of poly ADP-ribose 
polymers produced by the different PARPs, while being chemically very similar, 
can vary greatly. For example, PARP3 typically uses mono ADP-ribose to modifiy 
proteins, but it is also known to generate short chains (Johansson 1999, Ame, 
Spenlehauer et al. 2004, Rulten, Fisher et al. 2011). However, it is still not known 
how polymer length, or the consequences that follow, are regulated in vivo and 
why (Hakme, Wong et al. 2008).  
To date, there is a vast amount of evidence that various cellular and physiological 
processes are influenced by the biological properties of different PARPs (De Vos, 
Schreiber et al. 2012). Localisation of PARP family members to a multitude of 
cellular components, which include the nucleus, cytoplasm, mitochondria and 
vault particles, have been identified, however the function of all of the known 
PARPs is still to be determined (Ame, Spenlehauer et al. 2004, Hassa and Hottiger 
2008). Members of the PARP family that localise primarily to the nucleus are 
PARPs 1, 2 and 3, as well as tankyrase 1 and 2 (aka. PARP-5a and -5b) (Schreiber, 
Dantzer et al. 2006, Hassa and Hottiger 2008). Other family members such as v-
PARP (PARP-4), PARP-6, PARP-8, PARP-9, PARP-10 and the Bal proteins Bal1-3 
(PARP-13, -14, -15) can too be found in the nucleus, however they are not 
restricted here (Krishnakumar and Kraus 2010). 
The incredibly varied interaction between PARP family members with multiple 
processes gives rise to a plethora of biological outcomes, that include but aren’t 
limited to, differentiation, development, stress responses, inflammation and 
cancer and therefore makes them an attractive family of proteins to research 





























Figure 1.15. Functional domains of the key PARPs. Adapted from Rulten et 





The 113-kDa human protein, PARP1, is a nuclear enzyme involved in the 
detection of DNA strand breaks and is the founding member of the PARP 
superfamily.  
The most abundant and active of the three DNA-binding PARPs, PARP1 and its 
activation have been associated with acting downstream of multiple processes, 
including chromatin remodelling, transcription and telomere maintenance.  
PARP1 is thought to have an important role in DNA damage signalling and 
accelerating single strand break repair (SSBR) (Sanderson and Lindahl 2002, 
Fisher, Hochegger et al. 2007). It is a stable component of chromatin and accounts 
for 80-90% of the detectable PAR signal following DNA damage (Mullins, Giri et 
al. 1977, Giri, West et al. 1978, Lindahl, Satoh et al. 1995).  The N-terminal domain 
of PARP1 is responsible for its initial recruitment to sites of DNA damage, binding 
to this damage, whether it be a single strand or double strand break, its mediated 
by the two zinc fingers in this N-terminal domain. These zinc fingers also allow 
for the dimerization of PARP1 (Ali, Timinszky et al. 2012).  
Other repair factors are allowed to bind to sites of DNA damage after the 
dissociation of PARP1 from the break, this dissociation is an important step in the 
repair process that is mediated by auto-ribosylation of PARP1 with negatively 
charged PAR (Ferro and Olivera 1982, Zahradka and Ebisuzaki 1982). DNA 
binding and auto-modification of PARP1 attracts DNA repair proteins involved in 
SSBR, such as XRCC1, to the sites of damage, but is not thought to be essential for 
SSBR (de Murcia, Niedergang et al. 1997, Wang, Stingl et al. 1997, Shall and de 
Murcia 2000, El-Khamisy, Masutani et al. 2003). Recruitment of XRCC1 then acts 
as a scaffold for the further recruitment of other repair factors such as the end 
processing factors PNKP and Aprataxin and the chromain remodelers APLF and 
ALC1. Ligation of the repaired break is carried out by DNA ligase IIIα, which forms 
a heterodimer with XRCC1. 
PARP1 also binds to double strand breaks (DSBs) and has been implicated in 
several pathways that mediate DSB repair. The homologous recombination (HR) 
pathway, as described in section 1.1.3.2 uses the intact sister chromatid as a 
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template for repair. Loss or inhibition of PARP1 is able to induce a hyper-
recombination phenotype, presenting as spontaneously increased levels of sister 
chromatid exchange (SCE). Conversely, overexpression of PARP1 can suppress 
DNA damage-induced SCEs, suggesting the presence or absence of PARP1 is able 
to influence HR (de Murcia, Niedergang et al. 1997, Meyer, Muller et al. 2000). HR 
accessory factors, including breast cancer type 1 susceptibility protein (BRCA1), 
which forms a heterodimer with BRCA1-associated RING-domain protein 1 
(BARD1), can be recruited to sites of damage by PARP1 to accelerate repair (Li 
and Yu 2013, Curtin and Sharma 2015). PARP1 can also recruit the RNA-binding 
motif protein X-linked (RBMX) to sites of damage, positively regulating HR by the 
stabilisation of breast cancer type 2 susceptibility protein (BRCA2) (Adamson, 
Smogorzewska et al. 2012).  
 
1.7.3. PARP2  
 
PARP2 was first identified after the embryonic fibroblasts derived from PARP1 
deficient mice showed signs of residual DNA-dependent PARP activity (Shieh, 
Ame et al. 1998, Ame, Rolli et al. 1999). PARP2 is thought to have a key role in 
genome surveillance and protection and has been implicated in numerous 
cellular functions, which include genome and chromosome stability, 
heterochromatin integrity, cell death, differentiation and inflammation (Yelamos, 
Schreiber et al. 2008). Mammalian PARP2 is a 66.2kDa protein, with a catalytic 
domain that is 69% similar to that of PARP1 (Ame, Rolli et al. 1999, Oliver, Ame 
et al. 2004). Like PARP1, PARP2’s catalytic activity is stimulated by the presence 
of DNA strand breaks. Their targets, which include histones, DNA repair proteins 
and transcription factors, as well as themselves via auto-ribosylation, suggest 
they have a strong involvement in chromatin structure and DNA metabolism 
(Schreiber, Dantzer et al. 2006).  
PARP2 produces PAR that is of similar length and composition to PARP1, but it 
much less catalytically active, working at a rate of around 10-25% compared to 
PARP1 activity (Ame, Rolli et al. 1999). Similarly to PARP1, PARP2 is able to bind 
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DNA, with a functional DNA binding domain located at its N-terminus, together 
with a nuclear localisation signal (Shieh, Ame et al. 1998, Ame, Rolli et al. 1999, 
Leger, Bar et al. 2014). 
The DNA binding domain of PARP2 has similar homology to SAP domains that 
can be found in numerous nuclear proteins, such as AP-endonuclease and Ku70, 
which are known to be involved in chromosomal organisation and DNA repair 
(Aravind and Koonin 2000). 
PARP2 is able to form a homodimer with itself as well as a heterodimer with 
PARP1 and each protein can poly(ADP-ribosyl)ate the other (Schreiber, Ame et 
al. 2002). In PARP1 deficient systems, it is thought that PARP2 activity could 
compensate for this PARP1 loss, this is due to the proteins having similar targets 
as well as similar activity and profiles of stimulation (Curtin and Sharma 2015).  
As mentioned above, PARP1 and PARP2 have similar target proteins. Proteins 
involved in the base excision repair pathway, XRCC1 (x-ray cross complementing 
factor 1), DNA polymerase β and DNA ligase III, which are known partners of 
PARP1, have also been seen to interact with PARP2 (Schreiber, Ame et al. 2002). 
Like with PARP1, XRCC1 negatively regulates PARP2 activity as well as being a 
polymer acceptor for both PARP1 and PARP2 (Schreiber, Ame et al. 2002). To 
elucidate PARP2’s role in the DNA damage response, Schreiber et al treated 
PARP2-deficient cells with the alkylating agent N-nitroso-N-methylurea (MNU) 
and subsequently saw a delay in the repair of breaks that was comparable to the 
delay seen in PARP1 deficient cells, suggesting that PARP2 has an active role in 
base excision repair (Schreiber, Ame et al. 2002).  
It is worth mentioning that PARP2-/- mice, like PARP1-/- mice, are viable, however 
mice that are deficient in both genes are not, suggesting that there are 
overlapping essential development functions of PARP1 and PARP2 (Menissier de 
Murcia, Ricoul et al. 2003). Loss of PARP2 is also found to be embryonic lethal in 
mice in combination with ATM, where single deletion of each gene results in 
viable mice (Huber, Bai et al. 2004). 
As mentioned, PARP2 appears to have many overlapping functions and target 
proteins with PARP1 and it has been stipulated that it may act in a compensatory 
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manner following PARP1 deletion. However, PARP1 and PARP2 deficient mice 
are known to also exhibit different developmental and immunological defects, 
which could indicate a role for PARP2 in its own specific pathways, independent 
of PARP1 (Yelamos, Schreiber et al. 2008, Robert, Dantzer et al. 2009). 
 
1.7.4. PARP3  
 
PARP3 has a mass of 60.1kDa and was first discovered by searching an expressed 
sequence tag library with the sequence of human PARP1, with an aim to identify 
novel proteins with related sequences (Johansson 1999). Structurally, PARP3 is 
similar to PARP2 (Figure 1.15) and has a conserved catalytic domain, as identified 
by crystal structure, that is similar to PARP1 and PARP2 (Ruf, Mennissier de 
Murcia et al. 1996, Oliver, Ame et al. 2004, Lehtio, Jemth et al. 2009). PARP3 also 
has a DNA binding domain at the N-terminus that is divergent to PARP1 and 2 
and a WGR domain that is enriched with tryptophan, glycine and arginine (Dai, 
Rulten et al. 2015).  In mammalian cells, two isoforms of PARP3 exist, that vary at 
the N-terminal domain by just seven amino acids and it is unknown if the two 
isoforms carry out different functions, only the short isoform is present in mice 
(Augustin, Spenlehauer et al. 2003).  
PARP3 has diverse roles in multiple cellular processes, such as mitotic 
progression, maintenance of telomere stability and importantly in the damage 
response to repair DNA. 
PARP3 is implicated in the base excision repair pathway, as well as NHEJ, through 
its interaction with several proteins (Rouleau, McDonald et al. 2007). The ADP-
ribosyltransferase activity of PARP3 is thought to be able to be stimulated by DNA 
DSBs and has been shown to function together with APLF to promote NHEJ 
(Rulten, Fisher et al. 2011). 
PARP3 also has roles in the stabilisation of the mitotic spindle and in telomere 
integrity by regulating the mitotic components NuMA and tankyrase 1 (Boehler, 
Gauthier et al. 2011). After DNA damage occurs, PARP3 is also thought to affect 
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the choice between repair by HR and NHEJ pathways by limiting DNA end 











2 Materials and Methods 
 
2.1. Materials  
 
2.1.1.  Mammalian expression plasmids 
 
GIPZ lentiviral shRNA vectors 
BAF180 and non-silencing control (NSC) GIPZ lentiviral shRNA vectors were 
purchased from Thermo Scientific and grown from glycerol stocks on LB (low salt) 
Ampicillin plates before isolating plasmid DNA using an EndoFree (Endotoxin-
free) Maxi-prep kit (Qiagen). The purchased vectors contain TurboGFP 
fluorescent marker, which was switched out for either GFP or RFP(mCherry) with 
a nuclear localisation signal (NLS), using primers provided by Hung Quang Dang 
(as listed in Table 2.2). The GFP/NLS and mCherry/NLS PCR fusion products (as 
described in Figure 2.1) were cloned in to pGEM-T-Easy Vector acting as a holding 
vector to allow for amplification. Restriction enzymes XBaI/NotI and SpeI/NotI 
were used to insert the GFP/NLS and mCherry/NLS respectively in to the GIPZ 
shBAF180 and shControl vectors. The plasmids subsequently created were 
named shBAF180+GFP/NLS, shBAF180+mCherry/NLS, shNSC+GFP/NLS and 
shNSC+mCherry/NLS.  
 
CRISPR Cas9 wild type/gRNA plasmids 
Cas9 wild type/gRNA plasmids with five different guide RNA’s were obtained 
from Horizon discovery as part of a free CRISPR guide program, coordinated by 
Chris Thorne, guide sequences as shown in Table 2.1. Due to low transfection 
efficiency of the Cas9/gRNA plasmids, co-transfection with a second plasmid with 
a selection marker was necessary. The pcDNA4-GFP-IRES-Puro plasmid was 




Table 2.1. CRISPR Guide RNA’s used in this study 
Gene Gene ID Given Name  Sequence 
PBRM1 153269 CRISPR Construct 1 ATAGAAGAAGTTGGATTCCA 
PBRM1 153270 CRISPR Construct 2 CCCGCTGACACTGCTGGAAG 
PBRM1 153271 CRISPR Construct 3 GGCCTGGTGTTGACACAGAA 
PBRM1 153272 CRISPR Construct 4 AGGATCTACAGTTGGAAGAT 




Primers used in this study for cloning of GIPZ lentiviral shRNA vectors and for 
SURVEYOR mutation assay are shown in Table 2.2.  
Table 2.2. Primers used in this study 
















































Figure 2.1. Cloning strategy for the establishment of shRNA pGIPZ 





In this study two commercially available human BAF180 antibodies, 
BAF180/PB1 (A301-591A) and BAF180 (ABE70) were purchased from Bethyl 
Laboratories (via Cambridge Bioscience, Cambridge, UK) and Merck Millipore 
(Hertfordshire, UK) respectively. Antibodies against ASF1A/B (sc-53171), BAP1 
(sc-28383), CTF18 (sc-374632), GCN5 (sc-130654), HDAC1 (sc-7872), HDAC4 
(sc-46672), RNF4 (sc-21351), TIP60 (sc-5727), CENPF (sc-22791) and RAD51 
(sc-8349) were purchased from Santa Cruz (California, USA). 53BP1 BP13 (A300-
272A antibodies were obtained from Bethyl Laboratories (via Cambridge 
Bioscience, Cambridge, UK), EZH2 D2C9 (5246), cleaved Caspase 3 Asp175 (9661) 
and H2AZ (2718) antibodies were purchased from Cell Signalling (Massachusetts, 
USA) and PARP1 (MCA15226) and PARP3 (ab96601) were purchased from Bio-
Rad (California, USA) and AbCam (Cambridge, UK) respectively. The loading 
controls Alpha-actin (A5060) and Alpha-tubulin DM1A (ab7291) were obtained 
from Sigma-Aldrich (Dorset, UK) and AbCam (Cambridge, UK) respectively. 
Mouse (PO260), Goat (PO449) and Rabbit (PO448) HRP conjugated 
immunoglobulins for use as secondary antibodies were purchased from Dako 
(Denmark). 
Antibody dilutions used for Western blotting, flow cytometry and 




All cell lines used in this study were grown in 37oC incubators with 5% CO2 and 
all media was supplemented with 1% Penicillin/Streptomycin and 1% L-
Glutamine purchased from Gibco (Thermo Fisher), unless otherwise stated.  
The human osteosarcoma cell line, U2OS, were cultured in Dulbecco’s Modified 
Eagle Medium (DMEM) purchased from Gibco (Thermo Fisher) supplemented 
with 15% Foetal Bovine Serum (FBS). The lung cancer cell line, A549 and the two 
renal cell carcinoma cell lines, A-498 and A-704 were cultured in Minimum 
94 
 
Essential Media (MEM) purchased from Gibco (Thermo Fisher) supplemented 
with 10% FBS.The breast cancer cell line T47D and the two renal cell carcinoma 
cell lines, 786-0 and 769-P were cultured in Roswell Park Memorial Institute 
(RPMI) 1640 medium purchased from Gibco (Thermo Fisher), supplemented 
with 10% FBS. The renal cell carcinoma cell line Caki-1 was grown in McCoy’s 5a 
medium from Gibco (Thermo Fisher) and was supplemented with 10% FBS.  
All cell lines grow as a monolayer and were allowed to grow to around 70-90% 
confluency before being re-plated to Corning T-75 tissue culture flasks every 3-5 
days. No cell line was continually passaged for more than 6 weeks at a time to 
avoid sub-culturing, a decrease in cellular productivity and cellular 




Cells treated with irradiation were exposed to the radioisotope Caesium-137 
(137Cs 64 TBq – 1989). This radiation source emits radiation in the form of 
gamma rays and to a lesser extent, high-energy beta particles. As this source 



















2.2.1. siRNA knockdowns 
 
siRNA knockdowns were carried out using either HiPerfect transfection reagent 
(Qiagen) or Lipofectamine RNAiMAX reagent (Invitrogen). Cell lines were 
typically seeded at a density of 1-3x105 cells per 6cm dish in 3ml appropriate 
media and siRNA knockdowns were carried out as per the specific 
manufacturer’s instructions, using either single siRNA sequences or 
SMARTpool’s of four siRNA’s (Dharmacon ON-TARGETplus) on the day of seeding 
as well as 24 hours later. Treated cells were left for 72 hours from first 
transfection before being detached using 0.05% Tryspin-EDTA (Gibco) and were 
either harvested for whole cell extracts or taken on to further experiments.  
 
2.2.2. Whole cell extracts  
 
Cells were grown in either 6cm or 10cm dishes until confluent or until a specific 
time-point and de-attached using 0.05% Trypsin-EDTA (Gibco), which was 
deactivated by FBS containing media about 1 minute after Trypsin addition. Cells 
were pelleted by centrifugation at 1500 rpm at 4oC for 5 minutes. Pellets were 
washed twice with ice cold phosphate-buffered saline (PBS) and were either 
stored at -20oC or processed immediately. Whole cell extracts were prepared 
from the pellets using an edited version of Tanaka’s method (Tanaka et al., 1992). 
Method edited by Cornelia Meisenberg. The pellet was re-suspended in 1ml ice 
cold PBS and centrifuged at 3600 rpm at 4oC for 10 minutes and the supernatant 
was carefully removed. Pellets were re-suspended in around 4 packed cell 
volumes (PCV’s) of IP lysis buffer containing 20mM Tris-HCL ph7.5, 10mM EDTA 
ph 8.0, 100mM NaCl, 1% Triton X-100 and freshly added protease inhibitors 
(950μl IP lysis buffer with 50μl protease inhibitors). The cells were mixed 
thoroughly by rocking at 4oC for 30 minutes and subsequently sheered by two 
rounds of sonication set to 30 seconds on/30 seconds off pulses, using the 
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Diagenode Bioruptor sonicating water bath. Cell lysate was centrifuged at 13000 
rpm at 4oC for 10 minutes. Supernatant was carefully collected and stored at -
20oC or -80oC for long term storage until needed. 
 
2.2.3. Protein concentration - Bradford assay 
 
The Bradford assay was used to measure the protein concentrations of whole cell 
extracts for western blotting, using Bio-Rad protein assay reagent (Bio-Rad). 2μl 
of whole cell extract sample were diluted in 18μl ddH20 and further diluted in 
980μl of the dye reagent at 1 x concentration. A blank sample was used to 
standardize sample readings and absorbance measurements at an optical density 
of 595 nm were read using a UV spectrophotometer. A reference BSA protein 
standard at 0.2mg/ml sample was also measured for calculation of protein 
concentration. 
 
2.2.4. Western blotting – SDS-PAGE 
 
Proteins were resolved on 8, 10, 12 or 15% separating gels depending on the size 
of the protein of interest by sodium dodecyl sulfate (SDS) polyacrylamide gel 
electrophoresis (PAGE). Separating gel solutions were made as described in 
Table 2.4 below and poured between 1.5mm Mini-PROTEAN spacer plates (Bio-
Rad) leaving a 1-1.5 inch gap for the stacking gel. A layer of isopropanol was 
swiftly added to the top of the separating gel allowing it to set with a straight edge. 
The isopropanol was completely removed before the stacking gel solution (see 
Table 2.4) was added to the gel cast along with a protein gel comb and was 






Table 2.4. Separation and stacking gel components for SDS-PAGE 
Gel Type 8% 10% 12% 15% Stacking 
(2ml) 
ddH20 2.9ml 2.5ml 2.1ml 1.5ml 1.0ml 
Separation buffer 1.5ml 1.5ml 1.5ml 1.5ml -- 
Stacking buffer -- -- -- -- 0.5ml 
APS 75µl 75µl 75µl 75µl 25µl 
TEMED 7.5µl 7.5µl 7.5µl 7.5µl 2.5µl 
Acrylamide 
(30% - 37:5:1) 
1.6ml 2.0ml 2.4ml 3.0ml 0.5ml 
 
Protein concentration was determined by Bradford assay (as described in 2.2.3) 
to allow for accurate loading. 20-40μg of whole cell extract was diluted in 4x 
NuPAGE LDS Sample Buffer (Novex, Thermo Fisher) with 5% 2-Mercaptoethanol 
(BME) freshly added, before being denatured at 95oC for 5-10 minutes. The 
previously made gels were transferred to Mini-PROTEAN Tetra Vertical 
Electrophoresis Cell tanks (Bio-Rad), which were then filled with 1x SDS-PAGE 
running buffer. Samples were loaded in the gel alongside a molecular weight 
ladder, Precision Plus Protein Dual Color Standards (Bio-Rad) and run at 150 V 
for approximately 1 hour or until the dye front reached the bottom of the gel. 
Resolved proteins were then immobilised on nitrocellulose membrane (GE 
Healthcare) at 250 mA with constant Amps for 90 minutes in SDS-PAGE transfer 
buffer. Membranes were then blocked in 5% Milk-TBST (Tris-Buffered Saline and 
Tween 20) or 3% BSA-TBST for 1 hour at room temperature. Membranes were 
either left whole or cut with a sterile scalpel to further incubate with specific 
antibodies. Appropriate primary antibodies were diluted in 5% Milk-TBST or 3% 
BSA-TBST and added to the membrane, before being transferred to 4oC overnight 
with shaking. The membrane was washed three times for 5 minutes with PBS and 
then incubated for at least 1 hour with a similarly diluted secondary antibody. 
Membranes were washed again with PBS three times and then proteins were 





2.2.5. Agarose gel electrophoresis 
 
1% agarose gels were generally used throughout the study to analyse DNA 
samples, however in experiments such as the SURVEYOR mutation detection 
assay (as described in 2.2.15), where DNA fragments smaller than 500 bp are 
separated, 2% gels were used. Agarose powder (Sigma) was added to 1 x TAE 
buffer and heated using a microwave until completely dissolved. The mixture was 
allowed to cool for about 5 minutes before ethidium bromide was added to a final 
concentration of around 0.2-0.5μg/ml (usually around 1μl/40ml). The agarose 
mixture was poured in to a gel tray with gel combs and allowed to set. Gels were 
placed in to gel tanks filled with 1 x TAE buffer and DNA samples diluted in 6x 
loading buffer (NEB) were loaded alongside either 1 kb or 100 bp DNA ladders 
(NEB), depending on the expected size of DNA fragments, for size comparison. 
Electrophoresis was carried out, running the gels at around 90-120V, depending 
on gel size, for 30 minutes before DNA bands were analysed using UV 
transillumination.  
 
2.2.6. Gel Purification 
 
DNA bands were observed from agarose gels after separation by electrophoresis, 
using UV transillumination. Correct bands were excised from the gel using a 
sterile scalpel and DNA was subsequently purified using QIAquick Gel Extraction 
Kit (Qiagen), following the manufacturer’s instructions. 
 
2.2.7. Restriction Digests 
 
Double and single restriction digests were typically set up using restriction 
enzymes and CutSmart Buffer purchased from NEB. 1-3µg DNA, usually around 
2-5µl, was typically digested in a 50µl reaction, composed of 5µl 10x CutSmart 
buffer, 1µl of each restriction enzyme and made up to the total volume with 
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sterile water. Digestions were typically left for at least 1 hour, sometimes 
overnight, at 37oC. Digestions were analysed by agarose gel electrophoresis (see 
section 2.2.5) and correct fragments were gel purified (see section 2.2.6) before 




20µl ligation reactions were carried out using T4 DNA ligase (NEB), 10x T4 DNA 
Ligase Buffer (NEB), sterile water and a given ratio of purified DNA insert to 
vector. The amount of insert needed for a specific ratio was calculated by first 
observing the standard 1:1 ratio:  
[Length Insert (kb) / Length Vector (kb)] x ng of Vector = ng insert needed for 1:1 
Typically a 4:1 Insert : Vector ratio was used. Ligation reactions were incubated 
for at least 15 minutes at room temperature, but in most cases were typically left 
overnight before being transformed in to XL1-Blue Competent E. Coli cells (as 
described in section 2.2.9). 
 
2.2.9. XL1-Blue E. Coli transformation 
 
Freshly prepared ligation reactions (As described in 2.2.8) or plasmid DNA 
(around 100-200ng) were added to 50µl XL1-Blue competent cells that had 
previously been thawed on ice for 15 minutes. The DNA/E. Coli mixture was 
gently pipetted and incubated on ice for 40 minutes. The cells were heat shocked 
in a 42oC water bath for 40 seconds and then placed back on ice. 500µl LB broth, 
without antibiotic, was added and cells were allowed to recover at 37oC for 1 hour. 
Cells were pelleted using a bench top centrifuge at 1500rpm for 1 minute and all 
but 100µl of the supernatant was subsequently discarded. The cell pellet was re-
suspended in the remaining supernatant and spread on LB plates containing the 




2.2.10. Blue-white screening of bacterial colonies 
 
100µl of 100mM IPTG (Isopropyl β-D-1-thiogalactopyranoside) and 20µl of 
50mg/ml XGal (5-bromo-4-chloro-3-indolyl-β-D-galactopyranoside) were 
spread over solid LB plates with appropriate antibiotics and allowed to dry prior 
to use in transformation reactions (as described in 2.2.9). Blue white screening 
was used to analyse the correct intake of recombinant E. Coli containing plasmids 
by the production of blue or white colonies formed by either functional β-
galactosidase (encoded by the lacZ gene) or disrupted/inactivated β-
galactosidase production respectively.  
 
2.2.11. PCR Amplification of DNA 
 
PCR amplifications were carried out using the high-fidelity DNA polymerase, 
Phusion (NEB) and a typical 50µl reaction was set up on ice as follows:  
 
Component 50µl Reaction 
MilliQ H20 To 50 µl 
5X Phusion HF Buffer 10 µl 
5mM dNTPs 2 µl 
10 µM Forward Primer 1 µl 
10 µM Reverse Primer 1 µl 
Template DNA Variable 
Phusion DNA Polymerase 0.5 µl 
 
PCR reaction mixtures were immediately transferred to a bench top themocycler 
for amplification. 
A typical PCR cycling programme was as follows:  
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Step Temperature Time 
Initial Denaturation 98oC 2 min 









Final Extension 72oC 10 min 
Finish Hold 4oC Infinite 
 
PCR products were either stored at 4oC or 1-5µl was immediately analysed by 
agarose gel electrophoresis (as described in section 2.2.5). 
  
2.2.12. Stable shRNA cell line transfection 
 
Using both the unaltered and the altered pGIPZ shRNA plasmids (as described in 
2.1.1), cells were seeded at a density of 2x105 per well in a 24 well plate and 
transfected with the plasmid DNA 24 hours later as per the manufacturer’s 
instructions (Thermo Scientific). After optimisation of the protocol, 4µg rather 
than the recommended 1µg of DNA was used, as well as 6µl rather than the 
suggested range of 1-2.8µl of TurboFect was diluted in 100µl OptiMEM. 
Transgene expression was analysed in the 24-48-hour period following 
transfection and cells that appeared to express either the GFP or mCherry 
fluorescent proteins were put under continuous puromycin (Fisher Scientific) 
antibiotic selection. Antibiotic dose response curves were carried out for each cell 
line to determine the minimum dose of antibiotic to kill any non-transfected cells, 
details of which are noted in the table below: 
Cell Line Puromycin Dose 
U2OS 1.5 μg/ml 
A549 0.75 μg/ml 
786-0 0.9 μg/ml 




2.2.13. CRISPR cell line transfection 
 
Creation of BAF180 CRISPR knockout cell lines, using guide RNA’s (section 2.1.1.) 
was carried out with direction from Chris Thorne (Horizon Discovery), however 
optimisation of their protocol, as well as the introduction of a secondary plasmid 
(section 2.1.1.) was required to achieve significant transfection levels.  
Cells were seeded at a density of 5x104 cells per well in a 24 well plate and were 
transfected 24 hours later. A transfection reagent comprised of 100μl OptiMEM, 
2μl TurboFect, 0.5μg of each given CRISPR construct and 0.25μg of the empty 
vector pcDNA4-GFP-IRES-Puro was incubated for 30 minutes and then added 
drop wise to the cells. Transient GFP expression from the empty vector plasmid 
was analysed 24 hours later and successfully transfected cells were put under 
puromycin antibiotic selection for 3-5 days. Successfully transfected cells were 
grown for gDNA extraction (section 2.2.14) and the success of each CRISPR guide 
was determined using the SURVEYOR mutation detection assay (see section 
2.2.15). A single CRISPR guide was then chosen as ‘most efficient’ and cells that 
had been previously transfected with that guide were single cell diluted to 
establish a clonogenic cell line. Single clones were grown to confluency in 96 well 
plates and then split to three new 96 well plates, one for continuous passage, one 
for genomic DNA extraction and one for freezing. Genomic DNA was harvested 
from these plates (section 2.2.14) and successful clones were determined again 
by the SURVEYOR mutation detection assay (section 2.2.15). Any clones that 
appeared to have the mutation introduced by the CRISPR guide was then 
expanded and BAF180 expression was checked by Western blotting (section 
2.2.4) as well as by sequencing (GATC-biotech). 
 
2.2.14. Genomic DNA extraction  
 
Genomic DNA extraction from cultured cells – Large scale format 
U2OS and 786-0 cells were grown in 10cm tissue culture dishes and harvested 
when confluent, giving a typical yield of around 4x106 cells. Harvested cells were 
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pelleted by centrifugation at 1500 rpm for 5 minutes and then re-suspended in 
500µl Tail lysis buffer for genomic DNA extraction, composed of 50mM Tris-HCL, 
pH 8.8, 100mM EDTA, 100mM NaCl and 1% SDS. To this, 500µl 
Phenol/Chloroform/Isoamyl (25:24:1) alcohol was added and cells were agitated 
until an emulsion formed. The samples were centrifuged in a bench top microfuge 
at maximum speed for 5 minutes, here you can observe the lysis solution forming 
three distinct layers. The top layer, or aqueous phase, was carefully removed to a 
new Eppendorf and 200µl saturated NaCl (5-6M) was added and then the mixture 
was shaken vigorously for 5 minutes before being centrifuged for 10 minutes at 
maximum speed. The supernatant was carefully poured in to a new Eppendorf 
and 700µl Isopropanol was added and mixed by inversion. At this stage you can 
see the DNA appear as a cloud within the solution. The solution was then spun 
again at maximum speed for 10 minutes, revealing a very clear, spread out pellet 
of DNA. The pellet was washed with 70% ethanol for 1 minute and further 
centrifuged for 5 minutes at maximum speed, forming a smaller, more compact 
pellet. An appropriate amount of TE buffer was added to the pellet and was then 
left at room temperature overnight to aid DNA re-suspension.  
 
Genomic DNA extraction from cultured cells - 96 well plate format 
Genomic DNA was harvested from 96 well plates as set out by Sigma-Aldrich in a 
technical bulletin that describes the harvesting of genomic DNA after delivery of 
zinc finger nucleases (http://www.sigmaaldrich.com/content/dam/sigma-
aldrich/docs/Sigma/Bulletin/1/ckozfndbul.pdf).  
 
2.2.15. SURVEYOR mutation detection assay  
 
The detection of mutated/deleted DNA sequences, introduced by the transfection 
of CRISPR guides to cells, was carried out using the SURVEYOR mutation 
detection kit (Transgenomic). Genomic DNA was harvested from CRISPR gRNA 
transfected ‘test’ cells as well as from untreated ‘control’ cells (as described in 
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2.2.14) and the specific region of interest, i.e. where the CRISPR guide should ‘cut’ 
the DNA, was amplified by PCR (section 2.2.11) using primers listed in Table 2.2. 
The PCR products were analysed on 2% agarose gels. Alongside ‘test’ and ‘control’ 
DNA samples, the SURVEYOR mutation detection kit provides two reference 
plasmid DNAs, Control C and Control G, which were also PCR amplified, as per the 
manufacturer’s instructions. The PCR amplified DNA samples were then 
hybridized to form hetero- and homoduplexes. A typical set up of this reaction 
was as follows: 
 
PCR Amplified Component Amount 
SURVEYOR Control C  30 µl 
SURVEYOR Control C + Control G 15 µl + 15 µl 
Untreated ‘Control’ Cells 40 µl 
CRISPR gRNA treated Cells 40 µl 
Control Cells + CRISPR gRNA Cells 20 µl + 20 µl 
 
The hybridization reaction tubes were secured with Eppendorf cap locks, to stop 
the lids from popping open, and were heated in a heat block at 95oC for 5 minutes. 
The entire block was then allowed to cool to 30oC before digesting the samples 
with the SURVEYOR nuclease exactly as described in the manufacturer’s 
instructions. A typical set up of this digestion reaction was as follows:  
 
For SURVEYOR Control C and 
Control C + Control G Reactions 
 For ‘Control’ and ‘Test’ hetero- and 
homoduplexes 
Component Amount  Component Amount 
Hybridized Sample 12 µl  Hybridized Sample 30 µl 
0.15M MgCl2 1.2 µl  0.15M MgCl2 3 µl 
SURVEYOR Enhancer S 1 µl  SURVEYOR Enhancer S 1 µl 
SURVEYOR Nuclease S 1 µl  SURVEYOR Nuclease S 1 µl 
Stop Solution (added 
after incubation) 






The digestions were mixed gently by vortex and subsequently incubated at 42oC 
for 60 minutes. Immediately after the incubation period, the SURVEYOR Stop 
Solution was added to each reaction and products were either stored at -20oC or 
analysed by agarose gel electrophoresis immediately (section 2.2.5). 
Homoduplexes appear on 2% agarose gels as a single DNA band, whereas 
heteroduplexes are cleaved by the SURVEYOR nuclease enzyme and will appear 
as fragmented DNA.  
 
2.2.16. CellTiter-Glo viability assay 
 
Viability after siRNA gene knockdown 
For viability assays performed after siRNA treatment, cells were treated as 
described in 2.2.1, harvesting those 72 hours after primary transfection. Cells 
were counted and re-seeded at a density of 3x103 per well in triplicate per 
condition in to a flat bottom white 96 well microplate (Nunc – Thermo Scientific). 
Viable or metabolically active cells, determined by quantification of active ATP, 
were measured 24 hours later. CellTiter-Glo reagent (Promega) was added in a 
1:1 ratio with media to the cells and left at room temperature for 15 minutes, 
luminescence was observed using the GloMAX-Multi Microplate reader 
(Promega). 
 
Viability after drug treatment 
Cells were seeded at a density of 8x103 per well directly in to a flat bottom white 
96 well microplate (Nunc – Thermo Scientific) and left to adhere. 24 hours after 
seeding, fresh medium was added to the cells, supplemented with drug. Drug 
doses were performed in triplicate wells and DMSO was used as a vehicle control 
in all cases. Cells were left in the supplemented medium for a further 96 hours 




2.2.17. High-throughput siRNA screening 
 
shBAF180+GFP/NLS and shControl+mCherry/NLS U2OS cells were seeded at a 
1:1 density of 8000 cells per well in 96-well plates. Cells were reverse transfected 
with a RNAi library of 446 genes with Lipofectamine RNAi MAX at a final siRNA 
concentration of 20nM. Cells were grown for 72 hours, permeabilised, fixed in 4% 
PFA and stained with DAPI. Screened cells were imaged at 10x magnification in 
16 frames per well, imaging more than 10,000 cells per well. 
 
2.2.18. Clonogenic survival assay 
 
Clonogenic survival after siRNA gene knockdown 
siRNA knockdowns were carried out as described in 2.2.1 and at the 72 hour time 
point after primary transfection, cells were either harvested for Western blot 
(section 2.2.4) or were seeded to 6cm dishes at a density of 300 cells per dish, in 
triplicate per condition. Cells were allowed to grow for 12-14 days, or until visible 
colonies were observed. Media was discarded from the plates and cells were 
stained with methylene blue for 1 hour. The methylene blue stain was washed 
away gently with water and plates were allowed to dry before scoring colonies 
using a Stuart Scientific SC6 colony counter (Sigma-Aldrich). Any colony that 
appeared to contain 50 cells or more was counted and the surviving fraction was 
worked out as a percentage of the siRNA treated cells compared to siControl cells. 
 
Clonogenic survival after drug treatment (+/- Irradiation) 
Cells were plated to 10cm dishes at a density of 300 cells per plate in 9ml of 
appropriate medium and were left to adhere for at least 4 hours, or overnight if 
seeding took place late in the evening and treatment was carried out early the 
next morning to ensure cells haven’t gone through a cellular division before 
treatment. The cells were then treated with varying doses of drug in triplicate, 
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made up in 1ml of appropriate medium and this was added to the medium 
already in culture, making a total plate media volume of 10ml. The plates were 
incubated for 12-14 days or until visible colonies were observed. The plates were 
stained and counted as described above. For plates treated with irradiation as 
well as drug, the lowest concentration of drug where you are able to observe a 
difference was determined and varying doses of gamma irradiation was inflicted 




Cells were grown in 96 well plates and siRNA treated in the same manner as 
described in the high-throughput siRNA screen (section 2.2.17). When cells were 
70-90% confluent, media was removed and cells were washed with PBS before 
fixing in 4% paraformaldehyde for 10 minutes. Cells were washed twice with PBS 
and were either immediately subjected to antibody staining or were kept at 4oC 
for up to 72 hours. PBS was removed and cellular membranes were 
permeabilized with PBS + 0.2% Triton X-100 for 3 minutes before being 
incubated in primary antibody (at appropriate dilution) in PBS + 2% w/v BSA for 
1 hour. Cells were washed three times with PBS before incubating with secondary 
antibody (at appropriate dilution) in PBS + 2% w/v BSA for 30 minutes at room 
temperature in the dark. Cells were washed three times with PBS, incubated with 
DAPI and visualised at 20x objective using the EVOS fluorescent digital inverted 
microscope.   
 
2.2.20. Flow Cytometric Immunofluorescence Analysis 
 
For flow cytometric immunofluorescence analysis, U2OS stable shControl and 
shBAF180 cells were seeded at a density of around 1x106 in 10 cm dishes and 
cultured for 24 hours before the addition of the drugs Olaparib and Camptothecin 
at stated doses in duplicate per dose/time point. Cells were harvested at 0, 24, 48, 
72 and 96 hour time points and pelleted by centrifugation at 1500 rpm for 5 
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minutes. To fix the cells, 1ml 70% Ethanol (EtOH) was added drop wise to the 
pellets whilst gently vortexing, storing the fixed cells at -20oC until the final time 
point is harvested. Once all samples are collected, the fixed cells are then pelleted 
by centrifugation at 1000 rpm for 3 minutes and gently washed in PBS before a 
second round of centrifugation. The cells are then re-suspended in 1ml PBS + 0.1% 
BSA using a Gilson pipette and centrifuged again before re-suspending in 2ml PBS 
+ 0.5% BSA + 0.25% Triton X-100 and incubated on ice for 15 minutes and 
subsequently centrifuged again at 1000 rpm for 3 minutes. The pellet, depending 
on size was then re-suspended in 50-100µl PBS + 0.5% BSA + 0.25% Triton X-
100 cleaved Caspase 3 Asp175 (9661) at 1:500 dilution and incubated at room 
temperature for at least 1 hour. The cells were then washed with PBS + 0.5% BSA 
+ 0.25% Triton X-100, re-pelleted by centrifugation and further incubated in 50-
100µl PBS + 0.5% BSA + 0.25% Triton X-100 with anti-rabbit 488 secondary 
antibody at a 1:500 dilution at room temperature in the dark for 30 minutes. Cells 
were then washed with PBS + 0.5% BSA + 0.25% Triton X-100 and re-suspended 
in 200-400µl Propidium Iodide (PI) solution with 5µg/ml PI and 100µg/ml 
RNAase I and incubated at room temperature in the dark for 15 minutes. Samples 
were then transferred to 4oC for overnight storage. Cells were passed through a 
fine-gauge needle prior to sampling on the BD Accuri C6 plus flow cytometer (BD 
Bioscience). 
 
2.2.21. RAD51 foci formation assay 
 
For RAD51 foci formation, U2OS cells were seeded at a density of 3x105 in to two 
6cm tissue culture dishes in 3ml of medium per dish. A transfection reagent 
composed of 200µl OptiMEM (Gibco), 12µl HiPerfect (Qiagen) and 6µl of either 
siControl or siBAF180 (ON-TARGETplus SMARTpool Dharmacon) at 20μM stock 
was then added drop wise to the cells. 24 hours later the transfection reagent was 
made as before and was added to the area of two sterile coverslips in fresh 6cm 
dishes. The cells were gently detached, using trypsin and were re-seeded to the 
new 6cm dishes containing coverslips. 48 hours later, or when cells appear 
almost confluent on the coverslips, Aphidicolin (Sigma-Aldrich) was added to the 
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medium at a dilution of 1:1000 to prevent S phase cells from progressing to G2. 
One coverslip from each dish was then taken to a new dish and washed twice with 
PBS, permeabilization of the cellular membrane was then achieved by adding PBS 
+ 0.2% Triton to the cells for no more than 60 seconds. The cells were then fixed 
in 4% paraformaldehyde for 10 minutes before being washed three times with 
PBS and stored at 4oC. The coverslips that remain in the 6cm dishes with media 
were irradiated with gamma radiation to the extent of 3 Gy and were returned to 
the 37oC incubator with 5% CO2 for 2 hours before being permeabilised and fixed 
as described previously. Coverslips were either antibody stained immediately or 
stored at 4oC for up to 72 hours. If immediately sampling coverslips, PBS was 
removed and slips were incubated in PBS with 1:200 dilution of Anti-RAD51 (sc-
8349) primary antibody for 1 hour, with 1:200 dilution of Rabbit Cy3 secondary 
antibody for 30 minutes, with 1:1000 dilution of Anti-CENPF (sc-22791) primary 
antibody for 1 hour and finally with a 1:400 dilution of Alexa-488 secondary 
antibody for 30 minutes. Between each antibody addition, coverslips were 
washed with PBS three times. Coverslips were then mounted to microscope slides 
using VECTASHIELD Antifade Mounting Medium with DAPI (Vector 
Laboratories). RAD51 foci were scored by eye in G2 positive cells only using the 








The principle of synthetic lethality, as described fully in section 1.6, defines a 
genetic relationship between a pair of genes, where the loss of either gene is 
permissive for cell survival but the combinatory loss of both genes together is 
resultant in cell death or a retardation of growth. Synthetic lethality can be 
observed in genes that act in the same biochemical pathway as well as in distinct, 
but compensatory pathways (Pan, Ye et al. 2006).  
Originally, the phenomenon of synthetic lethality was exploited to elucidate 
functional relationships between genes in yeast, but more recently the principle 
has been harnessed in the search for targeted cancer therapy. As previously 
described, there have been multiple examples where yeast genetic interactions 
have been translated to mammalian cells (Yu, Lopez et al. 2008, Conde-Pueyo, 
Munteanu et al. 2009, McLellan, O'Neil et al. 2009, McManus, Barrett et al. 2009). 
Using this potentially translatable observation as well as the data from three 
independent synthetic lethal screens in yeast, we identified eight genes with 
synthetic lethal interactions with yeast homologues of BAF180 (Rsc1 and Rsc2) 
to take forward for experimentation in mammalian cells (Table 3.1). Of the many 
potential synthetic lethal candidate genes that could be explored, we chose these 
eight due to their strong sequence conservation from yeast to mammalian cells, 
they were all synthetic lethal or synthetic sick with Rsc1 and/or Rsc2, the 
deletion of all genes alone are not thought to be deleterious to ‘normal’ cells and 
they are all potentially targetable by drugs. 
Of the eight genes identified as potentially synthetic lethal with BAF180, four of 
them, Asf1 (ASF1A, ASF1B), CTF18 and SLX5 (RNF4), were identified in a screen 
that sought to use global genetic analysis to identify novel synthetic fitness or 
lethality defect interactions in the DNA integrity network of S. cerevisiae (Pan, Ye 






















































































































Anti-silencing function 1 (Asf1) is a histone chaperone that participates in both 
nucleosome assembly and disassembly (Park and Luger 2008, Krebs and Tora 
2009, Oh, Ruskoski et al. 2012). Asf1 is a histone H3/H4 chaperone in the context 
of DNA replication and together with CAF-1 and PCNA works to assemble 
nucleosomes on replicated DNA (Franco, Lam et al. 2005, Sanematsu, Takami et 
al. 2006, Groth, Corpet et al. 2007, Miller, Yang et al. 2008). Cells that have lost 
the Asf1 protein have impairments in DNA replication (Schulz and Tyler 2006). 
In mammalian cells there are two isoforms of Asf1, which are ASF1A and ASF1B. 
These mammalian isoforms have a highly conserved N-terminus, which acts as a 
binding interface for both the H3.1-H4 replicative histones and the H3.3-H4 
replacement histones (De Koning, Corpet et al. 2007, Corpet, De Koning et al. 
2011). Like Asf1 in yeast, the mammalian isoforms also interact with CAF-1 in the 
replication-coupled assembly pathway (Mello, Sillje et al. 2002). A good 
representation of the conservation between yeast Asf1 and the two human 
isoforms can be seen when human ASF1A introduced in to yeast is able to rescue 
the DNA damage response defect created from the depletion of endogenous Asf1 
(Tamburini, Carson et al. 2005, Corpet, De Koning et al. 2011). Furthermore, 
introduction of human ASF1B to Asf1 depleted yeast cells can compensate for the 
associated growth defects and the sensitivity to replication stress (Tamburini, 
Carson et al. 2005, Corpet, De Koning et al. 2011). 
The rather aptly named Chromosome transmission fidelity protein 18 (CTF18) is 
required for the faithful segregation of chromosomes (Hanna, Kroll et al. 2001). 
It is a component of the CTF18-RFC complex, composed of Ctf18, Ctf8, Dcc1 along 
with four small subunits (Rfc2-5) of replication factor C (RFC), which as a whole 
is necessary for sister chromatid cohesion and faithful chromosome transmission 
(Mayer, Gygi et al. 2001, Bylund and Burgers 2005). Loss of CTF18 is associated 
with a severe sister chromatid cohesion defect, failed maintenance of telomeres, 
and results in a preanaphase accumulation of cells that depends on the spindle 
assembly checkpoint. CTF18-defective cells have an increased sensitivity to 
microtubule depolymerizing drugs and hypersensitivity to the chemotherapeutic 
drugs methyl methanesulfonate (MMS) and hydroxyurea (HU) (Hanna, Kroll et al. 
2001, Mayer, Gygi et al. 2001, Kubota, Hiraga et al. 2011). 
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RING finger protein 4 (RNF4), also known as small nuclear RING finger protein 
(SNURF) (Moilanen, Poukka et al. 1998) is an E3 ubiquitin-protein ligase that 
mediates the proteasomal degradation of several proteins including the 
promyelocytic leukaemia (PML) protein and the transcriptional activator PEA3. 
A C3HC4 (RING-HC)-type RING finger motif resides at RNF4s C-terminal domain 
(Moilanen, Poukka et al. 1998). RNF4 is the best characterised SUMO targeted 
ubiquitin ligase (STUbL) in human cells. STUbLs can contain individual or 
multiple SUMO interacting motifs (SIMs) that can recognise SUMO chains and 
target poly-SUMOylated proteins for proteasome-mediated degradation. RNF4, 
using SIMs, can recognise SUMO chains, for example the poly-SUMOylated PML, 
acting to ubiquitinate the PML as well as the poly-SUMO chains attached to it, 
subsequently directing PML for proteasomal degradation (Tatham, Geoffroy et al. 
2008). RNF4 has also been associated with chromosome alignment and spindle 
assembly by the regulation of the kinetochore complex CENPH-CENPI-CENPK, 
targeting poly-SUMOylated CENPI for proteasomal degradation (Hickey, Wilson 
et al. 2012). 
Using genome wide analysis, Lin et al found that the yeast homologs of our two 
candidate HDACs, HDAC1 and HDAC4 and one HAT gene, KAT5 (TIP60), were all 
synthetic lethal with the BAF180 yeast homologue Rsc2 (Lin, Qi et al. 2008). Yeast 
counterparts of HDAC1 and KAT5 were also synthetic lethal with Rsc1 however 
HDAC4 had a less severe phenotype, exhibiting a synthetic growth defect with 
Rsc1 upon double deletion (Lin, Qi et al. 2008).  
Histone (lysine) acetyltransferase 5 (KAT5), also referred to as TIP60 and 
denoted as such in this thesis, is the catalytic subunit of the nucleosome 
acetyltransferase of H4 (NuA4)/TIP60 complex. NuA4 primarily acetylates the 
nucleosomal histones H4 and H2A to mediate transcriptional activation of 
various genes, but is also a regulator of the cellular response to DNA damage, 
apoptosis, cell signalling and cell cycle control (Doyon and Cote 2004, Sun, Jiang 
et al. 2005, Brown, Bourke et al. 2016). Mammalian NuA4, which confusingly is 
also referred to as TIP60, is a multi-protein complex (Jha, Gupta et al. 2013, 
Mahajan and Stanley 2014). Yeast NuA4 has 13 subunits with the Esa1 subunit as 
the catalytic core, homologous to TIP60 (Doyon and Cote 2004). TIP60 has a 
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direct role in histone exchange, working with SRCAP and p400 to remove 
H2A/H2B dimers and replace them with H2A.Z/H2B (Cai, Jin et al. 2005, Ruhl, Jin 
et al. 2006, Wong, Cox et al. 2007). The hypoxia inducible factor 1A (HIF1A) is 
known to interact with and recruit TIP60 to chromatin and TIP60 is thought to 
be required for HIF1A-dependent chromatin modification and RNA polymerase 
II activation in hypoxia (Perez-Perri, Dengler et al. 2016). An important role for 
TIP60 is in the regulation of the repair of DNA DSBs via acetylation and 
subsequent activation of ATM and other proteins involved in the DDR (Sapountzi, 
Logan et al. 2006, Judes, Rifai et al. 2015).  
Our final candidate gene, KAT2A (GCN5), was identified as synthetic lethal with 
both Rsc1 and Rsc2 in a small scale screen that aimed to identify whether RSC 
together with the SAGA genes were required for cell viability (Cairns, Schlichter 
et al. 1999). GCN5 is a histone acetyltransferase (HAT) that is part of the SAGA 
(SPT-ADA-GCN5 acetylase) coactivator complex and was first identified in the 
yeast S. cerevisiae, working to promote transcriptional activation in specific genes 
within chromatin (Martinez, Palhan et al. 2001). In mammalian cells there are 
two homologs of GCN5, GCN5L and PCAF, which have been found in multiple 
different complexes that resemble the yeast SAGA complex, the PCAF complex, 
TFTC (TATA-binding-protein-free TAFII-containing complex), STAGA (SPT3-
TAFII31-GCN5L acetylase) and more recently the ATAC complex, which 
resembles the ATAC (Ada Two-A containing) complex in Drosophila (Wang, 
Faiola et al. 2008) (Martinez, Palhan et al. 2001, Wang, Faiola et al. 2008, Guelman, 
Kozuka et al. 2009). These multi-protein complexes are involved in a wide range 
of biological processes by acetylating histones H3 and H4 as well as several non-
histone proteins, therefore regulating chromatin and gene specific transcription 
(Wang, Faiola et al. 2008). Yeast GCN5 is synthetic lethal with both homologues 
of BAF180 Rsc1 and Rsc2 (Cairns 1999). In mammalian cells it is known as KAT2A 
and the relationship between it and BAF180 has not been fully explored. 
In addition to our hypothesis driven candidate synthetic lethal genes that were 
chosen based on our knowledge of yeast gene interactions, we also used current 
mammalian cell literature as well as our knowledge of the genes frequently 
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mutated in renal cell carcinoma to identify two more potential synthetic lethal 
with BAF180 gene candidates: BAP1 and EZH2.  
As discussed in section 1.3.3, BAP1 is known to be one of the four main drivers of 
tumourigenesis in ccRCC, mutated at a frequency of around 15% in all tumours. 
Although it has been classified as a main driver mutation in ccRCC, these 
mutations do not tend to correlate with PBRM1 mutation. Mutations that occur 
in BAP1 in ccRCC are also though to exhibit different biology as well as leading to 
a different prognosis and overall survival (OS), when comparing to ccRCC’s with 
mutations in PBRM1. This, together with the mutually exclusive relationship 
observed between these mutation frequencies, suggested that they could be 
exploited therapeutically in a synthetic lethal manner. 
EZH2 is the catalytic subunit of the polycomb repressive complex 2 (PRC2) and 
works by catalysing the methylation of lysine 27 on histone H3, which is a 
chromatin modification that is associated with transcriptionally repressed 
heterochromatin.  
Recently, in our lab, it has been shown that depletion of EZH2, results in the 
formation of fewer H2AK119ub foci in irradiated cells, a phenotype that is 
mirrored in both BAF180 and BMI1 (PRC1) depleted cells. This suggests that 
PRC2 is required for IR-induced H2AK119ub and that PRC2 may promote PRC1 
activity at sites of DNA damage (Kakarougkas, Ismail et al. 2014). It was also 
observed that similar to cells lacking the PBAF complex, there was a delay in the 
repair of a subset of DSBs at early time points following IR in EZH2 depleted cells 
and this is consistent with the idea that a failure to repress transcription flanking 
DSBs impeded efficient repair. It was postulated that PBAF remodels chromatin 
surrounding DSBs in order to facilitate PRC2 and therefore PCR1 activity toward 
their respective substrates (Kakarougkas, Ismail et al. 2014).  
Wilson et al describe an imbalanced epigenetic antagonism between the 
SWI/SNF complex and the PRC2 complex (Wilson, Wang et al. 2010). They find 
that loss of a core SWI/SNF subunit, SNF5, in cancer cells results in the 
upregulation of EZH2 and that inactivation of EZH2 activity ultimately blocks 
tumour progression in mouse models (Wilson, Wang et al. 2010). An observation 
that could be exploited therapeutically in vivo.  
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Since this finding, multiple other studies have arisen to determine if this synthetic 
lethal interaction between SNF5 and EZH2 could be reproduced with other 
subunits of the SWI/SNF complex (Kim, Kim et al. 2015).  
It was shown recently that cancers that lack the ARID1A, PBRM1 and SMARCA4 
subunits of SWI/SNF were dependent on both the catalytic and non-catalytic 
activity of EZH2 (Kim, Kim et al. 2015). It was also found that treatment of 
ARID1A-mutated ovarian cancer cells with EZH2 methyltransferase inhibitors 
resulted in synthetic lethality (Bitler, Aird et al. 2015). In a combinatory approach, 
Fillmore et al found that treatment with EZH2 inhibitors in BRG1 and EGFR 
mutated non-small-cell lung cancers sensitized these tumours to treatment with 
TopoII inhibitors, presenting a new therapeutic strategy in a genetically complex 
disease (Fillmore, Xu et al. 2015). Our aim was to determine whether this 




The aim of this work was to use a hypothesis driven approach to explore and 













3.3. A subset of yeast synthetic lethal interactions are 
not conserved in mammalian cells  
 
To identify which candidate genes selected by yeast high-throughput screen data 
(Figure 3.1a) could have conserved synthetic lethal interactions between yeast 
and mammalian cells we first carried out viability assays after siRNA depletion. 
U2OS cells were transfected with short interfering RNA targeting human BAF180 
mRNA or a nonsense scrambled control mRNA as well as the candidate genes 
ASF1A, ASF1B, CTF18, HDAC1, HDAC4 and TIP60 and the viability measured 
(Figure 3.1b). Western blotting (Figure 3.1c) was used to confirm knockdown.  
For both ASF1A and ASF1B there was no significant decrease in viability in cells 
depleted for both ASF1 and BAF180 when compared to appropriate controls 
(Figure 3.1b). However, although not significant statistically, knockdown of 
ASF1B did appear to decrease viability of BAF180 depleted cells more favourably 
compared to the control. Similarly, no significant synthetic lethal interaction was 
detected between either HDAC1 or HDAC4 and BAF180. 
While the synthetic lethal interaction between TIP60 and BAF180 was not 
significant in these assays, there was a trend towards reduced viability in the cells 
depleted of both relative to either single depletion (Figure 3.1b), and further 
analyses uncovered a significant relationship (Hopkins, McGregor et al. 2016). 
The reasons for the lack of synthetic lethality in these assays are not clear, but 























































































Figure 3.1. A subset of yeast synthetic lethal interactions are not 
conserved in mammalian cells. (A) List of gene candidates chosen 
for hypothesis driven synthetic lethal mini screen. (B) U20S cells were 
transfected with short interfering RNA targeting human BAF180 
mRNA, as well as a scrambled ‘control’ siRNA and either ASF1A, ASF1B, 
CTF18, HDAC1, HDAC4 or TIP60 mRNA (C) Western blot analysis of 
siRNA treated U20S cells. Whole cell extracts were analysed with the 





3.4. U2OS cells have reduced viability after co-depletion 
of BAF180 and RNF4 
 
Cell titre glow viability assays were performed with cells depleted of BAF180 
and/or RNF4 to investigate a potential synthetic lethal relationship.  There was 
an 18% difference in average viability is seen between cells treated with siRNF4 
alone, compared to RNF4 and BAF180 siRNA treatment, with a p value of 0.086, 
determined by student T-test. Although the p value is not statistically significant, 
the trend is very reproducible. The siRNA depletion of RNF4 was not efficient, 
raising the possibility that further depletion would lead to more substantial 
effects on viability. 
 
3.5. U2OS cells have a reduced viability after co-
depletion of BAF180 and GCN5 
 
To establish if there was a conserved synthetic lethal interaction between KAT2A 
and BAF180, we used siRNA transfection in U2OS cells to knock down KAT2A 
alone, BAF180 alone and the two together and then viability was measured. We 
observed a significant reduction in viability after siRNA knockdown of KAT2A 
together with BAF180 (Figure 3.3a). Knockdown efficiency was determined by 
Western blotting (Figure 3.3b). These data suggests that the histone 








































































Figure 3.2. U20S cells have reduced viability after co-depletion 
of BAF180 and RNF4. (A) Viability was measured following siRNA 
treatment targeting either human BAF180 or RNF4 mRNA was 
introduced in to U20S cells alongside a sequence of scrambled or 
‘control’ siRNA. (B) Western blot analysis of siRNA treated U20S 
cells. Whole cell extracts were prepared and analysed using 



























Figure 3.3 U20S cells have reduced viability after co-depletion 
of BAF180 and GCN5. (A) Cell viability was observed after siRNA 
transfection of siBAF180, siGCN5 and siControl, in U20S cells. siRNA 
knockdown of both GCN5 and BAF180 in U20S cells results in a 
reduction of cell viability compared to each of the individual 
knockdowns. (B) Western blot analysis of siRNA treated U20S cells 
using antibodies raised against BAF180 or GCN5, using α-tubulin as 











































3.6. Depletion of EZH2 in BAF180 shU2OS cells results in 
a synthetic lethal interaction 
 
This hypothesis was tested in stable U2OS cell lines expressing short hairpin RNA 
(shRNA) targeting BAF180 or a control sequence described in Chapter 4.  
Clonogenic survival assays were carried out after siRNA depletion of either 
human EZH2 mRNA or a scrambled ‘control’ mRNA. shBAF180 cells were 
significantly more sensitive to EZH2 knockdown in three independent 
experiments (Figure 3.4a). A representative western blot of this knockdown is 
shown in (Figure 4.3). To confirm efficient siRNA knockdown of EZH2, whole cell 
extracts were harvested 72 hours after primary transfection and were analysed 
by western blot (Figure 3.4b). Interestingly, there appears to be increased EZH2 
levels in the shBAF180 cells compared with the shControl cells (Figure 3.4b). This 
is consistent with the finding by Wilson et al, where they see an overexpression 
of EZH2 after the loss of SNF5 (Wilson, Wang et al. 2010). These data suggest a 
synthetic lethal interaction between BAF180 deficiency and EZH2 loss.  
To further investigate this interaction, we used the drug GSK126, which acts by 
inhibiting the methyltransferase activity of EZH2. The cells deficient in BAF180 
were inherently more sensitive to treatment with GSK126 at all doses, in 
agreement with Kim et al (Kim, Kim et al. 2015). These data suggest that EZH2 
inhibitors may be a new therapeutic treatment for BAF180-mutated cancers, 








































































































Figure 3.4 BAF180 depleted shU20S are more sensitive to EZH2 siRNA and 
inhibitors. (A) shBAF180 cells (see chapter 4) were more sensitive to EZH2 
knockdown in clonogenic survival assays (n=3). Statistical significance is 
represented by * for p<0.05, as analysed by Student’s t-test. (B) Western Blot 
analysis of depletion of EZH2 in shControl and shBAF180 cells. (C) shBAF180 cells 





3.7. BAP1 and BAF180 are synthetic lethal 
 
3.7.1. BAF180 depleted shU2OS are more sensitive to depletion 
of BAP1 
 
To test the hypothesis that BAF180 and BAP1 exhibit a synthetic lethal 
interaction we first tested survival after siRNA knockdown in shControl and 
shBAF180 cells. Colony formation assays were carried out in triplicate to assess 
viability changes in these stable U2OS cells after knockdown with both siControl 
and siBAP1 (Figure 3.5a).  
First, we found that BAP1 depletion reduced the viability of both shControl and 
shBAF180 cells (Figure 3.5a). It is the hope that depletion of a single gene that we 
wish to exploit therapeutically would not have such a significant effect on our 
‘normal’ cell population. However, we know that cancer cells can grow efficiently 
without the presence of BAP1 in vivo and so a severe reduction in total cell 
viability here may be specific to U2OS cells. Alternatively, there may be off target 
siRNA effects. Nevertheless, there was still a small, yet statistically significant 
decrease in the surviving fraction of shBAF180 cells compared to shControl 
(Figure 3.5a). The knockdown efficiency was assessed by Western blot (Figure 
3.5b). 
 
3.7.2. BAP1 and BAF180 are synthetic lethal in a ccRCC model 
 
To investigate the relationship between BAF180 and BAP1 in a more clinically 
relevant manner, we then decided to look at cell viability after BAP1 and BAF180 
siRNA depletion in a panel of renal cell cancers. The A704 and 769-P cell lines 
were derived from human ccRCC and have inactivating mutations in BAF180 and 
BAP1 respectively.  In the renal cells, A704, lacking BAF180, cell viability is 
greatly compromised after further depletion of BAP1 (Figure 3.6a). Similarly, but 
not as strikingly, depletion of BAF180 in a BAP1 mutant cell line, 769-P, also 
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resulted in a reduction of viability compared to siControl only (Figure 3.6a). By 
Western blot analysis, we find that the A704 cell line harbouring the BAF180 
mutation leads to a total loss of protein. Whereas the 769-P cell line that harbours 
the BAP1 mutation, does not abrogate protein expression but does result in a loss 
of function (Pena-Llopis, Vega-Rubin-de-Celis et al. 2012). Together, these data 
suggest that BAP1 is synthetic lethal with BAF180 in a number of systems, 






































































p = 0.044 
Figure 3.5 BAF180 depleted shU20S are more sensitive to depletion of BAP1. 
(A) shBAF180 cells (see Chapter 4) were more sensitive to siRNA knockdown of 
BAP1 in triplicate experiments. Statistical significance is represented by * for 
p<0.05, as analysed by Student t-test. (B) Western Blot Analysis of siRNA treated 
shU20S cells. Whole cell extracts were prepared and separated by 8% SDS-PAGE 
gels, transferred to nitrocellulose and probed with antibodies raised against BAP1. 






























































































































Figure 3.6 BAP1 and BAF180 are synthetic lethal in a ccRCC model (A) Promega 
Cell Titre Glo Viability Assay in RCC’s. siRNA against human BAP1 as well as 
scrambled or ‘control’ siRNA was transfected in to the BAF180 lacking A704 renal 
cancer cell line and likewise, BAF180 siRNA was transfected in to the BAP1 mutated 
renal cell line 769-P, using Lipofectamine RNAiMAX transfection reagent. 72hrs 
after primary transfection the cells were re-seeded in triplicate per condition to 96 
well plates. Viable cells were measured 24 hours later using cell titre glo reagent. 
Both the A704 and 769-P cell lines showed a sensitivity to siRNA knockdown of 
BAP1 and BAF180 respectively, suggesting a synthetic lethal interaction between 





In this chapter we demonstrated that multiple genes exhibit a synthetic lethal 
phenotype when knocked down in mammalian cells in combination with BAF180 
(PBRM1). Consistent with data from yeast high-throughput synthetic fitness 
screening (Cairns, Schlichter et al. 1999, Pan, Ye et al. 2006, Lin, Qi et al. 2008), 
we found that RNF4 and GCN5 (KAT2A) have a conserved synthetic lethal 
interaction with mammalian BAF180. While not statistically significant in the 
assays carried out in this study, we have illuminated a possible synthetic lethal 
interaction between BAF180 and ASF1B, HDAC4 and TIP60 that have potential to 
be validated with further testing.  
In corroboration with multiple studies that identify EZH2 as an essential gene in 
cancers that have lost subunits of the SWI/SNF complex (Wilson, Wang et al. 2010, 
Bitler, Aird et al. 2015, Fillmore, Xu et al. 2015, Kim, Kim et al. 2015), we were 
able to confirm a synthetic lethal relationship between BAF180 and EZH2 that 
can be applied to clinical therapy using drugs that target EZH2s 
methyltransferase activity, such as GSK126.  
We also identified BAP1 as a synthetic lethal interactor of BAF180, which could 
be exploited clinically with the use of BAP1 inhibitors.  
A summary of all synthetic lethal interactions studies in this chapter are shown 





































Table 3.2. Overview of interactions tested in hypothesis driven 
screen. *Note: While ASF1B and HDAC4 are noted as not synthetic lethal 
with BAF180 in this table, this conclusion is limited to this specific 




3.8.1. Histone acetyltransferases and synthetic lethality with 
BAF180 
 
Two histone acetyltransferases (HAT) genes have been identified as being 
synthetic lethal with mammalian BAF180 from this data, TIP60 (KAT5) and GCN5 
(KAT2A).  
As mentioned, TIP60 is the catalytic subunit of the NuA4/TIP60 complex and has 
well established roles in the regulation of the DNA DSB response (Ikura, Ogryzko 
et al. 2000, Sun, Jiang et al. 2005). TIP60 has also been linked to regulating faithful 
mitotic chromosome segregation via the acetylation of Aurora B, with TIP60 
working to stabilize Aurora B’s activity during the transition from metaphase to 
anaphase (Mo, Zhuang et al. 2016). Work in our lab has shown that BAF180 also 
regulates mitotic stability, but unlike TIP60, BAF180 promotes the correct 
establishment of centromere cohesion, subsequently preventing genome 
instability and aneuploidy (Brownlee, Chambers et al. 2014). One possibility is 
that a combined defect in both mechanisms could be the contributing cause of the 
synthetic lethal effect we see (Figure 3.1) (Hopkins, McGregor et al. 2016). 
The second and more convincing evidence of synthetic lethality between BAF180 
and HAT genes was seen with GCN5 (Figure 3.3). GCN5 was found to be synthetic 
lethal with BAF180’s yeast homologs Rsc1 and Rsc2 (Cairns, Schlichter et al. 
1999).  
Bromodomains are found in many proteins and are important for the regulation 
of transcription and chromatin structure and can be found in proteins with HAT 
activity, like GCN5 as well as in members of the SWI/SNF family, including 
BAF180 (Jeanmougin, Wurtz et al. 1997, Winston and Allis 1999). Bromodomains 
bind to the amino-terminal tails of histones H3 and H4 (Ornaghi, Ballario et al. 
1999) and function as acetyl-lysine binding motifs (Dhalluin, Carlson et al. 1999). 
In GCN5 the bromodomains are not thought to play an important role (Candau, 
Zhou et al. 1997), however genetic cooperativity has been found between the 
bromodomains of Rsc4, another homologue of BAF180, and GCN5. Lys14 of 
histone H3 is the preferred site of acetylation by GCN5 and is also a critical 
residue for Rsc4 bromodomain function. It could be speculated that loss of this 
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interaction between both bromodomain containing complexes, including loss of 
acetylation at Lys14 of histone H3, could be the underlying reason for the 
synthetic lethality found in this study. 
 
 
3.8.2.  Possible mechanisms for synthetic lethality between 
BAF180 and RNF4 
 
As previously mentioned, RNF4 is an E3 ubiquitin-protein ligase that is one of the 
most characterised SUMO targeted ubiquitin ligase (STUbL) in mammalian cells. 
Ubiquitylation and SUMOylation can simply be described as the covalent 
attachment of ubiquitin and/or SUMO polypeptides to target proteins, thus 
providing a mechanism to regulate cellular functions, which is important for the 
maintenance of genome stability (Jackson and Durocher 2013). These post-
translational modifications are important for the coordination of multiple 
pathways, including the DNA damage recognition pathway, the cell signalling 
pathway and DNA repair (Jackson and Durocher 2013). Work in our lab has 
shown BA180 to have an important role in the repriming of replication 
downstream from replication forks that have been blocked at sites of DNA 
damage (Niimi, Chambers et al. 2012). Depletion of BAF180 after DNA-damage 
with UV-irradiation, resulted in a reduction of PCNA ubiquitination as well as 
unmodified chromatin-associated PCNA and the STUbL E3 ligase that 
ubiquitinates PCNA, Rad18. Interestingly, we found that the BAH domains of 
BAF180 are specifically required for the ubiquitination of PCNA (Niimi, Hopkins 
et al. 2015). The cooperation between BAF180 and ubiquitylating ligases could 
explain the mechanism behind the synthetic lethality observed after double 
depletion of BAF180 and RNF4. In vitro, the ubiquitylation targets of STUbLs are 
relatively unspecific (Sun, Leverson et al. 2007), so it is possible that RNF4 acts 
to compensate for the decrease in Rad18 after BAF180 depletion and when this 
compensatory pathway is removed, could result in replication fork collapse and 
subsequently the cell death we observe in Figure 3.2.  
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Alternatively, I found that depletion of BAF180 results in a defect in HR (Chapter 
6). Inactivation of RNF4 in both mammalian and chicken cells results in the 
defective repair of DNA DSBs by both HR and NHEJ (Galanty, Belotserkovskaya et 
al. 2012, Luo, Zhang et al. 2012, Yin, Seifert et al. 2012). Therefore, it is plausible 
to assume that loss of two pathways that are responsible for the repair of 
damaged DNA via HR and NHEJ could be sufficient to trigger apoptosis in these 
cells. 
Although RNF4 is potentially targetable by drugs, there are currently no known 
inhibitors, making the transition from bench to clinic more difficult than with 
other genes we have found to be synthetic lethal with BAF180 in this study.  
 
3.8.3. Synthetic lethality by targeting EZH2 methyltransferase 
activity in BAF180-mutated cancers 
 
EZH2 is an epigenetic regulator that silences the expression of its target genes 
(Bitler, Aird et al. 2016). EZH2 is upregulated in a variety of cancers including 
breast, prostate and lymphomas and can often be associated with advance 
staging of tumour progression and poor prognosis, suggesting it has an important 
role in oncogenic transformation (Varambally, Dhanasekaran et al. 2002, Bracken, 
Pasini et al. 2003, Simon and Lange 2008, Wilson, Wang et al. 2010). It is already 
known that there is a genetic dependence on EZH2 in cancers that lack the SNF5 
subunit of SWI/SNF and that the complexes they belong to are antagonistic with 
each other (Wilson, Wang et al. 2010). EZH2 catalyses the methylation of lysine 
27 on histone H3, which is associated with transcriptionally repressed 
heterochromatin. Whereas the catalytic activity exhibited by SWI/SNF complexes 
is associated with euchromatin, an open, relaxed state of chromatin that is 
transcriptionally active. It is thought that the chromatin remodelling activities 
mediated by SWI/SNF complexes can be counteracted by polycomb proteins, 
such as EZH2. 
In this study, congruent to the findings between EZH2 and SNF5 (Wilson, Wang 
et al. 2010), we observe an increase in EZH2 protein expression after BAF180 loss, 
suggesting there may be a functional relationship between BAF180 and EZH2 in 
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oncogenic transformation. And in agreement with Kim et al(Kim, Kim et al. 2015), 
we found that treatment with GSK126 in BAF180 (PBRM1) mutant cell lines 
results in impaired colony formation. These data suggest that like SNF5, BAF180 
deficiency also leads to upregulated EZH2 expression and that survival of our 
BAF180-deficient cancer cells is directly dependent on this upregulated EZH2. 
This is a phenotype that can be exploited therapeutically using inhibitors against 
EZH2 in cancers that are deficient in BAF180. 
It has been shown that the ARID1A subunit of SWI/SNF and EZH2 have 
antagonistic roles and regulate many genes that overlap (Bitler, Aird et al. 2016). 
In ARID1A mutated ovarian clear cell carcinoma (OCCC), PIK3IP1 was found to 
contribute to the observed synthetic lethality seen after these ARID1A –deficient 
cancers were treated with EZH2 inhibitors. PIK3IP1 is a target gene that was 
reactivated after EZH2 inhibition in ARID1A mutated OCCC, subsequently 
responsible for triggering apoptosis, leading to cell specific killing of the ARID1A-
mutated cancer cells but not wild type cells. They suggest using EZH2 inhibitors 
in combination with an inhibitor of the PI3K/AKT pathway to achieve a greater 
clinical benefit in OCCC. This is something to consider with the synthetic lethality 
observed in our case with BAF180 and EZH2. Further investigation in to target 
genes that are potentially upregulated after EZH2 inhibition in BAF180-deficient 
cancers could generate a new approach to therapeutic treatment of ccRCC. The 
discovery of another target that could be inhibited in combination with EZH2 
inhibitors would result in a much greater clinical benefit for cancers that lack 
BAF180, like ccRCC. 
 
3.8.4. Therapeutic exploitation of the mutually exclusive BAF180 
and BAP1 mutations for treatment of ccRCC 
 
Meta-analysis (Pena-Llopis, Christie et al. 2013) and independent validation 
(Hakimi, Ostrovnaya et al. 2013) have determined that mutations in BAP1 and 
BAF180 (PBRM1) tend to be mutually exclusive in ccRCC (Pena-Llopis, Vega-
Rubin-de-Celis et al. 2012, Kapur, Christie et al. 2014). 
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As previously mentioned, mutation exclusivity often suggests that two genes 
function in the same pathway, which could itself result in synthetic lethality. 
However, in the case of BAP1 and BAF180, it is more likely that the two genes 
function in two different pathways. As mentioned before BAF180 and BAP1 
mutations give rise to markedly different clinical outcomes, they have non-
overlapping gene expression signatures and BAP1 mutations are associated with 
high Fuhrman grade (a widely used grading system for renal cell carcinoma, on a 
scale of I-IV, where grade I is associated with best prognosis and grade IV the 
worst)  and mTORC1 activation while PBRM1 mutations are associated with low 
Fuhrman grade and a lack of mTORC1 activation, supporting the argument that 
BAP1 and BAF180 must act in two distinct pathways (Brugarolas 2013). Work in 
our lab has speculated a role for BAF180 in HR and it is known that loss of BAP1 
results in impaired recruitment of HR factors like BRCA1 and RAD51 (Ismail, 
Davidson et al. 2014). Therefore, combined loss of two pathways that contribute 
to HR, together with other impaired pathways and factors due to loss of either 
gene, is most likely to be the underlying reason why these two genes exhibit a 
synthetic lethal relationship. To exploit this interaction clinically, it would be 

















The manipulation of cell lines in scientific research is important for the functional 
study of specific genes, to observe what effect the loss or gain of these genes has 
on the cells. There are multiple ways of carrying out gene manipulation in human 
cell lines in culture, but the two I will focus on in this chapter are the formation 
of stable cell lines through shRNA knockdowns and the production of gene 
knockout cells using CRISPR technology. 
 
4.1.1. RNA Interference (RNAi) 
 
RNA interference (RNAi), also known as co-suppression, post-transcriptional 
gene silencing (PTGS) and quelling, has proved itself a valuable tool for the study 
of gene function in mammalian cells in recent years. The mechanism was first 
discovered in the nematode Caenorhabditis elegans after double-stranded RNA 
(dsRNA) delivered by injection resulted in the sequence specific silencing of 
genes (Fire, Xu et al. 1998). It is believed that the natural endogenous function of 
RNAi works to protect the genome against invasion from dynamic genetic 
elements that form aberrant RNA or dsRNA in a host cell when they are activated, 
such as transposons and viruses (Elbashir, Lendeckel et al. 2001). 
The principle of RNAi works by specifically degrading the sequence of the host 
mRNA after double-stranded RNA (dsRNA) that is homologous to the target 
sequence is delivered through the cytoplasm (Fire, Xu et al. 1998). An 
endogenous complex called RISC (RNA-induced silencing complex) is involved in 
the enzymatic pathway used to degrade target gene expression. RISC, with 
assistance from the proteins Argonaute (Ago) and dsRNA binding proteins, 
allows for the loading of the guide siRNA strand to the complex, which is then able 
to localise the guide to the complementary sequence of mRNA. This mRNA is 
cleaved by the protein Ago and subsequently degraded by other endogenous 
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nucleases (Elbashir, Lendeckel et al. 2001, Moore, Guthrie et al. 2010). The 
mechanism of RNAi is served by several methods, the simplest being the 
transfection of chemically synthesized short interfering RNA oligonucleotides 
(siRNAs) in to the cytosol and the method that I will focus on here, which involves 
the use of short hairpin RNAs (shRNAs) (Moore, Guthrie et al. 2010). shRNAs can 
be introduced to cells via transfection within plasmid vectors, where the shRNAs 
are encoded within and transcribed from these vectors by RNA pol III or modified 
pol II promoters (Moore, Guthrie et al. 2010). Delivery of shRNAs to cells can also 
be achieved by the infection of the cell using virally produced vectors (Moore, 
Guthrie et al. 2010). The benefit of using shRNA rather than siRNA is that due to 
cytosolic delivery, siRNA gene knockdowns are transient, whereas shRNAs allow 
for the production of a stable gene knockdown within a cell line (Moore, Guthrie 
et al. 2010). shRNAs are typically formed of two complementary sequences that 
are between 19-22 base pairs in length, these are linked by a short loop of 4-11 
nucleotides, which is reminiscent of the naturally occurring microRNA (miRNA) 
hairpin.  After transcription, the endogenous enzyme Dicer detects the shRNA 
sequence in the cytosol. Dicer enables the processing of dsRNA and pre-
microRNAs to synthesize functional intermediates such as siRNA duplexes and 
miRNAs, that can subsequently bind to the target mRNA and are incorporated in 
to the RISC complex for sequence-specific gene degradation (Vermeulen, Behlen 
et al. 2005, Moore, Guthrie et al. 2010).  
The shRNA plasmids used in this study were expressed as unique human 
microRNA-30 (miR-30) primary transcripts and were designed to add a Drosha 
processing site to the hairpin construct, which is thought to increase gene-
silencing efficiency (Boden, Pusch et al. 2004). Drosha is a nuclease that mediates 
initial miRNA processing in the nucleus from pri-miRNA to pre-miRNA, which is 
further processed by Dicer in to mature miRNAs (Lee, Ahn et al. 2003).  
Using a cell line with stable depletion of a protein has several experimental 
advantages over transient depletion. For example, it would not be possible to 
create a long-term cell line using siRNA gene knockdowns when taking in to 
consideration that the oligonucleotide concentration is diluted over time during 
normal cells division and constant transfection with siRNA can become extremely 
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expensive over time. We therefore created multiple shRNA-expressing cell lines. 
I will discuss exactly how these cell lines were generated in detail in section 4.3. 
 
4.1.2. CRISPR/Cas9 targeted genome editing 
 
Clustered, regularly interspaced, short, palindromic repeats (CRISPR) technology 
is rapidly becoming the gold standard method used to introduce precise and 
targeted changes in the genome of living cells. Endogenous CRISPR, together with 
CRISPR-associated (Cas) genes, are essential in adaptive immunity in both 
bacteria and archaea, providing a defence mechanism that eradicates invading 
genetic material (Barrangou, Fremaux et al. 2007). CRISPR is defined as genetic 
code that incorporates short repetitions of base sequences followed by spacer 
DNA segments. It is a bacterial system that normally functions in adaptive 
immunity. This mechanism observed in bacteria has been subsequently exploited 
and adapted in to a form of genome editing that is essential in mainstream 
research today. The CRISPR/Cas9 technology that has developed from this 
knowledge of bacteria uses the endonuclease activity of Cas9 along with a 
synthetic guide RNA, that can be tailored to your specific gene, to introduce a 
double strand break at that specific location within the genome. When these 
breaks are recognised within the cell, DNA repair pathways are stimulated to 
repair these breaks, either by NHEJ or HR (Ran, Hsu et al. 2013). NHEJ will most 
typically be used to repair double strand breaks that are introduced in this 
manner, this pathway choice is error prone and introduces insertions and 
deletions, resulting in frameshift mutations in the genes coding sequence (Figure 
4.1).  
HR can also be used to repair DNA DSBs induced by CRISPR/Cas9. This can be 
exploited by providing a donor sequence with modifications at a target site (Ran, 




























Figure 4.1. Cells will repair DNA DSBs by NHEJ or HDR after 





The aim of the work described in this chapter was to create multiple cell lines 
with reduced/null BAF180 protein expression by shRNA depletion as well as 
CRISPR knockout for use in the experiments discussed in this thesis as well as to 
understand the biological impact of BAF180 in cells.  
 
4.3. Establishing stably depleted BAF180 cell lines using 
GIPZ lentiviral shRNA 
 
To establish cell lines that have stably reduced BAF180 expression, we chose to 
use BAF180 and non-silencing control (NSC) GIPZ lentiviral shRNA vectors. Six 
different BAF180 shRNA constructs were acquired from Thermo Scientific, 
each targeting different regions of mammalian BAF180. Four of the BAF180 
shRNA constructs targeted BAF180s bromodomains, in either bromodomains 
2, 3, 4 or 6 (Figure 4.2a). The remaining two constructs targeted sequences 
either in the second BAH domain or the C-terminal region (Figure 4.2a). 
Important features of the mammalian expression plasmid include TurboGFP for 
monitoring transgene expression, a puromycin resistance gene for selection of 
successfully transfected cells and, of course, the short hairpin RNA (Figure 4.2b). 
The TurboGFP and shRNA are part of a bicistronic transcript, driven by the 
human cytomegalovirus (hCMV) promoter. 
After transfection of the constructs, GFP expression was monitored over a 
period of 10-15 days in the presence of puromycin selection (Figure 4.2.c). 
Puromycin resistant colonies were isolated, and Western blot analysis was 
carried out on whole cell extracts, revealing that all of the constructs apart from 
one (targeting bromodomain 4 of BAF180), resulted in good depletion of 
BAF180 protein levels (Figure 4.2d). Cells expressing construct 1 seemed to 
consistently show good levels of BAF180 reduction and so were chosen to be 



























Figure 4.2. Establishing six BAF180 shRNA stable U20S cell lines using 
GIPZ lentiviral shRNA. (A) Illustration showing the domains of BAF180 and 
where each BAF180 shRNA sequence targets. (B) Features of the GIPZ 
lentiviral shRNA plasmid. Purchased from Thermo Scientific. (C) 
Representative images of GFP expressed 24 hours after transfection of each 
shRNA construct and 11 days after being under Puromycin selection. (D) 







For the purpose of the high-throughput siRNA screen (HTS), which I will talk 
about in chapter 5, it was necessary to have cell lines that were visually 
distinguishable when mixed together. To this end we then went about 
establishing sets of cell lines that expressed different fluorescent proteins. 
Using the shRNA constructs purchased from Thermo Scientific (shBAF180 – 
construct 1/V3LHS_318943 and shControl) we set about exchanging the 
TurboGFP for either GFP or mCherry with a nuclear localisation signal (Figure 
4.3a), resulting in the following constructs, shNSC+mCherry/NLS, 
shNSC+GFP/NLS, shBAF180+mCherry/NLS and shBAF180+GFP/NLS.  
To build a set of cell lines that were able to be used in the HTS as well as cell 
lines that were useful for other ongoing projects in the lab, we chose to express 
these modified plasmids in the osteosarcoma cell line U2OS, the lung cancer cell 
line A549, the breast cancer cell line T47D and the renal cell line 786-0, which 
is the most clinically relevant. Sixteen stable cell lines were established from 
these transfections and a representative image of one set of the U2OS cell lines 
created can be seen in Figure 4.3b. Whole cell extracts were gathered from all 
cell lines and BAF180 protein expression levels were analysed by western blot. 
A representative BAF180 blot is shown in Figure 4.3c, showing reduced levels 
of BAF180 in U2OS cells expressing the modified shBAF180+GFP/NLS, in 



































Figure 4.3. Substitution of TurboGFP for either GFP or mCherry with a 
nuclear localisation signal. (A) Illustration of the exchange of flurophores 
in shControl and shBAF180 GIPZ constructs (described in text). (B) 
Representative images of one of the sets of cell lines established from 
manipulated shRNA constructs. (C) Western blot showing BAF180 expression 












4.4. Establishing BAF180 CRISPR Knockout cell lines 
 
Genome engineering techniques are constantly evolving and CRISPR gene 
manipulations are becoming the gold standard. Five CRISPR guide RNAs were 
tested (Figure 4.4a) and these guides, like our shRNA constructs, targeted 
different areas of mammalian BAF180. We chose to create BAF180 CRISPR 
knockouts in the cell lines U2OS as well as the renal cells 786-0. A renal carcinoma 
cell line was chosen for clinical relevance, as we know that BAF180 is frequently 
mutated in ccRCC. 786-0 cells have a 3n copy number for BAF180 (PBRM1) and 
U2OS are well known to be aneuploid, making the full knockout of each copy of 
the gene would be slightly more difficult in these cell lines, than a cell line with 
normal ploidy. The guides from Horizon were integrated as part of an ‘all in one’ 
plasmid, that contained the Cas9 enzyme needed to introduce the break, 
DasherGFP to act as a transient marker of successful transfection, and the target 
guide sequence (Figure 4.4b - left). Transfection of the U2OS and 786-0 cells with 
each of our five CRISPR guides was originally not successful. Instead we 
harnessed the principle of co-transfection with the empty vector pcDNA4-GFP-
IRES-Puro (kindly given to us by the Caldecott Lab – University of Sussex) to 
introduce a puromycin selection marker and a nuclear GFP signal, in contrast to 
the CRISPR constructs that express a cytosolic DasherGFP. Co-transfection with 
both plasmids allowed us to place the cells under antibiotic selection long enough 
to ensure the resultant population would only be cells that had successfully taken 
up both plasmids. A representative image of the two forms of GFP expressed by 
U2OS cells after transfection with both the CRISPR plasmid and the pcDNA4-GFP-
IRES-Puro plasmid is seen in Figure 4.4c. Figure 4.5 provides an overview of the 
CRISPR process, showing a step-by-step break down of the multiple steps carried 
out from initial transfection with these two plasmids to confirming the final 






























Figure 4.4. Establishment of a BAF180 CRISPR Knockout cell line. (A) 
Table showing target sequences of five BAF180 CRISPR guide RNAs. (donated 
from Horizon Discovery as part of their free CRISPR guide initiative. (B) 
Representative image of both types of GFP expression created by co-






























































































































































































After ensuring that we were getting successful transfection in our cells we then 
wanted to identify which CRISPR guide was working the most efficiently in a 
pooled population. U2OS and 786-0 cells were transfected with each CRISPR 
gRNA along with the pcDNA4 plasmid and were allowed to expand enough to 
harvest genomic DNA and continue to culture the samples. Genomic DNA was 
prepared and analysed by PCR using primers in Table 2.2 from test samples and 
in non-transfected control cells. CRISPR guides 1-4 were all in a region small 
enough to be serviced by one set of primers and CRISPR guide 5 targeted a region 
further away, requiring its own set of primers. Test and control PCR products 
were hybridized together and subsequently digested using the SURVEYOR 
mutation detection assay and visualised by gel electrophoresis. Homoduplexes 
appear on gels as a single DNA band, whereas heteroduplexes are cleaved by the 
SURVEYOR nuclease enzyme and will appear as fragmented DNA. Therefore, 
products that are digested by the nuclease in to multiple fragments suggest there 
is a mixed population of DNA, suggesting that genetic alterations have been 
introduced in the test samples.  Pooled populations of U2OS cells transfected with 
all CRISPR constructs resulted in digested products when analysed by gel 
electrophoresis (Figure 4.6a). Control gDNA that was amplified with the PCR 
primers for constructs 1-4 and construct 5 treated with the SURVEYOR nuclease, 
as expected showed a homogeneous population, represented by a single band 
when analysed by electrophoresis (Figure 4.6a/b). If the pooled population of 
transfected cells had all been efficiently targeted by the CRISPR gRNA then you 
would expect to see a homogeneous population and a single band when analysed 
alone and a heteroduplex when mixed with the control gDNA. We observed a 
heteroduplex in all U2OS test samples when digested by themselves as well as 
when digested with the control, suggesting not all cells in our pooled population 
were successfully transfected and would require single cell clonal expansion to 
determine which cells had been successfully targeted (Figure 4.6a). The CRISPR 
guide efficiency appeared to be significantly lower in pooled populations of 786-





























Figure 4.6. Identification of most efficient BAF180 CRISPR construct. 
Cells were initially transfected with each CRISPR guide to assess which guide 
would be most likely to establish a BAF180 KO cell line. Genomic DNA was 
harvested from treated and untreated cells and were hybridized together 
before treatment with the surveyor nucleases. Cleavage by surveyor 
nucleases indicates a heterogeneous population in the hybridization mixture. 
(A) Surveyor nuclease assay carried out using PCR amplified gDNA from 
U20S cells transfected with CRISPR guide RNAs. (B) Surveyor nuclease assay 
carried out using PCR amplified gDNA from 786-0 cells transfected with 





To establish full knockout cell lines, we next had to isolate clonal populations 
from single cells. For this we chose to dilute the U2OS cells that had been 
transfected with both constructs 2 and 3 and the 786-0 cells that had been 
transfected with construct 2. Genomic DNA was harvested from the 96 well plates 
as described in 2.2.14, PCR amplified and digested with SURVEYOR nuclease as 
before. Multiple clones were analysed per cell line and representative analyses 
are shown in Figure 4.7a, Figure 4.8a and Figure 4.9a.  
Twelve U2OS-based clones generated from CRISPR guide 2 were chosen for 
further analysis. Many appeared to have a reduced level of BAF180 protein 
expression, but two in particular, clones 26 and 39 had little or no BAF180 
expression (Figure 4.7b). Stocks from all clones were frozen and have been stored 
in liquid nitrogen for future use.  
Four 786-0 based clones were further investigated and all appeared to have lost 
BAF180 expression (Figure 4.8b). However, upon sequencing these clones, wild 
type BAF180 sequences were detected, raising the possibility that we did not 
have a full knockout cell line. Again all clones were frozen and stored in liquid 
nitrogen for future use.  
Of the U2OS cells transfected with CRISPR guide 3, we chose five clones for 
further analysis, of which three appeared to have lost all or most BAF180 protein 
expression (Figure 4.9b). Sequencing analysis confirmed a deletion in the DNA 
sequence targeted by CRISPR construct 3 in clone 15 (Appendix Figure 1) and 
this clone chosen for use in further experiments. Although sequencing and 
western blot analysis (Figure 4.9b) was consistent with BAF180 knockout in our 
U2OS CRISPR-C3-Clone 15 cells, we noticed that there were still proteins detected 
by the BAF180 antibody, albeit at lower molecular weight and lower abundance 
than the normal BAF180 protein signal. To work out if these remaining bands 
were related to BAF180, we treated U2OS and our BAF180 knockout cells with 
either control siRNA or BAF180 siRNA. Using two different BAF180 antibodies, 
we found that the extra bands did in fact decrease in intensity after BAF180 siRNA 
treatment, suggesting that some form of BAF180 remains within these knockouts 
(Figure 4.10). These data may suggest that there is a truncated version of the 
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protein present in these cells as it runs at a molecular weight below the 
observable full length BAF180 band.  
Importantly, however the cell line exhibits phenotypes that are in accord with 
BAF180 knockdown, such as an increased nucleus size and increased micronuclei 
(C. Meisenberg – unpublished data), suggesting that these putative truncated 


























































































































































































































































































































































































































































































































Figure 4.8. Identification of successful BAF180 Knockout clones in 786-
0 using CRISPR guide 2. Cells transfected with the BAF180 CRISPR guide 2 
were diluted to leave a single cell and allowed to form individual clones. 
Genomic DNA was extracted from various clones and was PCR amplified 
using specific primers that lie either side of the DNA sequence targeted by 
the CRISPR guide RNA (A) Surveyor nuclease assay. Agarose gel 
electrophoresis showing digestion products of multiple 786-0 clones that 
appear to have a heterogeneous population after cleavage by surveyor 
nuclease enzymes. (B) Western blot showing BAF180 protein expression 
corresponding to the 786-0 BAF180 CRISPR clones analysed in (A), using our 





























Figure 4.9. Identification of successful BAF180 Knockout clones in U20S 
using CRISPR guide 3. Cells transfected with the BAF180 CRISPR guide 3 
were single cell diluted and allowed to form individual clones. Genomic DNA 
was extracted from various clones and was PCR amplified using specific 
primers that lie either side of the DNA sequence targeted by the CRISPR 
guide RNA (A) Surveyor nuclease assay. Agarose gel electrophoresis showing 
digestion products of multiple U20S clones that appear to have a 
heterogeneous population after cleavage by surveyor nuclease enzymes. (B) 
Western blot showing BAF180 protein expression corresponding to the U20S 
BAF180 CRISPR clones analysed in (A). Clone 15 was chosen as the most 




























































































































BAF180 low exposure 


























Figure 4.10. A truncated version of BAF180 may still exist in our 
U20S BAF180 CRISPR Knockout cells. Western blot showing 
BAF180 expression after BAF180 siRNA treatment in U20S and 





Here we established multiple BAF180 depleted cell lines. Four U2OS cell lines 
were created expressing shControl+mCherry/NLS, shControl+GFP/NLS, 
shBAF180+mCherry/NLS and shBAF180+GFP/NLS. Four 786-0 cell lines were 
created expressing shControl+mCherry/NLS, shControl+GFP/NLS, 
shBAF180+mCherry/NLS and shBAF180+GFP/NLS. Four T47D cell lines were 
created expressing shControl+mCherry/NLS, shControl+GFP/NLS, 
shBAF180+mCherry/NLS and shBAF180+GFP/NLS. Four A549 cell lines were 
created expressing shControl+mCherry/NLS, shControl+GFP/NLS, 
shBAF180+mCherry/NLS and shBAF180+GFP/NLS. Six U2OS cell lines were 
established to express the various shBAF180+TurboGFP constructs and one with 
the corresponding shControl+TurboGFP.  
U2OS shControl and shBAF180 cells with the original TurboGFP-expressing 
plasmids were used by Brownlee et al in experiments identifying that BAF180 
promotes cohesion and prevents genome instability and aneuploidy (Brownlee, 
Chambers et al. 2014). shBAF180 and shControl plasmids were also used by Niimi 
et al to create MRC5V1 cell lines, identifying that the BAH domain of BAF180 is 
required for PCNA ubiquitination (Niimi, Hopkins et al. 2015). U2OS cells 
expressing shControl+mCherry/NLS and shBAF180+GFP/NLS were used by 
myself in collaboration with V. Savic in the identification of TIP60-dependent 
radiation sensitivity in the absence of BAF180 (Hopkins, McGregor et al. 2016). 
We have also shown the creation of multiple CRISPR BAF180 knockout cell lines 
in U2OS and 786-0, with one line being used by other lab members for 
characterisation experiments.  
 
4.5.1. The advantages and limitations of genetic engineering 
using shRNA 
 
Short hairpin RNA (shRNA) is a widely used approach for the creation of stable 
gene knockdowns and can be achieved using viral or non-viral DNA vectors.  
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Both siRNA and shRNA exploit the same cellular mechanism (RISC), but choosing 
between the use of siRNA or shRNA to achieve your target gene knockdown 
depends on multiple factors, such as cell type, time demands and the need for 
transient versus stable integration (Moore, Guthrie et al. 2010). An increasing 
concern with siRNA is the probability of experiencing off-target effects due to the 
high concentration of cytoplasmic siRNA. Also as the cells divide, the siRNA 
concentration becomes more dilute and therefore creation of a long-term cell line 
with your target gene knockdown is unfeasible. The generation of long-term 
stable cell lines using shRNA, on the other hand, completely eliminates the need 
for multiple rounds of transfection and therefore increases the reproducibility of 
results (Moore, Guthrie et al. 2010). 
The generation of stable knockdown cell lines using shRNA silencing of a specific 
target gene can be greatly beneficial, however there are limitations and this 
approach can be time-consuming. The benefit here though is that you can carry 
out long-term experiments, such as clonogenic survival assays, without having to 
perform multiple siRNA transfections. The benefit of establishing stable cell lines 
is also that you can carry out experiments on a much larger scale than if you had 
to use siRNA. 
A limitation that we have observed with our stable shRNA cells is that BAF180 
knockdown correlates with GFP intensity, rather than being standard throughout 
the cell population (Hopkins, McGregor et al. 2016). In collaboration with the 
Savic lab (University of Sussex), we observed that cells that expressed high levels 
of GFP appeared to have the greatest level of BAF180 knockdown (Hopkins, 
McGregor et al. 2016). This is not a problem when you are able to ‘bin’ your data 
based on the specific cells you want to see using microscopy (discussed in 
Chapter 5). But becomes a slight problem, when you are carrying out an 
experiment where you cannot exclude the cells that have low GFP expression and 
therefore higher BAF180 expression, for experiments such as clonogenic survival 
assays that rely on data from a relatively small number of cells. 
We also observed that BAF180 protein expression levels tend to drift over time, 
even under constant puromycin selection (Figure 4.11) (Hopkins, McGregor et al. 
2016). The puromycin selection marker, the fluorescent protein and the shRNA 
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are all under the control of the same mammalian CMV promoter, with the shRNA 
being the furthest from the promoter. It is possible that the efficiency of this 
promoter to drive the constitutive expression of all three elements over time may 
drift.  
We may have seen longer silencing of BAF80 by the shRNA used in this study if 
we had implemented a lentiviral system for infection of the cells during stable cell 
production. Lentiviral systems have higher transfection efficiencies than non-
viral systems, this is due to the host genome being able to stably integrate the 
lentiviruses, thus establishing long-term stable expression of the integrated DNA 
sequence. However, this process is much more involved than simple transfection 
and also carries drawbacks, such as nuclear accumulation cellular toxicity 










































Figure 4.11. Endogenous BAF180 expression re-appears in shBAF180 
U20S after continuous culture. Western blot showing BAF180 expression in 




4.5.2. The pros and cons of CRISPR/Cas9 gene editing 
 
As previously mentioned, the CRISPR/ Cas systems are an RNA-based bacterial 
defence mechanism designed to recognise and eliminate foreign DNA from 
invading bacteriophage and plasmids, using the Cas endonuclease to introduce a 
cleavage site that is directed to a target sequence by a specific guide RNA (gRNA). 
The development of this advancing technology has revolutionised molecular 
genetics, allowing for the introduction of permanent changes to specific genes. 
Although the system is a relatively new technology it is rapidly becoming the gold 
standard choice for gene editing. This is due to the fact that CRISPR can make 
changes to the genetic code of a cell, resulting in a gene knockout, rather than a 
gene knockdown, like those achieved by siRNA and shRNA. Design of target guide 
RNAs is relatively simple because the target specificity relies on ribonucleotide 
complex formation and not protein/DNA recognition, therefore guides can be 
designed quickly and cheaply for any given gene sequence in the genome. 
However, there are limitations to the CRSIPR/Cas 9 system. The first being that 
establishing a CRISPR gene knock out is labour intensive and requires clonal 
isolation, whereas shRNA transfection and antibiotic selection is relatively quick 
in comparison. Screening for successful CRISPR clones can be time consuming.  
The CRISPR/Cas 9 system can also produce unwanted off-target effects by 
introducing a mutation at a non-specific locus that has similar, but not identical, 
sequence homology to the target sites. These off-target sites are hard to identify 
as you would have to sequence and scan the entire host genome to identify 
whether there are in fact mutations at sites with sequence similarity to the guide 
RNA. Sequencing the whole genome of cell lines is becoming less expensive than 
in previous years, but it is still extremely costly.  
Although there are advantages and disadvantages to the CRISPR/Cas 9 system as 
well as it still being a developing technology, it remains a powerful tool for 
manipulating the genomes of cell lines, mice and even somatic and embryonic 
stem cells from mice and humans. It can be exploited as such to create 
sophisticated and precise models for the study of gene and cellular function and 
can provide deeper insights into the underlying mechanisms of human disease 
160 
 
(Chiang, le Sage et al. 2016). Establishment of our BAF180 CRISPR knock out cell 
lines provides a system where we can observe BAF180 loss in a more genetically 































RNAi interference (RNAi) is an effective tool for genome-scale high-throughput 
analysis of gene function. The use of high-throughput screens can be exploited in 
many ways, for example to isolate multiple members of a functional pathway as 
well as implicate new genes in a given biological function, process, complex or 
behaviour. 
When the normal function of a gene is required for a given function, RNAi 
knockdown may lead to a phenotype detectable in an assay that tests that 
function either directly or indirectly. In our case we are using shRNA knockdown 
cell lines treated with a library of 446 siRNAs, purchased from Dharmacon, to 
identify novel genes whose normal function is essential in BAF180-deficient cell 
lines. 
Typically, before high-throughput screening can take place, it is generally 
necessary to incorporate bioinformatics analysis at a genome scale to identify a 
subset of candidate genes followed by experimental testing. As described in 
Chapter 3, we described a subset of hypothesis driven candidate genes that test 
our hypothesis as well as our chosen cell lines. From this data, we are able to 
progress to more inclusive high-throughput testing to identify synthetic lethal 
genes with BAF180-deficient cells. Data resulting from high-throughput 




The aim of this work was to use a novel method of high-throughput RNAi 
screening to identify genes that are synthetic lethal when depleted in 




5.3. siRNA screen 
 
To identify novel genes whose expression is essential in BAF180-deficient cells, 
we designed a high-throughput RNA interference (RNAi) synthetic lethality 
screen. For this screen we selected the osteosarcoma cell line, U2OS. U2OS cells 
are known to be readily transfectable and amenable to high-content imaging. 
Two U2OS cell lines were established, as described in detail in section 4.3, by 
transfection with pGIPZ plasmids expressing shControl+mCherry/NLS or 
shBAF180+GFP/NLS Figure 5.1a. The expression of two unique fluorescent tags 
allows for the co-culturing of cell lines, enabling us to treat both control and 
BAF180-deficient cells with exactly the same conditions and measure cell 
response via fluorescent readout. Optimisation of screen conditions resulted in 
the choice to mix our red-control and green-BAF180 cell lines in a 1:1 ratio 
(Figure 5.1a), seeding a total of 8000 cells per well. Cells were transfected with a 
human siRNA library encompassing 446 human protein-coding genes, with one 
gene per well of a 96-well plate and each gene being targeted by a pool of 4 
siRNAs (Figure 5.1a). More than 10,000 cells per well were imaged using the 
Olympus ScanR microscope (Figure 5.1a). Previous work with our shControl and 
shBAF180 U2OS cell lines identified a relationship between the level of 
fluorescence and shRNA construct expression (Hopkins, McGregor et al. 2016). 
As described in Chapter 4, our shRNA is part of a bicistronic construct, that 
expresses its fluorescent marker and the specific shRNA under the same CMV 
promoter and therefore allows us to exploit the overall GFP level as a readout for 
the average shRNA expression. Figure 5.1b shows representative BAF180 
immunofluorescence images, identifying low expressing GFP cells that correlate 
with a higher BAF180 antibody signal. To eliminate cells that may still be 
expressing BAF180, we chose to specifically analyse shBAF180 cells with high 
levels of GFP. Olympus ScanR analysis software was used to analyse the images 
taken by the ScanR microscope. Each cell in the screen was given an arbitrary 
value corresponding to ‘mean fluorescence’. We created gates to count cells in 
each and shBAF180 with the highest mean fluorescence were normalised to 
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control wells that were treated with control siRNA only. Using this, a ratio was 
established between our high-GFP expressing BAF180-deficient cells and total 
mCherry expressing shControl cells. We did not restrict our analysis of the 
mCherry control cells by fluorescence, as level of shRNA expression in these cells 
was not required to be high. Each screen was repeated in triplicate and average 
z-scores were calculated. Using the ratio established between high expressing 
GFP shBAF180 cells and total mCherry cells, each well was given a value. Each of 
these ratios were averaged for each plate and the standard deviation for the 
whole plate was calculated. To determine z-scores we used the calculation:  
(GFP:mCherry ratio in specific well – Plate average)/Plate STDEV = gene Z-score 
These z-scores were averaged between the three screens and plotted as a 
waterfall graph (Figure 5.1d). Genes with negative z-scores indicate there may be 
a synthetic lethal interaction specifically with our BAF180-depleted cells and 
those with positive z-scores stimulate BAF180-depleted cell growth more than 
the control. Top gene ‘hits’ were considered in the z-score range -2.039 to -1.07 











































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Before a synthetic lethal screen could be carried out a number of optimisation 
experiments had to be performed to ensure all aspects were working sufficiently. 
As mentioned above, cell seeding density and ratio were established in 
optimisation experiments (data not shown). Transfection efficiency was 
optimised using immunofluorescence analysis with an antibody against 53BP1. 
Using this, we identified conditions for optimal transfection, Figure 5.3a shows 
representative. 
In addition to optimisation of all conditions before running our HTS, we also 
added internal controls to each plate treated to confirm conditions were 
regulated across the screen. Due to the large number of siRNAs in our library, 
each screen was spread across six plates and in triplicate resulting in eighteen 
plates to analyse, thus these internal controls were extremely important. Each 
plate had multiple control wells to ensure conditions were standard throughout 
the screens. Wells treated with control siRNA only, as well as those treated with 
just transfection reagent were included to show that the seeding density was 
uniform from well to well and that both cell lines were viable in culture with this 
treatment (Figure 5.3b). siRNA against TIP60 was included as a control as in 
previous work we saw a reliable difference in viability between the shControl and 
shBAF180 U2OS cells, with shBAF180 being more sensitive to knockdown of 
TIP60 (Hopkins, McGregor et al. 2016). As an additional control that gave visual 
confirmation of successful transfection, we included control wells where the 
shControl and shBAF180 cells were treated with siRNA against GFP (Figure 5.3b-
c). We visually assessed successful knockdown of GFP in each plate in the screen, 
shown by representative images in Figure 5.3c, giving us confidence in the 














































































































































































































































































































































































































































































































5.4. Hit selection and validation 
 
The objective of the screen was to determine a defined hit (or hits) whose 
silencing in combination with BAF180 depletion resulted in synthetic lethality. 
From the 446 siRNAs tested in the screen, we chose 33 genes from the top 10%, 
as ranked by Z-score, as potential synthetic lethal interactors (Figure 5.4). The 
library of siRNAs included a commercially available library of genes involved in 
the DNA damage response (DDR), combined with a ‘custom’ library that was 
chosen by Genome Centre researchers. Many genes involved in the DDR came out 
as synthetic lethal hits with our BAF180-depleted cells, including the excision 
repair proteins ERCC6 (top hit), ERCC1 and ERCC3 to name a few. Interestingly, 
genes involved in cell cycle regulation, like cyclin D1 (CCND1), cyclin C (CCNC) 
and cyclin B1 (CCNB1) were also found to be synthetic lethal with BAF180. TIP60 
(KAT5) was included as a gene in the library as well as being one of our internal 
screen controls. Interestingly, the siRNA targeting TIP60 from the screen library 
resulted in synthetic lethality with BAF180 and ranked 28th in the top hits, 
corroborating the interaction that we had seen previously. Another gene that was 
included in our hypothesis driven mini-screen (see Chapter 3), KAT2A (GCN5), 
was also identified as a top hit in our HTS, again the interaction being validated 
by different SMARTpool siRNAs. The other genes tested in our hypothesis driven 
mini-screen were not included in our HTS siRNA library, but the appearance of 
the two that were included, in our top hit list, not only validates these interactions, 
but also gives us confidence in the other results of the screen. 
To choose genes identified in our HTS for further analysis, we first determined 
(in collaboration with Frances Pearl – University of Sussex) which were 
potentially targetable by drugs and which already had commercially available 
inhibitors. Of the 33 hits, five had inhibitors (at the time of study), which were 
DNTT, CCND1, PARP3, TP53 and CCNB1 and so were taken as a subset of hits to 
further validate using small inhibitors. Of the candidate gene hits that did not 
have an inhibitor, we chose six genes to further validate using siRNA knockdown 
based experiments and these were, ERCC6, PLRG1, due to their high ranking in 
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the HTS, as well as H2AZ, NCAPG, SMARCC1 and GCN5, due to their known 














































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Of the six genes we chose to validate using different siRNAs the most notable and 
convincingly reproducible synthetic lethal interaction was H2AZ. Clonogenic 
survival assays were carried out after siRNA knockdown of H2AZ in shControl 
and shBAF180 U2OS cells. shBAF180 cells were significantly more sensitive to 
siH2AZ knockdown (Figure 5.5a). Gene knockdown of H2AZ was confirmed by 
western blot analysis (Figure 5.5b). Because there was still significant protein 
detected after siRNA depletion, it is possible that a full reduction of H2AZ protein 
expression could result in a more severe synthetic lethal phenotype.   
GCN5, which was independently validated in section 3.5, was identified as a hit in 
high-throughput screening analysis. Although this interaction had already been 
studied in our hypothesis driven mini-screen using cell viability as a readout 
(Figure 3.3), we wanted to further validate this interaction in a different way. 
shBAF180 U2OS cells treated with siRNA against GCN5 had a lower colony 
forming potential compared to the control (Figure 5.5c), providing additional 
evidence of a synthetic lethal interaction seen between these two genes. 
In clonogenic survival assays, the siRNAs targeting ERCC6, PLRG1, NCAPG and 
SMARCC1 did not selectively target either the shControl or shBAF180 U2OS cell 
lines (Figure 5.5d), suggesting these genes are not synthetic lethal with BAF180. 
Many RNAi screens produce false positive results, these can be contributed to by 
experimental noise that is inherent in large-scale studies, bias that can be 
inherent in the screen assay, off-target effects and even incomplete or incorrect 
gene models. While these genes may be false positives, further investigation is 



























































































































































































































































































































































































































































































































In addition to testing synthetic lethal interactions with different siRNAs, we also 
wanted to investigate the conditional viability reduction in our shBAF180 U2OS 
cells seen in the HTS using small molecule inhibitors. As mentioned above we 
chose five targets with inhibitors, DNTT, CCND1, PARP3, TP53 and CCNB1 
(Figure 5.6a). As a first, we used viability assays to determine if each drug had 
potential to selectively kill our shBAF180 U2OS before taking on to further assays.  
A small difference in viability between shBAF180 and the control was seen after 
treatment with Genistin, a small molecule inhibitor targeting DNTT (Figure 5.6b). 
However, the drug seemed to aid cell growth at low concentrations with both cell 
lines doing better at these low concentrations compared to the 0μM control. The 
difference in viability between these cell lines was only seen at these low doses 
when both cell lines had more improved viability. Higher doses of Genistin 
resulted in loss of viability in an equal manner for both cell lines.  
Interestingly, two drugs targeting the PARP proteins, ME0328, a PARP3 specific 
inhibitor and Olaparib a pan inhibitor of PARP genes, selectively reduced viability 
in the shBAF180 U2OS cell line compared to the control (Figure 5.6c-d). We chose 
two small inhibitors to validate the synthetic lethal interaction between TP53 and 
BAF180, Cyclic Pifithrin-α-hydrobromide and Pifithrin-μ, both of which resulted 
in no observable difference in cell viability or colony forming potential after 
treatment in shControl and shBAF180 U2OS cells (Figure 5.7b-c and 5.8b-c). 
The drug Palbociclib (aka PD0332991) showed a slight difference in cell viability 
at the 7.5μM dose between the shBAF180 and shControl cells (Figure 5.9b), 
however no difference was apparent when investigated further in clonogenic 
survival assays (Figure 5.9c). It should be noted however, that the cells were 
more sensitive to the inhibitor in clonogenic survival assays. Thus, there is scope 

















































































Figure 5.6. Small molecule inhibitor validation of HTS hits. (A) Inhibitors 
against HTS gene hits. (B) Cell viability in shControl and shBAF180 U20S after 
treatment with Genistin. (C-D) Cell viability in shControl and shBAF180 U20S 
after treatment with the PARP inhibitors ME0328 and Olaparib respectively. 































































Figure 5.7. Small molecule inhibition of TP53 does not confirm HTS 
synthetic lethal interaction with BAF180. (A) Inhibitors against HTS gene 
hits. (B) Cell viability curve of shControl and shBAF180 U20S after exposure 
to Cyclic Pifithrin-α-hydrobromide. (C) shBAF180 U20S were no more 
sensitive to treatment with Cyclic Pifithrin-α-hydrobromide than the control 

































































Figure 5.8. Small molecule inhibition of TP53 does not confirm HTS 
synthetic lethal interaction with BAF180. (A) Inhibitors against HTS gene 
hits. (B) Cell viability curve of shControl and shBAF180 U20S after exposure 
to Pifithrin-μ (C) shBAF180 U20S were no more sensitive to treatment with 


































































Figure 5.9. Small molecule inhibition of Cyclin D1 (CDK4/6) does not 
confirm HTS synthetic lethal interaction with BAF180. (A) Inhibitors 
against HTS gene hits. (B) Cell viability curve of shControl and shBAF180 
U20S after exposure to Palbociclib(C) shBAF180 U20S were no more 




Heptelidic Acid, which also targets DNTT was analysed to further develop the 
potential synthetic relationship with BAF180. An unusual cell viability curve was 
seen after treatment with Heptelidic acid, possibly due to the drug precipitating 
in the media. Nevertheless, we did see a small difference in viability between the 
shBAF180 cells and the control at 2.5μM in duplicate experiments (Figure 5.10b). 
We therefore further tested this drug in clonogenic survival assays. We observed 
a consistent difference in colony forming potential between the two cell lines, 
with the shBAF180 cells being more sensitive to treatment with Heptelidic Acid 
(Figure 5.10c). While there was a consistent trend, the differences were not 
significant (Figure 5.10c). 
The drug RO-3306, targeting CCNB1, modestly targeted BAF180-depleted cells 
more than the control cell line in both cell viability assays and clonogenic survival 
assays (Figure 5.11b-c). This difference was enhanced by the addition of IR to low 
dose treatment of RO-3306 in clonogenic survival assays (Figure 5.11d). As 
chemotherapeutic drugs are often given in combination with radiation therapy, 
it is important to see whether there is an increase in selective effects on viability 










































































Figure 5.10. Small molecule inhibition of DNTT consistently shows a 
trend of synthetic lethality in shBAF180 U2OS. (A) Inhibitors against HTS 
gene hits. (B) Cell viability curve of shControl and shBAF180 U20S after 
exposure to Heptelidic Acid (n=2). shBAF180 appear marginally more 
sensitive to the control after treatment 2.5𝜇M. (C) shBAF180 U20S were more 
sensitive to treatment with Heptelidic Acid than the control in clonogenic 















































Figure 5.11. Small molecule inhibition of Cyclin B1 (CDK1) validates HTS 
synthetic lethal interaction with BAF180. (A) Inhibitors against HTS gene 
hits. (B) Cell viability curve of shControl and shBAF180 U20S after exposure 
to RO-3306 (n=2). shBAF180 appear marginally more sensitive to the control 
after treatment. (C) shBAF180 U20S were more sensitive to treatment with 
RO-3306 than the control in clonogenic survival, but was not statistically 
significant (n=3). (D) shBAF180 U20S are more sensitive to low dose 
treatment with RO-3306 than the control after irradiation. (n=3) Statistical 








The objective of our high-throughput screen was to determine a hit, or multiple 
hits, whose depletion in combination with BAF180 resulted in synthetic lethality. 
Moreover, we wanted to improve on current RNAi screening methods by 
developing a novel system with improved sensitivity and reproducibility. We 
created shBAF180 and shControl isogenic cell lines that we were able to identify 
when co-cultured, enabling us to observe specific cell differences within the same 
well microenvironment, reducing the amount of experimental variation and 
increase screen sensitivity and therefore giving us a better chance at potential hit 
validation. From a library consisting of 446 genes, we identified 33 genes as 
synthetic lethal gene candidates with shBAF180 U2OS cells. The RNAi library 
used in the screen was designed to deliberately target genes involved in the DNA 
damage response (DDR). We know that the DDR is essential for maintaining the 
genomic integrity of the cell and its disruption is one of the hallmarks of cancer. 
We also know that synthetic lethality can either occur due to the loss of two genes 
in one essential pathway, the loss of two genes in independent survival pathways 
or the loss of two genes in independent pathways where an essential product is 
normally formed.  
Recent work in our lab has shown that phosphorylation of BAF180 by ATM is 
required for early DNA repair activity in that lack of transcriptional repression of 
genes flanking DNA DSBs impedes repair (Kakarougkas, Ismail et al. 2014). It is 
possible that loss of two genes involved in the DDR, whether they be on the same 
or parallel pathways, could result in synthetic lethality. It is known that defects 
in the DNA damage response and repair pathways lead to genomic instability in 
tumour cells and this instability can cause sensitivity to DNA damaging drugs 
more than normal cells. For example, treatment with PARP inhibitors in BRCA-
negative cancers cause synthetic lethality by the combination of impairment of 
both single- and double-stranded DNA break repair respectively. As previously 
mentioned, BRCA1 and BRCA2 are important for the repair of DNA DSBs by 
homologous recombination (HR) and mutations here are commonly associated 
with breast and ovarian cancer (Hall, Friedman et al. 1992, Casey, Plummer et al. 
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1993, Wooster, Neuhausen et al. 1994, Parikh and Advani 1996). PARP recruits 
DNA repair proteins to sites of single-strand DNA breaks and if this is inhibited, 
stalled replication forks arise, which are typically repaired by HR (Petermann, 
Keil et al. 2005). In BRCA-negative cancers, treated with PARP inhibitors, PARP1 
is trapped on DNA, blocking replication fork progression, which usually requires 
homologous recombination repair (HRR). Due to the HRR defect observed in 
BRCA-negative cancers, treatment with PARP inhibitors results in cell specific 
synthetic lethality. 
We could speculate that BAF180-depleted cells are more sensitive to knockdown 
of other DDR genes because of impairments in two repair processes, like BRCA 
and PARP. However, the underlying mechanism for synthetic lethality between 
BAF180 and each gene identified in the HTS, must be reasoned individually.  
 
PARP3, a gene that is implicated in the DDR, was identified as a candidate gene 
hit with BAF180 in the HTS and was validated by the PARP inhibitors ME3028 
and Olaparib in this chapter, however the mechanism of this synthetic lethality 
and the further development of this interaction will be discussed in detail in 
Chapter 6. 
 
5.5.1. H2A.Z is synthetic lethal when knocked down in 
combination with BAF180. 
 
We identified H2AZ as a candidate gene hit in our synthetic lethal HTS with 
BAF180, and this interaction was validated using siRNAs non-overlapping with 
those used in the HTS. H2A.Z is a well-characterised variant of the canonical H2A 
histone and acetylation of H2A.Z is important for the regulation of gene 
expression. Acetylation of H2A.Z is typically associated with highly transcribed 
genes and a more open chromatin structure, whereas unacetylated H2A.Z is 
found in silent genes (Josling, Selvarajah et al. 2012) and is therefore linked to 
both the activation and repression of transcription. H2A.Z is also present at 
centromeres and is thought to have an important role in the organization of 
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pericentric heterochromatin centromere structure and function (Greaves, 
Rangasamy et al. 2007). BAF180 has well-characterised roles in transcriptional 
regulation, however recent work in our lab has also implicated BAF180 in sister 
chromatid cohesion, specifically at centromeres in mammalian cells (Brownlee, 
Chambers et al. 2014). The rationale behind why H2AZ and BAF180 might be 
synthetic lethal could therefore be explained by one of two mechanisms. Firstly, 
that the loss of two genes that are important for transcriptional regulation could 
be enough to cause synthetic lethality or secondly, that to the loss of two genes 
that have important functional roles at centromeres may be the cause of the 
observed synthetic lethality.  
 
5.5.2. Possible mechanisms for BAF180 and SMARCC1 synthetic 
lethality  
 
Although we were not able to validate the interaction found in our high-
throughput screen between BAF180 and SMARCC1 with the use of non-
overlapping siRNAs, it does not necessarily suggest that this ‘hit’ was a false 
positive. It is interesting to think about SMARCC1 as a candidate synthetic lethal 
interactor with BAF180. As discussed previously, in clear cell renal cell carcinoma 
VHL, PBRM1 (BAF180), BAP1 and SETD2 are frequently mutated, they also all 
reside on the short arm of chromosome 3p. SMARCC1 is a subunit of both 
SWI/SNF chromatin remodelling complexes, BAF and PBAF. Like BAF180, the 
gene encoding SMARCC1 is found on chromosome 3p21.31 between BAF180 and 
VHL. It has been determined, that given its location, ~90% of ccRCC would be 
expected to lose at least one SMARCC1 allele, with the second being susceptible 
to loss. It was also determined that statistically, by chance alone, SMARCC1 would 
be expected to be mutated at around 70% of the frequency of BAF180, however, 
its mutation rate in ccRCC are actually extremely low (Brugarolas 2013). It has 
been suggested that SMARCC1 may be broadly essential for survival and that 
mutations here may be detrimental for ccRCC. We identified SMARCC1 as the 17th 
out of 446 genes that are likely to be synthetic lethal with BAF180 in high-
throughput siRNA screening. It is possible that if SMARCC1 is indeed required for 
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ccRCC cell survival, then loss of this gene could result in the synthetic lethality 
seen here with BAF180-depleted cells. The exploitation of SWI/SNF subunit 
inhibition for cancer therapy is intriguing and could provide a novel approach to 
the treatment of cancers that currently have poor treatment options, like ccRCC. 
 
5.5.3. Possible mechanisms for BAF180 and Cyclin B1 synthetic lethality 
 
As mentioned in section 1.5, in bladder cancer, PBRM1 is thought to regulate the 
expression of cyclin B1. Overexpression of PBRM1 is thought to reduce mRNA 
levels of cyclin B1 and loss of PBRM1 is thought to increase mRNA levels of cyclin 
B1 (Huang, Peng et al. 2015). The cell cycle is controlled by cyclins and cyclin-
dependent kinases (Sherr 1996). Cyclin B1 is a key molecule for G2/M phase 
transition of the cell cycle and is needed for initiation of mitosis. Cyclin B1 
overexpression has been linked to disease recurrence in cancers such as 
colorectal, prostate, breast and lung cancer to name just a few (Mashal, Lester et 
al. 1996, Kawamoto, Koizumi et al. 1997, Wang, Yoshimi et al. 1997, Malumbres 
and Barbacid 2005, Kim, Ackerson et al. 2006).  
Defects in cell cycle control are essential to carcinogenesis. It has been suggested 
that PBRM1 reduction can induce cell cycle arrest and subsequently promotes 
cell proliferation (Huang, Peng et al. 2015). We have identified a synthetic lethal 
relationship between PBRM1 (BAF180) and cyclin B1 (CCNB1). Previous studies 
have shown the increase in cyclin B1 upon BAF180 depletion. It is possible that 
this upregulation of cyclin B1 is necessary for cancer cell survival and that the 
combined loss of this gene together with BAF180 may result in the inability to 
maintain chromatin in a transcriptionally permissive state and may be the 
underlying cause for the synthetic lethality seen in this study. To study this 
interaction further, it would be interesting to analyse our set of BAF180-depleted 
cell lines by western blot to see if cyclin B1 is upregulated after BAF180 loss via 
shRNA, CRISPR knockout or in our naturally occurring BAF180-negative cancer 
cell lines, A704.  
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In conclusion, we have presented a novel synthetic lethal high-throughput RNAi 
screening method that is capable of assaying synthetic lethal interactions in a cell 
specific manner. Multiple candidate genes were identified as synthetic lethal hits 
with BAF180-depleted shU2OS cells, some of which we were able to validate at a 
further level, however further work is required before translating this data in to 
something clinically relevant. PARP3 was in the top 1% of genes tested for 
synthetic lethality with shBAF180 cells in our screen. Due to the presence of PARP 
inhibitors already being used in a synthetic lethal manner in clinical studies for 
BRCA-deficient cancers, the translational aspect of validating this gene swiftly 
became extremely interesting to us. This synthetic lethal interaction and further 

























Poly (ADP-ribose) Polymerase (PARP), as described in section 1.7, has a well 
characterised role in the repair of DNA damage. Small molecule inhibitors of 
PARP were originally developed to sensitize patients to chemotherapy during 
cancer treatment. However, more recently, PARP inhibitors have been 
demonstrated as a potential therapy for targeting cancers with a deficiency in the 
homologous recombination (HR) pathway. 
PARP inhibition in BRCA mutated cancers is one of the first clinically 
implemented examples of harnessing the principle of synthetic lethality for 
cancer therapy (Lord and Ashworth 2008). BRCA1 and BRCA2 are essential for 
the repair of DNA double strand breaks (DSBs) and collapsed replication forks 
using the HR pathway. Loss of wild type BRCA1 or BRCA2, results in the complete 
absence of HR and the increase in the cells usage of non-conservative 
mechanisms to repair DSBs/replication forks (Lord and Ashworth 2008). It has 
been well established that the HR defect in BRCA-deficient cells is the primary 
cause of PARP inhibitor sensitivity (Lord and Ashworth 2008). It has been shown 
that deficiencies in other HR proteins can also lead to sensitivity to PARP 
inhibitors (McCabe, Turner et al. 2006). 
Previous work in our lab has identified the SWI/SNF complex PBAF as important 
for mediating sister chromatid cohesion. Specifically, this activity is dependent 
on the BAF180 subunit of PBAF (Brownlee, Chambers et al. 2014). As described 
in section 1.1.3.2, the process of HR utilizes an intact sister chromatid as a repair 
template for the repair of damaged DNA in the S/G2 phase of the mammalian cell 
cycle (Kong, Ball et al. 2014).  It is known that efficient homologous 
recombination is promoted by the recruitment of sister chromatid cohesion to 
DNA DSBs (Kong, Ball et al. 2014, Gelot, Guirouilh-Barbat et al. 2016). We found 
that cells with deficient BAF180 demonstrate phenotypes that are consistent 
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with a defect in cohesin-mediated DNA repair (Brownlee, Chambers et al. 2014). 
Therefore, it is possible that the PBAF complex may also promote HR. 
We identified multiple PARP genes, as being synthetic lethal with BAF180 in the 
RNAi screen presented in Chapter 5. In this chapter we sought to address whether 
a defect in HR in BAF180-deficient cells was the underlying cause for this 




The aims of the work described in this chapter were firstly to validate the 
synthetic lethal interaction found between BAF180 and the PARP genes identified 
by our high-throughput screen (Chapter 5), using siRNA and drug based in vitro 
experiments. Secondly, to confirm that the biological interactions observed could 
be reproduced in multiple cell lines, using multiple PARP inhibitors. And finally, 
to explore a potential HR defect in BAF180 deficient cells, to uncover a 
mechanism of why BAF180 and PARP genes have a synthetic lethal relationship. 
 
6.3. BAF180 and PARP genes are synthetic lethal 
 
High-throughput screening techniques, as described in Chapter 5, identified a 
potential synthetic lethal interaction between BAF180 and PARP3.  
To validate this interaction, it was necessary to reproduce the synthetic lethal 
observation, using a different pool of siRNAs, to confirm that the ‘hit’ wasn’t 
simply due to off target effects. In addition, when not performing high-
throughput analyses, a more rigorous analysis of cell viability can be used. 
Therefore, using siRNA sequences targeting different regions of the gene, 
clonogenic survival assays were performed. This revealed a large decrease in 
survival after treatment with siPARP3 in shBAF180 cells (Figure 6.1a), 
consolidating our findings from our high-throughput screen. The fact that the 
interaction could be reproduced in a different assay, with a different siRNA 
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sequence, suggests that this interaction is robust, but would still need to be 
explored further.   
Notably, we also identified PARP1, PARP2 and PARP4 in the screen (Figure 6.1b). 
Although these PARP genes did not make it to the top ‘hit’ list as described in 
Chapter 5, the BAF180 depleted shU2OS cells were still classed as more sensitive 
to these gene knockdowns when compared to the control. To test whether these 
other PARPs are genuinely synthetic lethal with loss of BAF180, we tested colony 
survival potential as we did for PARP3 (Figure 6.1.a), with different siRNAs to 
those included in the screen for PARPs 1 and 2. A striking decrease in colony 
formation potential was seen after depletion of PARP1 in our shBAF180 cells, 
whereas depletion of PARP2 resulted in no difference in survival between 
shBAF180 and shControl cell lines (Figure 6.1c).  
Interestingly, co-depletion of PARP1, PARP2 and PARP3, reduced survival of the 
shBAF180 to a percentage that was lower than PARP2 siRNA alone, but 
marginally higher than both PARP1 and PARP3 siRNA depletions alone (Figure 
6.1c). This could suggest either that the removal of PARP2 alongside PARP1 and 
PARP3, could slightly rescue the synthetic lethal phenotype, or that the siRNA 
depletions were not as effective in combination. 
Western blot analysis of whole cell extracts was used to determine knockdown 
efficiency in these siPARP treated cells (Figure 6.1d). PARP1, which runs at 116-
kDa, was significantly reduced, as expected in the cells treated with siPARP1 as 
well as the cells treated with siPARP1, 2 and 3. PARP3, which runs at 60-kDa, was 




































































































































































































































































































































































































6.4. Multiple cell lines with depleted BAF180 are 
sensitive to treatment with the PARP inhibitor drug Olaparib 
 
In parallel with the confirmation that the same synthetic lethality can be seen 
with various siRNA sequences against our PARP targets (Figure 6.1a-d), we 
wanted to replicate the conditional viability reduction in a more therapeutically 
relevant way, with small molecule inhibitors that are commercially available. The 
rationale behind validation using small molecule inhibitors as well as siRNA was 
multifaceted. Firstly, we can speculate that gene targeting by RNAi may not 
completely downregulate the targets, perhaps due to incomplete depletion of the 
gene. As no genes in the screen showed 100% shBAF180 specific synthetic 
lethality we postulated that residual gene product activity may have prevented a 
strong conditional response. Secondly, often loss of a protein by siRNA depletion 
does not always produce the same biological effects as drug inhibition. Finally, 
small molecule inhibitors of PARP are currently in clinical trials and are already 
treating cancers by exploiting the principle of synthetic lethality.  
Olaparib, otherwise known as Lynparza, is known to be a potent inhibitor of 
PARP1 and PARP2 with some activity also against tankyrase-1 
and is currently tested for the treatment of BRCA deficient cancers. 
Colony survival assays were carried out using shBAF180 and shControl U2OS 
cells after treatment with Olaparib. BAF180 depleted cells were significantly 
more sensitive to treatment with Olaparib compared to the control (Figure 6.2a). 
This sensitivity was conserved when moving in to a different cell line (Figure 
6.2b), the more clinically relevant renal cell line, 786-0. As previously described 
(Chapter 4), 786-0 cells were made to stably express shRNA against both BAF180 
with a GFP/NLS, as well as separately a control shRNA with mCherry/NLS. The 
renal cells lacking BAF180 were significantly more sensitive to treatment with 




























Figure 6.2. Two cell lines with depleted BAF180 are sensitive to 
treatment with the PARP inhibitor drug Olaparib. (A) shBAF180 U20S 
cells were more sensitive to treatment with Olaparib compared to the control 
in clonogenic survival assay. (n=3). (B) shBAF180 786-0 cells were more 
sensitive to treatment with Olaparib compared to the control in clonogenic 
survival assay. (n=3).  
 Statistical significance is represented by * for p<0.05 and ** for p<0.01, as 





6.5. Sensitivity to Olaparib is not due to off target shRNA 
effects 
 
When synthesising our cell lines, as described in Chapter 4, we generated stable 
shBAF180 cell lines with several different shRNA sequences. This provided us 
with an opportunity to determine whether the synthetic lethal relationship with 
PARP activity is a consequence of off target effects from the shRNA sequence used. 
We therefore performed colony survival assays with the panel of stable 
shBAF180 cells. Figure 6.3a shows the varying degree of sensitivity of each 
BAF180 shRNA construct in comparison to a U2OS only control. The construct 
that we chose to take forward for further modification, V3LHS_318943, which 
target sequence is located in the sixth of BAF180’s bromodomains (Figure 6.3c), 
came out as one of the most sensitive to Olaparib treatment and was statistically 
significant at 0.5µM (p<0.05* - not shown in figure) (Figure 6.3a). This result was 
as expected, due to its modified counterpart shBAF180+GFP/NLS (U20S) being 
found to be sensitive to Olaparib treatment previously (Figure 6.2). 
Constructs V2LHS_174969 and V2LHS_200596, which target sequences located 
in the third and fourth bromodomain respectively (Figure 6.3c), both show the 
strongest sensitivity of the constructs to PARP inhibitor treatment with 
statistically significant p values at each concentration (p<0.05* - not shown in 
figure). While constructs V2LHS_174972, located in the C-terminal domain and 
V3LHS_318948, located in the second BAH domain (Figure 6.3c), appear to be the 
least sensitive of the five (Figure 6.3a).  
Western blot analysis (Figure 6.3b) demonstrates suppression of BAF180 protein 
expression in each of the shRNA constructs stable cell lines, when compared to 
relative BAF180 expression in control U2OS cells. Importantly, depletion of 
BAF180 by any of the given constructs, which target very different regions of the 
protein, all ultimately confer a sensitivity to the PARP inhibitor Olaparib. 
Together, these data suggest that the synthetic lethality between BAF180 loss and 
















































Figure 6.3 Sensitivity to Olaparib is not due to off target shRNA effects. 
(A) Five different shBAF180 construct expressing U20S cell lines were more 
sensitive to treatment with Olaparib compared to the control in clonogenic 
survival assays (n=3). (B) Western blot analysis of BAF180 protein 
expression in shBAF180 construct expressing U20S cell lines. (C) Illustration 






6.6. Multiple cancer cell lines with depleted BAF180 are 
sensitive to the PARP inhibitor Rucaparib 
 
To further investigate the relationship between BAF180 loss and the inhibition 
of PARP activity, we repeated the assays using different PARP inhibitor drugs.  
There are currently multiple commercially available PARP inhibitors that are in 
various stages of clinical trials.  
Rucaparib has binding affinity with nine PARP proteins (PARP1, 2, 3, 4, 10. 15. 16. 
TNKS1 and TNKS2), but is thought to be a potent inhibitor specifically of PARP1, 
compared to Olaparib which is a potent PARP1/2 inhibitor. We chose to test 
Rucaparib in addition to Olaparib as we hypothesised that we may see a more 
dramatic synthetic lethal effect with a drug with binding affinity for both PARP1 
and PARP3.  
Colony survival assays were carried out in both the U2OS as well as the 786-0 
stable shControl and shBAF180 cell lines, under constant exposure from the 
PARP inhibitor Rucaparib. Statistically significant differences in survival were 
observed in shBAF180 U2OS treated with Rucaparib at a subset of doses tested. 
Although survival differences were not significant at all doses, a reduction in 
colony formation ability was consistently apparent. There was a tendency for the 
shBAF180 renal cells to be slightly more sensitive to Rucaparib compared to 
shControl at the doses studied. While this was less dramatic than the differences 
observed in the U2OS-based cell lines, we could speculate that this may be due to 















































Figure 6.4 Multiple cancer cell lines with depleted BAF180 are sensitive 
to the PARP inhibitor Rucaparib. (A) shBAF180 U20S cells were more 
sensitive to treatment with Rucaparib compared to the control in clonogenic 
survival assay. (n=3). (B) shBAF180 786-0 cells were more sensitive to 
treatment with Rucaparib compared to the control in clonogenic survival 
assay. (n=3).  
 Statistical significance is represented by * for p<0.05 and ** for p<0.01, as 





6.7. Sensitivity to Olaparib in BAF180 shU2OS is 
exacerbated by treatment with Ionising Radiation 
 
We chose to combine PARP inhibition with ionising radiation (IR), to see if there 
was potential for amplifying problems repairing breaks in our cells with already 
impaired pathways.  
To test how BAF180 depleted cells treated with olaparib, responded to the 
addition of IR, we chose a dose of olaparib that gave a small difference between 
cell lines and examine if we could exacerbate the difference with gamma 
irradiation. 
shU2OS cells were irradiated in the presence of olaparib (Figure 6.5). Survival 
assays revealed a significant decrease in survival after the addition of Olaparib in 
the shBAF180 cells compared to the control at 2, 3 and 4Gy (Figure 6.5). The 
sensitivity to ionizing radiation after BAF180 knockdown and treatment with 
Olaparib, suggests that BAF180-depleted cells may have a defect in the HR 
pathway. 
 
6.8. siBAF180 depleted U2OS cells exhibit a mild defect in 
HR 
 
Cells that are sensitive to treatment to PARP inhibitors have a defect in HR 
(McCabe, Turner et al. 2006). Here we wanted to identify if the loss of BAF180 
corresponded with a defect in HR. RAD51 foci formation is a readout of 
homologous recombination (Tarsounas, Davies et al. 2003).  
Cells with a defect in HR will not be able to repair irradiation induced damage as 
readily and therefore will have fewer RAD51 foci. CENPF staining was used to 
visualise cells in the G2 stage of the cell cycle and antibodies against human 
RAD51 were used to visualise RAD51 foci formation, DNA content was stained 
using DAPI.  
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Here we see BAF180 depleted cells forming statistically significantly less foci per 
cell compared to the control, which is indicative of a partial HR defect (Figure 

















































Figure 6.5 Sensitivity to Olaparib in BAF180 shU20S cells is exacerbated 
by treatment with IR. shBAF180 U20S cells were more sensitive to 
treatment with Olaparib compared to the control in clonogenic survival assay. 
This sensitivity was increased upon addition of IR. (n=3).  



























Figure 6.6 BAF180 depleted U20S cells exhibit a mild defect in HR. IR 
induced RAD51 focus formation in U20S cells treated with siControl or 
siBAF180. (A) Mean number of foci scored after 0Gy and 2 hours after 3Gy 
irradiation. Statistical significance is represented by * for p<0.05, as analysed 




6.9. Exposure of camptothecin in BAF180 shU2OS cells 
results in a sub G1 pile up and an increase of apoptotic cells 
 
Camptothecin (CPT) is a Topoisomerase I inhibitor, that forms a tight complex 
with TOP1-DNA adducts. The stabilisation of TOP1-DNA adducts by CPT activates 
an ATR-dependent pathway to promote the repair of DNA damage by 
homologous recombination after encountering replication stress (O'Connell, 
Adamson et al. 2010). Consequently, cells with defects in the HR pathway display 
sensitivity to treatment with CPT. 
 
6.9.1. BAF180 depleted shU2OS cells treated with camptothecin 
accumulate in sub G1 
 
To further investigate the defect in HR in BAF180 deficient cells, we used the drug 
camptothecin and analysed the data by flow cytometry. U2OS stable shControl 
and shBAF180 cells were treated with camptothecin and analysed by FACS to 
monitor apoptotic responses and cell cycle progression. 
FACS profiles showed an increase in the sub G1 population, in shBAF180 cells 
after treatment with camptothecin (Figure 6.7a, Figure 6.7b). Addition of 
camptothecin had an effect on cell viability in both cell lines, however, strikingly 
there was a more rapid accumulation in the sub G1 population in the shBAF180 
cells compared to the control. In both the shControl and shBAF180 cells exposure 
to camptothecin was severely toxic after 96 hours and therefore, sub G1 






6.9.2. BAF180 depleted shU2OS cells treated with camptothecin 
are positive for the apoptotic indicator, Caspase 3 
 
In order to determine whether the sub-G1 population was due to apoptosis in 
response to CPT treatment, we monitored this response directly using antibodies 
raised against Caspase 3. Caspase 3 is part of the Caspase family of endoproteases, 
that play a key role in cell regulatory networks that control inflammation and cell 
death. Multiple caspases are sequentially activated during cellular apoptosis, or 
programmed cell death. The presence of caspase 3 in cells can be used as a 
readout of activation of the apoptotic pathway. Both FACS analysis (Figure 6.8a), 
as well as Western blot (Figure 6.8c) demonstrated that apoptosis has been 
stimulated in both cell lines after the treatment with camptothecin. The caspase 
positive fraction of cells was quantitated by gating in the FACs assays, and this 
suggested that the proportion of cells undergoing apoptosis was significantly 
higher for the shBAF180 cells (Figure 6.8a, Figure 6.8b). Another readout of 
apoptosis is PARP cleavage (Yang, Zhao et al. 2004). Western blot analysis 
showed the formation of cleaved PARP after treatment with camptothecin at 
early time points (Figure 6.8c), suggesting that the drug did indeed stimulate 




































































Figure 6.7. BAF180 depleted shU20S cells treated with camptothecin 
accumulate in sub G1. FACS analysis of shControl and shBAF180 U20S 
treated with camptothecin or the vehicle control DMSO at 0, 24, 48, 72 and 96 
hour time points. (A) Representative cell cycle profiles after treatment with 
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Figure 6.8. BAF180 depleted shU20S cells treated with camptothecin 
have more caspase 3 positive cells compared to the control. FACS analysis 
of shControl and shBAF180 U20S treated with camptothecin or the vehicle 
control DMSO at 0, 24, 48, 72 and 96 hour time points. (A) Representative 
caspase 3 levels after treatment with camptothecin (n=2) (B) Histogram 
representation of caspase 3 in gated population after camptothecin 
treatment. (C) Western blot of apoptosis. Analysis of PARP and cleaved PARP 







6.10. Exposure of Olaparib in BAF180 shU2OS cells results 
in a sub G1 accumulation and an increase of apoptotic cells 
 
We wished to understand how our shU2OS cells were dying after treatment with 
the PARP inhibitor Olaparib. Our hypothesis was that the cells were being made 
to enter the apoptotic pathway, rather than cell death by necrosis. 
 
6.10.1. BAF180 depleted shU2OS cells treated with Olaparib 
accumulate in sub G1 
 
In order to test whether the shBAF180 cells were dying by apoptosis after PARP 
inhibitor treatment, U2OS stable shControl and shBAF180 cells were analysed 
after olaparib treatment by FACS. Addition of Olaparib to the stable U2OS cell 
lines shControl and shBAF180 resulted in a slight increase in the sub G1 
population of both cell lines at high doses and late time points (Figure 6.9). At 
high doses over long periods of exposure to any drug would stimulate some level 
of cell death or apoptosis because the cells can no longer tolerate the treatment, 
but it is interesting to see that this level of apoptosis is increased significantly in 
the cells lacking BAF180.  
 
6.10.2. BAF180 depleted shU2OS cells treated with Olaparib 
are positive for the apoptotic indicator, Caspase 3 
 
Consistent with the data shown in Figure 6.9, a shift in the total cells apoptotic 
population can be seen in both cell lines at the 10 and 20uM dose of Olaparib at 
late time points when looking at Caspase 3 expression (Figure 6.10). Caspase 3 
levels show us a clearer indication that the shBAF180 cells are more prone to 
enter apoptosis after Olaparib treatment, than looking at the sub G1 population 
alone. shBAF180 cells have an increase in Caspase-3 positive cells at all time 
points after treatment with 10 and 20µM Olaparib compared to the control. 
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These data demonstrate that loss of BAF180 results in a modest, but clear, defect 
in the HR pathway, which provides a potential mechanistic explanation for the 





































































































































































































































































































































































































































































































Figure 6.11. shBAF180 U20S appear to die through apoptosis after 
treatment with Olaparib.  
FACS analysis of shControl and shBAF180 U20S treated with Olaparib or the 
vehicle control DMSO at 0, 24, 48, 72 and 96 hour time points. (A) Histogram 
representation of sub G1 population after camptothecin treatment (B) Histogram 
representation of caspase 3 in gated population after Olaparib treatment. (C) 
Western blot of apoptosis. Analysis of PARP and cleaved PARP expression 









In this section we validated the siPARP:shBAF180 interaction observed in our 
high-throughput synthetic lethal siRNA screen, described in Chapter 5. We found 
that the interaction seen between PARP1 and PARP3 with shBAF180 U2OS cells 
was not due to off-target effects, confirming the interaction with different siRNAs 
and small molecule inhibitors of PARP in two different BAF180-deficient cell lines. 
We confirmed that multiple shBAF180 constructs expressing in U2OS cells confer 
sensitivity to the PARP inhibitor Olaparib, demonstrating that the synthetic 
lethality observed was not shRNA construct specific. We saw that sensitivity to 
Olaparib in shBAF180 U2OS cells was exacerbated upon addition of IR, suggesting 
that there may be a HR defect in BAF180-deficient cell lines. We confirmed that 
there is a modest defect in the HR pathway in BAF180-deficient cells by observing 
RAD51 foci formation and camptothecin sensitivity. And finally we demonstrated 
that BAF180-deficient U2OS cells treated with Olaparib show increased levels of 
cells in apoptosis. 
 
6.11.1. Is there a more important role for PARP3 than the 
other PARP genes in regards to BAF180 synthetic lethality? 
 
Our high-throughput screen, as discussed in Chapter 5, identified PARP3 as 
having the 4th highest synthetic lethal interaction with shBAF180 U2OS out of 446 
siRNAs. The other PARP genes followed the same trend and were also identified 
as having a modest synthetic lethality with BAF180. But it is interesting to think 
about why this might be.  
Technical errors, for example errors in pipetting on a large scale, may be 
responsible for why PARP3 came higher in our screen than the other PARP genes. 
Due to the high-throughput nature of a screen, there is more potential for 
variability here on such a large scale, compared with manual/individual 
validation. Because we further validated PARP1’s synthetic lethal interaction 
with BAF180 at levels comparable to PARP3 (Figure 6.1a and 6.1c), it is likely that 
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technical errors in the HTS resulted in the more favourable killing of shBAF180 
U2OS by loss of PARP3, however it is interesting to speculate why PARP3, in a 
PARP1-independent way, is synthetic lethal with BAF180. 
PARP1 was the first gene discovered in the PARP family, is well characterised and 
has clear roles in the DNA damage response. However, increasing evidence 
demonstrates that PARP3 is too an important player in the cellular response to 
DNA double strand breaks (Beck, Boehler et al. 2014). It has been shown that 
PARP3 interacts with and PARylates Ku70/Ku80 and specifically it works 
together with Ku80 to limit DNA end resection and helps to make the choice 
between HR and NHEJ pathways (Beck, Boehler et al. 2014). PARP3 has also been 
found to interact with the chromatin-associated Polycomb Group (PcG) 
components EZH2, Suz12 and YY1 (Rouleau, McDonald et al. 2007). It has been 
suggested that PARP3 cooperates with EZH2 to regulate the expression and/or 
binding of BRCA1 at sites of DNA damage (Beck, Boehler et al. 2014).  
Recent work in our lab, as previously described, has linked the EZH2 containing 
PRC2 complex with the BAF180 containing PBAF complex. The data suggested 
that PBAF remodels chromatin surrounding DSBs in order to facilitate PRC2 
activity and found that loss of EZH2 mirrored phenotypes exhibited by BAF180-
deficent cells, for example the reduced formation of H2AK119ub foci after 
irradiation and the delay in the repair of a subset of DSBs at early time points 
following IR, suggesting that the failure to repress transcription around DSBs 
affects efficient repair. (Kakarougkas, Ismail et al. 2014). We could speculate that 
loss of two pathways responsible for interaction with EZH2 at DNA damage sites, 
together with the other pathways and factors affected by loss of either PARP3 or 
BAF180, could be the underlying reason for the synthetic lethality demonstrated 
here. 
The most likely underlying reason for BAF180/PARP synthetic lethality is due to 
BAF180 contributing to the HR pathway (discussed in more detail below). 
However, there are other possible explanations for this observed phenotype. For 
example, as mentioned previously, the gene encoding BAF180, PBRM1, is located 
on chromosome 3p21 (Brugarolas 2013). Like BAF180, PARP3 is also found on 
chromosome 3p21 (Johansson 1999). In Chapter 5, we introduced the possibility 
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that SMARCC1 was found as a top hit from our high-throughput synthetic lethal 
screen with BAF180 because it also resides on chromosome 3p21. Given its 
location on a short chromosome arm that has multiple ccRCC genes mutated, it 
would be expected to be mutated by chance alone at 70% of the frequency of 
BAF180 (Brugarolas 2013). However, mutation of SMARCC1 in ccRCC are very 
rare, suggesting that the gene may be required for ccRCC survival (Brugarolas 
2013). Out of 1777 kidney cancer samples tested for PARP3 mutation, just 0.11% 
(2 samples) harboured a mutation (Forbes, Beare et al. 2015). It is possible to 
speculate that after loss of VHL and BAF180 tumour suppressors, PARP3 gene 
expression may be essential for cell growth and may account for the synthetic 
lethality we observe in this study. Of course, this theory does not account for the 
synthetic lethality seen between BAF180 and other PARP family members such 
as PARP1, 2 and 4 as they are found on chromosome 1, 14 and 13 respectively.  
 
6.11.2. BAF180-deficient cells have a defect in homologous 
recombination 
 
Deficiency in the homologous recombination pathway causes cellular sensitivity 
to PARP inhibitors, therefore PARP inhibitor sensitivity may indicate a defect in 
HR directed repair. We identified a sensitivity to both Olaparib and Rucaparib in 
two of our BAF180-deficient cell lines (U2OS and 786-0), suggesting that there 
may be an underlying defect in HR in our BAF180-depleted cells causing the PARP 
inhibitor sensitivity.  
Recent work in our lab has identified PBAF, and specifically the BAF180 subunit, 
as being important for mediating correct sister chromatid cohesion (Brownlee, 
Chambers et al. 2014). Cohesin is thought to be involved in sister chromatid HR 
but not NHEJ in human cells (Potts, Porteus et al. 2006). Cohesin is recruited to 
sites of DNA damage and facilitates sister chromatid HR by mediating local 
cohesion between a damaged chromatid and its intact sister template (Kim, 
Krasieva et al. 2002).  
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It is known that cohesin complex related genes, with defects in the HR pathway, 
are sensitive to PARP inhibition. For example, PDS5B (APRIN) is a cohesion-
associated protein, that interacts with BRCA2. BRCA2 is known to interact with a 
number of proteins that control HR including PALB2 (Xia, Sheng et al. 2006), 
FANCG (Hussain, Witt et al. 2003), FANCD2 (Hussain, Wilson et al. 2004), BRCA1 
(Chen, Silver et al. 1998) and DSS1 (Marston, Richards et al. 1999). Like BRCA2-
deficient cells, mutations in BRCA2-binding proteins can also result in 
compromised HR efficiency and sensitisation to DNA damage. It was determined 
that PDS5B expression is required for the normal response to DNA-damaging 
agents, the nuclear localisation of RAD51 and BRCA2 and efficient homologous 
recombination (Brough, Bajrami et al. 2012). Silencing of PDS5B results in a 
sensitisation to the PARP inhibitor Olaparib (Brough, Bajrami et al. 2012).  
A number of other cohesion-associated genes, for example, RAD21, ESCO1, 
ESCO2 and SMC3, when silenced, have also been found to be sensitive to PARP 
inhibition (Bajrami, Frankum et al. 2014). This highlights the importance for 
factors involved in correct sister chromatid cohesion in the DNA damage 
response. 
The yeast homologues of BAF180, Rsc1 and Rsc2 are already known to have 
defects in HR-dependent DNA repair (Chai, Huang et al. 2005, Oum, Seong et al. 
2011). The defective sister chromatid HR at double strand break sites, in Rsc2 
mutant cells specifically, is thought to be due to impaired accumulation of DSB-
induced cohesin at the break (Oum, Seong et al. 2011). It is possible that 
mammalian BAF180, like its yeast homologues, cooperates with cohesion factors 
to facilitate cohesin-dependent HR. Therefore, silencing of BAF180 gives rise to 
defective HR and sensitivity to PARP inhibitors as seen in this study. 
 
6.11.3. Future work 
 
Consistent with data from the Lord lab (C. Lord – The Institute of Cancer Research 
– personal communication), we find that BAF180-depleted cells are sensitive to 
treatment with PARP inhibitors. They observe sensitivity to Olaparib, Rucaparib 
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and Talazoparib in siPBRM1 depleted mouse embryonic stem cells in clonogenic 
survival assays (C. Lord – unpublished data).  
To test whether the human renal cell line, 786-0, expressing shBAF180 has a 
conserved synthetic lethal interaction with PARP inhibitors in a different model 
to those tested here, we chose to perform mouse xenografts in collaboration with 
Prof. Sue Eccles (The Institute of Cancer Research). Immunodeficient mice were 
injected with shControl and shBAF180 cells and tumours were allowed to form 
for twelve days before treatment was given. No significant difference in tumour 
volume was seen between shControl and shBAF180 after treatment with 
15mg/kg Olaparib for five consecutive weeks (data not shown). In BRCA1-/- 
mouse xenografts, the Lord lab have previously observed a non-significant 
difference in tumour cell growth between the BRCA1-depleted and control cells 
treated with PARP inhibitor. However, upon Hematoxylin and Eosin (HE) staining 
of tumours, they find a higher level of necrosis in the BRCA1-depleted cells after 
PARP inhibitor treatment (C. Lord – unpublished data). 
Ongoing work is currently being performed to determine whether, consistent 
with the Lord lab data, upon HE staining we will also see a higher level of necrosis 
in the shBAF180 cells. Failing this, we can also pursue repeating the xenograft 
study with a higher dose of PARP inhibitor, as retrospectively we learned that 
15mg/kg is a relatively low dose treatment and standard PARP inhibitor 
xenograft studies use ~50mg/kg doses.  
Observing the response of a human tumour to therapy is important for the 
progression of new drug treatments for cancer. Performing mouse xenografts 
with transplanted human cells is a good preliminary model for the examination 
of response to therapy. Our aim is to confirm that shBAF180 depleted cells are 
more sensitive to PARP inhibitor treatment in this model, either in decreased 
tumour volume or increased levels of necrosis, with an overall view to utilizing 
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